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ABSTRACT 
 
Breast Cancer is one of the major causes of mortality among women in the world.  During 
normal tissue development, cell growth is controlled by a mechanism of cell death called 
apoptosis. However, during cancer, the balance between cell division & apoptosis is altered, 
leading to cell survival, cell proliferation and tumour formation. The nuclear receptor Farnesoid 
X Receptor (FXR) is expressed in human breast cancer tissue and the breast cancer cell lines 
MCF-7 and MDA-MB-468. In these cells, activators of FXR caused apoptosis, but the exact 
mechanism of how FXR regulates apoptosis in breast cancer is unknown. The aim of this 
research is to elucidate the mechanism of FXR-mediated apoptosis using human breast 
cancer cell lines MCF-7 and MDA-MB-231.  
 
Cell viability after treatment with FXR agonists chenodeoxycholic acid (CDCA) & GW4064 was 
measured by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. The 
effect of staurosporine was also examined as a positive control for induction of apoptosis.  All 
three chemicals significantly decreased the viability of MCF-7 and MDA-MB-231 cells in a 
concentration dependent manner, with IC50 values determined as 35µM, 245µM and 6µM for 
GW4064, CDCA and staurosporine, respectively for MCF-7 cells and 22µM, 440µM and 4µM 
for GW4064, CDCA and staurosporine, respectively for MDA-MB-231 cells.  
The difference in efficacy of the two FXR agonists corresponds to differing potency as 
GW4064 is a high affinity synthetic ligand for FXR, whereas CDCA is an endogenous bile acid 
that has much lower affinity for FXR. 
 
FXR expression was confirmed in both MCF-7 and MDA-MB-231 cell lines by Western 
blotting.  Poly-ADP ribose polymerase (PARP) cleavage is the classical marker for apoptosis. 
Cleaved PARP, indicative of active caspase-3, was observed in MCF-7 and MDA-MB-231 
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cells exposed to staurosporine (positive control for apoptosis) or the FXR agonists GW4064 
and CDCA. Luminescent analysis for caspases: 3/7, 9 and 8 were measured for MCF-7 and 
MDA-MB-231 cells treated with staurosporine (positive control for apoptosis), FXR agonists 
GW4064 and CDCA. Further research focused more specifically on the mechanism of 
apoptosis. Proteins involved in apoptotic pathway such as BAX, Bcl-2, and cytochrome c were 
studied through Western blotting performed on MCF-7 and MDA-MB-231 cell lines treated 
with staurosporine and FXR agonists. Reactive oxygen species were studied on MCF-7 and 
MDA-MB-231 cell lines treated with FXR agonists, measured using ROS luminescence assay. 
The results showed that FXR agonists GW4064 and CDCA induced intrinsic apoptotic 
pathway via ROS activation in both MCF-7 and MDA-MB-231 cell lines. 
Chemotherapy has been extensively used to treat patients with breast cancer. Tamoxifen 
(Tam) has been in use for over 30 years to treat patients. However, due to its toxicity and 
resistance, there is constant need for new therapeutic alternatives. In this study, the interaction 
between tam and FXR agonists was studied using MTT and clonogenic assay. The results 
showed a synergistic interaction of GW4064 with tam in both MCF-7 and MDA-MB-231 cell 
line. However, the mechanism needs further investigation. 
In summary, FXR agonists induce mitochondrial dependent apoptosis in breast cancer cells. 
Also GW4064 synergises with tam and reduces cell proliferation in MCF-7 and MDA-MB-231 
irrespective of their estrogen status.   
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1. INTRODUCTION 
Throughout one’s lifespan, the cells in the body are continuously growing, dividing and 
replacing themselves. A series of well-coordinated signals are used to control this 
process, commanding the cells to undergo division or death as required. On the 
contrary, tumour cells escape this control system and survive outside this balance, 
leading towards uncontrolled proliferation. Cancer is a multi-step process starting with 
abnormality in a single cell due to mutation. These cells are now termed as neoplasm. 
These then form into a cluster of cells called tumour as in Figure 1-1. The main stages 
of cancer development are initiation, promotion and progression. Proto-Oncogenes 
and tumour suppressor genes play vital role in maintaining cellular growth. Due to 
mutations and loss in DNA repair mechanisms these oncogenes promotes 
uncontrolled cellular division, discussed in section 1.2.2. On this basis, the majority of 
cancer chemotherapeutics have been targeted at aspects of this control system, or 
the processes of cell division themselves. However, it is becoming increasingly clear 
that cancer cannot be viewed as a single disease with a single biological phenotype, 
but rather involves alterations in the complete metabolic functioning of cells, which 
underpins the ability to rapidly divide. An exciting new area of cancer 
chemotherapeutics is, thus, the exploitation of cancer cell metabolism.   
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Figure 1-1: Normal vs cancerous cell growth 
 
Normal cells have are characterised by a relatively large cytoplasmic to nucleus ratio, intact 
organelles, smooth cytoplasmic and nuclear border. In addition, normal cell division is a 
controlled process and the rate of division and death is balanced [Blue cells; panel A]. Several 
forms of cell damage result in defective or damaged control mechanisms, leading to cells that 
divide uncontrollably, plus the loss of programmed cell death. Such cells may be termed 
cancerous, and are further characterised by a distorted cytoplasmic and nuclear border. This 
uncontrolled division leads to tumour growth [Green cells; panel B]. 
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1.1.  Cancer Incidence 
 
Cancer accounts for nearly one in every four deaths in the US and UK. Around the 
globe, 14 million new cases and 8.2 million cancer related deaths were reported in 
2012, (Stewart, 2014), cancer type distribution is given in Figure 1-2. Deaths from 
cancer worldwide are projected to rise to over 22 million by 2030 (Stewart, 2014).   
 
 
 
 
 
 
Figure 1-2: Cancer Incidence and Mortality worldwide data (Data from Cancer 
Research UK) 
 
Perhaps unsurprisingly, most interest has focussed on the most commonly diagnosed 
cancers, namely lung, colorectal and breast cancers. Breast cancer is the most 
frequent cancer among women, with nearly 1.5 million diagnoses in 2010 worldwide, 
including an estimated 207,090 new cases of invasive breast cancer among US 
women, along with 54,010 new cases of non-invasive (in-situ) breast cancer (Ferlay 
et al., 2010). As can be seen from Figure 1-3, the rate of breast cancer diagnosis 
remains relatively constant, with an estimated 1.7 million women diagnosed with 
breast cancer. 
58%
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Figure 1-3: Breast cancer incidence/death statistics (Breast Cancer Research 
UK) 
  
Despite the advancement to date in the treatment of breast cancer, it is still a leading 
cause of high mortality among women worldwide. One of the major cause is the 
genomic variability within breast cancer subtypes. The different subtypes display 
significant differences in their molecular paradigm which imposes difficulty for both 
clinicians and researchers to develop personalised treatment for patients. Certain 
subtypes imposes worst prognosis as there is no targeted treatment owing to lack of 
molecular targets (Berry et al., 2006). The treatments are based upon the clinical 
characteristics of breast cancer often arrayed according to their heterogeneity (van de 
Vijver et al., 2002). DNA microarray based profiling classify breast cancer subtypes 
based on this heterogeneity, but still have limitations. Often this classification leads to 
histological similar type of tumour. Also, current prognostic markers does not 
appropriately establish correct therapy for the patient (Draghici et al., 2006, Rouzier et 
al., 2005). Recent most important classification of 2000 breast tumours based upon 
their genomic and transcriptomic data by METABRIC, provides a landmark in 
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establishing correlation between treatments and patient survival (Curtis et al., 2012). 
Despite the advancement in systems biology research and technology, clearly most 
prominent molecular markers couldn’t determine so far. Therefore, it is important to 
develop in-depth understanding of the molecular mechanism underlying the disease. 
This will in turn develop much more robust-targeted therapies for patients and design 
novel therapeutic drugs.     
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1.2 Breast Cancer  
 
Breast cancer is the second most common cancer in the world, and the leading cause 
of mortality in women among age group 20-60 years (Jemal et al., 2011). Breast 
cancer, also known as malignant breast neoplasm, is a cancer originating from breast 
tissue, and hence it is important to understand the physiology of the breast first.  
 
1.2.1 Physiology of breast: 
 
The normal breast functions to produce milk for lactation. The epithelial tissue consists 
of the lobules, where milk is produced. The ducts perform the function of transferring 
milk from breast to nipple. Each lobe consisting of several lobules, which in turn are 
comprised of alveoli. These lobules and ducts are located throughout the fibrous tissue 
mesh and adipose tissue (Chawla et al., 2001). Each alveolus has ducts that join with 
others to form a single, much larger lactiferous duct within each lobe (Figure 1-4).  
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Figure 1-4: Physiology of breast 
Breast is made up of connective tissue, fatty tissue, duct, lobules and areola. Lobules: for milk 
production, ducts: carry milk from lobules, nipple: centre of the areola for lactation and fatty 
and connective tissue: make up the mass of the breast. (What is breast cancer? Retrieved June 
5, 2015, from http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-what-is-
breast-cancer) 
 
Within the breast, lymph nodes are one of the major sites for the development of 
tumours. This is because cancerous cells may flow through the lymphatic system and 
develop cancerous tumours in the lymph nodes. Depending upon the site of origin, 
breast cancer can be broadly subdivided into ductal or lobular carcinomas. Ductal 
carcinomas accounts for 75% of all invasive breast cancers whereas lobular 
carcinoma only contributes 5% to 10%. Other forms are Lobular Carcinoma In-situ or 
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inflammatory breast cancer (Weigelt and Reis-Filho, 2009, Yerushalmi et al., 2009). 
Beyond this general sub-division, ductal and lobular carcinomas can be further sub-
divided into invasive or non-invasive. Ductal carcinoma in situ starts in the cells lining 
the duct, but does not invade the ducts or surrounding tissues of the breast, and is the 
most common type of non-invasive breast cancer. On the other hand, Invasive or 
infiltrating ductal carcinoma (IDC) is not confined in the duct and invades tissues of 
the breast, and represents one of the commonest types of breast cancer. Finally, 
cancer originating from the cells lining the milk ducts (lobules) is termed invasive 
lobular carcinoma (Malhotra et al., 2010).  
 
Two hormones play important physiological roles in the development and functioning 
of the human female breast: progesterone and estrogen. The active form of estrogen 
17β-estradiol (Borgna and Rochefort, 1980), is produced by the granulosa cells of the 
ovaries and plays a central role in the development of the ductal system. Estrogen 
achieves these actions through interaction with the estrogen receptor (ER) a member 
of the nuclear receptor family of ligand-activated transcription factors (section 1.4.3.1). 
Once activated, the ER controls transcriptional activities within breast cells, as well as 
regulating proliferation and apoptosis (Pike et al., 1993). For example, estrogen 
positively regulates the B-cell lymphoma 2  families of proteins that are involved in the 
mitochondrial apoptotic pathway (Schacter et al., 2014), discussed in detail in section 
1.3.2.2 However, ER activation is not obligate for tumorigenesis, with ER-α knockout 
mice exhibited breast cancer cell proliferation, indicating that non-ERα-dependent 
growth can also occur (Bocchinfuso et al., 2000). Also, when MCF10A cells, a non-
tumourigenic immortalized breast epithelial cell line, where exposed to 17-β-estradiol 
neoplastic transformations could be initiated irrespective of the ER status (Liu and Lin, 
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2004). Knockout studies of both estrogen and progesterone have shown the 
importance of both hormones in the normal development of breast. Progesterone 
isoforms are required to produce the terminal milk ducts. Progesterone-A and 
Progesterone-B isoforms function in normal mammary gland development and uterine 
development, respectively (Feng et al., 2007, Ruan et al., 2005). Once activated PR 
regulates signalling pathways and the subtypes with negative expression of these 
receptors are linked with poor prognosis and limited therapeutic range discussed in 
section 1.4.3.2 Thus, they are responsible for the normal physiology and development 
of breast. Also dysregulation of these receptors poses potential risk of development of 
tumours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
1.2.2 Cancer Risk Factors 
 
There are a number of reasons for the uncontrolled cell division which are DNA 
mutation and loss of DNA repair mechanisms. Perhaps the simplest source of 
mutations is spontaneous mutations caused through faulty replicative machinery in the 
cell. Depsite the well-established repair system, the system is not infallible and if a cell 
divides before the mutation can be repaired then it can be fixed within the cell 
population. DNA repair is a process that involves the excision of bases and DNA 
synthesis. This involves the double stranded DNA. Repair mechanisms such as base 
excision repair replace a damaged base by excision of the base, removing the 
deoxyribose and repaired by addition of a nucleotide. Errors such as mispaired bases 
occurring during faulty DNA replication and are repaired by single nucleotide, termed 
as mismatch repair (Alberts B, 2002). Mutations can also be due to external factors 
such as physical agents, chemical agents, biological agents or inherited genetic 
factors. Physical risk factors include carcinogens such as ultraviolet and ionizing 
radiation emitted by X-rays, gamma rays and particle radiation emitted by radioactive 
substances. Chemical risk factors are numerous, including for example asbestos, 
tobacco smoke components, aflatoxin (a food contaminant) and arsenic (a drinking 
water contaminant) (Bertram, 2000). Biological factors include infections from certain 
viruses, bacteria or parasites. Finally, genetic factors involve the generational transfer 
of specific gene variants that encode for proteins such as tumour suppressors or 
tumour promoters, and increase the chance of fixation of mutations in the cell 
population (Alberts B, 2002). 
 
With regard to breast cancer, there are a number of well-established risk factors. 
Approximately 5% of breast cancers are familial (i.e. due to a genetic predisposition), 
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and women, with either a mother, sister or daughter with breast cancer are, on 
average, at twice the risk of developing breast cancer than those that do not have any 
familial cancer history. Perhaps the most famous genetic predisposition traits for 
breast cancer are the tumour suppressor BRCA1 and BRCA2. For example, women 
with germ line mutations in BRCA1 and BRCA2 have a 40-80% higher estimated life-
time risk of breast cancer (Thompson et al., 2002). The BRCA1 and BRCA2 genes 
are located at chromosomal positions 17q21 and 13q12, respectively, and encode 
multi-tasking proteins that function as tumour suppressors through their regulation of 
cell cycle progression, DNA repair, cell cycle checkpoints and programmed cell death 
or apoptosis (Narod and Foulkes, 2004). Studies are still being conducted to elucidate 
the reason behind the development of specific tumour types such as breast cancer in 
women carrying the mutated BRCA1 gene. In cells with a defective inherited copy of 
BRCA1 or BRCA2, if the second copy is inactivated by a mutation, then a tumour may 
develop due to the loss of this tumour suppressive ability (Narod and Foulkes, 2004). 
Hormone exposure such as estrogen is linked with increased risk of developing breast 
cancer. This includes hormone fluctuations during the menstrual cycle if there is a late 
onset and late menopause (Brinton et al., 1988, Clavel-Chapelon and Gerber, 2002, 
Newcomb et al., 2011). In addition there are a number of general risk factors 
associated with breast cancer. The incidence of breast cancer rises dramatically with 
age, with approximately 80 per cent of all cancers occurring in people aged 50 or 
above. Diet also has an impact as obese women are at higher risk of developing breast 
cancer, while other risk factors in breast cancer include alcohol consumption and 
cigarette smoking (Modugno et al., 2006, Singletary and Gapstur, 2001). 
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The relative risk factors for breast cancer are summarized in table below. (Singletary 
and Gapstur, 2001) 
 
Table 1-1 RISK FACTOR FOR BREAST CANCER 
RISK FACTOR FOR BREAST CANCER IN WOMEN Approx. Relative 
risk 
Age group ≥ 25 very high 
First degree relative with breast cancer 3.3 
Genetic susceptibility: BRCA1 or BRCA2 gene  15 
High alcohol consumption and cigarette smoking 1.2 
High fat diet 1.2 
Obesity 1.2 
Early Menarche and late menopause 1.3/1.5 
Estrogen exposure such as estrogen replacement therapy 1.3 
Radiation exposure 1.6 
Lack of exercise  1.2 
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1.2.3. Treatments for breast cancer 
Breast cancer treatments are targeted on the basis of the site of the tumour within the 
breast and/or specific hallmarks of the tumour itself. The treatments include both local 
and systemic therapies, often used in combination. One of the most common types of 
treatment is surgery or radiotherapy targeted directly at the tumour for local control 
over the disease. Such treatments are commonly followed-up by chemotherapy to 
treat both any remaining breast tumour and any distant spread of the disease through 
metastasis. The choice of treatment depends upon the properties of tumour, its grade, 
and the extent of any metastasis. Sometimes more than one therapy is used as a 
combination to most effectively combat the disease.  
 
1.2.3.1 Surgery and Radiotherapy 
 
 One of the classical ways to treat breast cancer is surgery. The basis of surgery is to 
remove all the tumour (mass of cancerous tissue) including the removal of lymph 
nodes called lumpectomy. This was traditionally through radical mastectomy, but more 
advanced methods of surgery are been used such as quadrantectomy, which is a 
partial or segmental mastectomy (Recht and Houlihan, 1995). Sometimes, axillary 
lymph node dissection (ALND) or axillary clearance is performed to remove many of 
the lymph nodes, reducing the risk of metastasis. However, this can lead to swelling 
of the arm termed as lymphoedema, and has been largely replaced by sentinel lymph 
node biopsies.  
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A key limitation of surgical procedures is that they are effective at the local level only, 
meaning that they have reduced effectiveness for patients with advanced breast 
cancer where tumour invasion will be higher and metastasis highly likely (Matsen and 
Neumayer, 2013). Even after surgery there is always a chance of recurrence, and 
therefore radiotherapy is often applied in addition to surgery. Radiotherapy is another 
treatment of the localised tumour and patients receiving radiotherapy after surgery 
shown better improvement and have lowered chance of recurrence, giving patients 
higher survival rates. Data suggests that such an approach is particularly important for 
the better survival of patients with positive node status (EBCTCG) (2005), and that it 
is effective in treating patients with more than two positive lymph nodes. Radiotherapy 
is also used sometimes to reduce the size of the tumour before surgically removing it.  
 
 1.2.3.2 Systemic therapy 
 
Although patients with a localised tumour can be treated with surgery and/or 
radiotherapy, even in early breast cancer cases tumours do metastasise to distant 
parts of the body: Under such circumstances, local treatment is ineffective. In addition, 
the side effects and the magnitude of surgery and radiotherapy required to treat 
advanced local tumours can become limiting, meaning that all local tumour cells may 
not be removed. Given these facts, it is important to develop robust systemic therapies 
to treat patients with advanced and/or metastatic presentations. This is supported by 
clinical data that suggests that chemotherapy is highly beneficial to patients, and 
markedly increases survival rates (Tripathy, 2007).  
Chemotherapy can be given to patients before (neo-adjuvant) and after (adjuvant) 
surgery. Initially, adjuvant therapy was administered through single drug treatments, 
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but it is much more common now to give a combination of two or more drugs. Such 
combinations help to overcome resistance (i.e. when patients stop responding to the 
single drug), as well as reducing the adverse effect profile, as each drug is often 
needed at a lower concentration to achieve efficacy.  
One of the first combination chemotherapeutic drugs regimes applied to the treatment 
of breast cancer was the anthracycline combination consisting of the 
cyclophosphamide, methotrexate and 5-fluorouracil (Fisher et al., 1975, Hortobagyi et 
al., 1980, Wadler et al., 1986). Their mechanism of action was to induce DNA single 
strand breaks or double strand breaks, and inhibit nucleotide synthesis (Hortobagyi et 
al.), with a clear synergy seen between these two processes. Another combination 
used commonly in the treatment of breast cancer is 5-fluorouracil, doxorubicin and 
cyclophosphamide: in this case, doxorubicin provides inhibition of topoisomerase II 
activity, preventing DNA replications. The high efficacy of this combination treatment 
can be seen in both good initial survival rates, and decreased rates of recurrence 
(Fukuda et al., 1999).  
 
Hormone therapy is another most widely used approach to treat patients. One of the 
classical drug used is Tamoxifen (Tam) and been extensively studied over decades 
and been in use for more than 30 years. It is the standard for the endocrine treatment 
for breast cancer with positive ER and been successful so far in treating 400,000 
women and benefited patients survival (Fisher et al., 1981, Jordan, 1993). It was first 
demonstrated as the anti-fertility agent in 1960s but over years of extensive research 
accepted as first targeted therapy to treat patients with metastatic breast cancer in 
1977 (Jordan, 2003). In a study done by National Surgical Adjuvant Breast and Bowel 
Project (NSABP) in 1992, it was shown that breast cancer incidence lowered by 50% 
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treated with tamoxifen compared to controls (Fisher et al., 2005). Food and Drug 
Administration approved tam in 1999 for treating and reducing breast cancer risk in 
both pre and post-menopausal women. The major advantage of tam is its efficacy in 
treating even younger women (Patel et al., 2007). Although with such advantageous 
properties, one of the major setbacks is its un-effectiveness in treating breast cancer 
with negative estrogen status and much more aggressive tumour cases and resistance 
towards treatment.  
Trastuzumab or Herceptin is another class of chemotherapeutic drug commonly used 
to treat breast cancer. It is used to treat breast cancer with positive HER2 status and 
binds to the receptor with high affinity. Herceptin functions by inhibiting the activity of 
cyclin E/cdk2 via p27kip1 regulation in human breast cancer cell lines (Hudis, 2007). 
Also it inhibits the activity of Akt and PI3 Kinase by disruption the HER2-PI3 kinase 
complex in human breast cancer cell lines. This interaction with the signalling complex 
causes the cell cycle arrest and apoptosis (Simonds and Miles, 2007). 
Other commonly used drugs are Paclitaxel, Doxorubicin and Cisplatin, but they are 
not breast cancer specific. These drugs are used in combination to treat breast as well 
as other cancers such as lung, prostate, ovarian, neck and bowel (Cancer Research 
UK). 
If the tumour does not respond to the initially tried drug combination, other 
combinations are usually tried, with the aim of identifying one that is optimal against 
the individual tumour phenotype. This is, in effect, a form of personalised medicine, 
whereby treatment is tailored against the individual tumour. An obvious extension of 
this is a priori identification of unique tumour properties that can be used to effectively 
target treatment; such is the approach used during biological treatment of tumours 
with antibodies (Scott et al., 2012). 
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1.2.4 Tamoxifen and drug resistance 
 
One of the critical roadblocks in the successful treatment of all cancers, including 
breast cancer, is that not all patients can be cured through a single chemotherapy 
regime, as over time patients develop resistance. The development of resistance will 
be examined using tam as a case study. For this, it is important to understand the tam 
mode of action.  
 
1.2.4.1 Tamoxifen mechanism of action: 
 
The estrogen-ER complex along with activation function 1 and 2 (AF1 and AF2) 
interact with the transcriptional coactivators to regulate the gene activity. The 
homodimerisation of this complex with estrogen response elements regulates the 
genes involved. Tam prevents the conformational change that occurs to ER upon 
estrogen binding acts as an antagonist and prevents ER-mediated gene transcription, 
see Figure 1-5. Thus named as selective ER modulator (Lewis and Jordan, 2005). 
Although this process is tissue specific as for some genes relying on AF1 rather than 
AF2 tam acts as an agonists. The inactivation of AF-2 results in an unresponsiveness 
of the estrogen response elements (ERE’s) resulting in G1 phase cell cycle arrest 
(Borgna and Rochefort, 1980, Coezy et al., 1982, Robertson et al., 1982). The p21 
and p27 are CDK inhibitors that play an important role in cell cycle regulation 
(discussed in section 1.3.1). Both functions by inhibiting cyclin-D1 activity. Tam 
increases the expression of these proteins and induces cell cycle arrest in breast 
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cancer cells (Abukhdeir et al., 2008, Cariou et al., 2000, Carroll et al., 2003).  Two 
active metabolities, 4-hydroxytamoxifen and endoxifen are important for achieving the 
maximal efficacy of tam, metabolised in liver by cytochrome P450 2D6. 4-
hydroxytamoxifen stimulates transforming growth factor β (TGFβ) that inhibits cell 
proliferation (Butta et al., 1992). Also, it downregulates insulin-like growth factor, a 
potent mitogen for breast cancer and blocks ErbB2/Her2 growth factors (Ho et al., 
1998, Hurtado et al., 2008). Inhibition of IGF-1R decreases growth of tam resistant 
MCF-7 breast cancer cell lines (Massarweh et al., 2008).  In in-vitro studies tam 
induces cytotoxic effect on breast cancer cell lines (Sutherland et al., 1986).  
 
 
Figure 1-5: Tamoxifen mode of action 
A). Tam blocks estrogen (E) binding to the estrogen receptor (ER). B). Tam-ER forms the 
homodimer C). The homodimer binds to the estrogen response elements (ERE) and 
blocks the transcription of the genes.   
 
1.2.4.2 Tamoxifen resistance  
Despite tam’s effectiveness in the treatment of breast cancer, some tumours do not 
respond, and acquire resistance towards it. There are certain mechanisms that lead 
to resistance towards the tam over the time course of treatment or sometimes 
completely unresponsive towards the treatment (de-novo). The common mechanisms 
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are loss of an estrogen receptor, altered signalling, downregulation or mutations 
(Riggins et al., 2007).  
Mechanisms of resistance are mentioned below in detail.  
(a) Loss of Estrogen Receptor-α: Loss of function either by mutations, point 
deletions or insertions have been investigated. But as it is a rare event and 
does not explain the 30% of negative status breast cancer cases, it is not 
regarded as a best predictive marker. In-vitro studies suggest that loss of 
estrogen receptor α (ERα) is associated with increased methylated DNA 
(Ottaviano et al., 1994). Loss of ER, accounts for tam ineffectiveness, as tam 
binds to the receptor and blocks its activity. It has been shown that estrogen 
alpha solely does not account for tam resistance but together with progesterone 
receptor indicate more robustly respond to tam. Nearly 70% of ER-α 
positive/Progesterone receptor-positive tumours effectively respond to tam, 
while only 34% of ERα-positive/PgR-negative tumours could respond to tam 
(Clarke et al., 2001). Estrogen Receptor β also alter the expression of ER-α and 
represses its activity. Studies so far has been contradictory on the expression 
levels of ER-β as a predictive marker for tam resistance. This area needs a lot 
of research work to investigate the potential role in altering the expression of 
ER-α (Hall and McDonnell, 1999, Pettersson et al., 2000).  
(b) Co-regulators and co-repressors expression: transcriptional activity of ER is 
mediated by the co-regulators. The imbalance between the co-regulators and 
co-repressors create the impaired tam effect. They completely alter the ER 
signalling pathway and thus is a vital component of tam resistance. Co-
activators such as steroid receptor coactivator 1, SRC-1 is an ER co-activator 
plays an important role. Steroid receptor coactivator-1 (SRC-1) phosphorylated 
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and activated by mitogen-activated protein kinase (MAPK) serves as a marker 
for tumours over-expressing HER-2 receptor. Thus, it increases an agonist’s 
effects of tam. Studies have also suggested that higher expression of SRC-1 
and HER2 show poor prognosis and do not respond to tam, indicating co-
regulators role in resistance (Osborne et al., 2003). Co-repressor- NCoR has 
been shown to interact with ER. It silences the gene activity when bound to tam 
through chromatin condensation (Girault et al., 2003, Graham et al., 2000, Hu 
and Lazar, 2000, Jonas and Privalsky, 2004). The declined expression of NCoR 
has been associated with shorter relapse survival of patients treated with tam 
as indicated in the study undertaken by Girault et al. (2003).  
(c) Growth factor signalling complex: ER initiates the signalling complex both 
genomic and non-genomic mechanisms. Activation of ER via non-genomic 
pathway is resulted in the activation and phosphorylation of the surface kinase 
receptors such as EGFR, HER2, IGF1-R and some cellular proteins such as c-
Src and PI3K. This further initiates the downstream signalling pathways such 
as MAPK and AKT phosphorylating and activating the estogen receptor and its 
co-activators (Lichtner, 2003, Nicholson et al., 2005, Zilli et al., 2009). 
Alterations in the activation of these signalling pathways lead to un-
effectiveness of the anti-estrogenic targeted therapies such as tam. Tam has 
been shown to increase the phosphorylation of the MAPK and (Simoncini et al., 
2000) promote higher interaction between ER-α (ER-α) and EGFR in resistant 
cells (Fan et al., 2007, Hutcheson et al., 2003). Blocking AKT/PI3-K by mTOR 
inhibition restores tam effects on MCF-7 breast cancer cell lines with active 
AKT, suggesting the resistance (Boulay et al., 2005, Campbell et al., 2001, 
deGraffenried et al., 2004, Faridi et al., 2003, Jordan, 2003, Mamane et al., 
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2006, Simoncini et al., 2000). Also, it acts as an agonist for MCF-7 cells 
expressing high levels of HER2 and enable tumour cells to proliferate (Fan et 
al., 2007). Tam bound ER resistance is evident by the fact that when resistant 
cells are administered with Gefitnib, it reverses the agonist activity of tam (Fan 
et al., 2007). 
(d) Cell cycle regulators: cyclins and cyclin-dependent kinases are key regulators 
of cell cycle (Nigg, 1995) (discussed in section 1.3.1). These are the targets for 
tam therapy as estrogen progresses the cells from phase G1 to S (Taylor et al., 
1983). Cyclin D1 is a direct target of estrogen signalling and tam reduced its 
expression thus negatively regulating cell cycle progression. When breast 
cancer cells attain resistance towards tam, cyclin D1 expression increases. On 
the other hand, studies have shown decrease in cyclin D1 expression in in-vitro 
with tam sensitive cells (Kilker et al., 2004). Clinical data also suggests that 
patients with negative cyclin-D1 expression have better prognosis and tam 
therapeutic results as compared associated with higher expression (Rudas et 
al., 2008).  
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1.3 Mechanisms of cell death 
 
As introduced in section 1.0, normal organ physiology (homeostasis) is maintained by 
the balance of cell division and death. It is important to understand the cell division 
cycle and mechanisms of death in normal and cancerous state.   
 
1.3.1 Cell cycle 
While decreased cell death increases the lifespan of individual tumour cells, increased 
cell division is critical for the development of the tumour as a whole. Cell division is 
tightly controlled under normal conditions, with the cell cycle having various 
checkpoints that control progression through the phases of cell division and arrest 
(Figure 1-6).  
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Figure 1-6. The phases of cell cycle and checkpoints 
The cell goes through mitotic division in four phases. G1 = gap phase 1, S= synthesis phase, G2 
= gap phase 2, M = mitosis phase and G0 = resting phase. Cell cycle is regulated by cyclins and 
cyclin dependent kinases (CDKs). The restriction point at G1/S checkpoint verifies if the cell is 
ready for synthesis otherwise it remains at G0 resting phase until ready. The G2/M checkpoint 
verifies the mitosis completion.   
 
The cell cycle can be divided into four main phases: G1, S, G2 and M. The first phase 
is the G1 phase (gap phase 1) of the cell cycle, where the cell decides to progress to 
division based upon the growth factors. The mitogens and cyclin/cdk’s association 
leads to cell progression through G1 to S phase. The tumour suppressor gene pRB 
acts as a checkpoint for progression through the G1/S phase. This allows the cell to 
enter S (DNA Synthesis) phase where the accurate duplication of the genome occurs. 
pRb protein inactivation is the restriction point at which cell-cycle progression is 
mitogen independent and releases E2F transcription factors which in turn stimulates 
downstream cyclins for DNA synthesis. Following this, the G2 phase (gap phase 2) is 
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where microtubules are in preparation for division of cellular contents into the daughter 
cells. There is another restriction or checkpoint at the G2/M boundary, which prevents 
the cell from dividing if cellular damage has occurred. Finally, in the M phase or mitosis 
phase, the segregation of a complete set of chromosomes into each daughter cell 
occurs. Depending upon the intracellular signals, these daughter cells decide between 
further rounds of division or termination of cell cycle progression or remain into the 
non-proliferative G0 phase (Schafer et al, 1998). 
Cyclins and cyclin dependent kinases (CDK’s) are the main regulators of progression 
through the cell cycle. The cyclins and the cyclin-dependent kinases are small 
serine/threonine protein kinases that regulate the cell cycle.  Cyclins bind and activate 
members of the cyclin-dependent kinase (CDK) family, which act as gatekeepers of 
cell cycle progression. Progression, through G1-S-G2-M phases, depends on the 
levels of cyclins, D, E, A and B, respectively. The level of these proteins acts as an 
important checkpoint for progression, where cells respond to DNA damage by either 
halting the cell cycle or by initiating a regulated programme of apoptosis (Malumbres 
and Barbacid, 2009, Morgan, 1997, Vermeulen et al., 2003).   
Tumour cells that evade cell cycle checkpoints drive the accumulation of these 
transformed cells and, hence, tumour growth. As can be seen from the previous 
sections, tumour growth is determined to a large extent by the relative rate of negative 
(cell death) and positive (cell division) processes. The proteins that control these 
processes may thus be seen as being pro- or anti-tumourigenic, and are commonly 
referred to as tumour promotors and tumour suppressors, respectively (Burkhart and 
Sage, 2008).  
Examples of tumour suppressors include pRB1 and TP53; pRB1 encodes the 
retinoblastoma protein, whose normal role is to sequester the E2F transcription factor, 
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while TP53 encodes p53, a transcription factor that is one of the most commonly 
mutated genes in human cancers (Alberts, 2002, Osborne et al., 2004). Mutation of 
either pRB1 or TP53 results in unregulated progression through the cell cycle due to 
loss of the encoded checkpoint proteins. In addition, many other checkpoint proteins, 
such as p27KIP, are found to have reduced in expression in breast cancer, 
demonstrating the importance of these cellular brakes in preventing tumour formation 
and progression (Alkarain et al., 2004, Cariou et al., 2000). 
Tumour promoters act in the contrary manner to tumour suppressors, with 
overexpression leading to increased cell cycling. For example, cyclin D1 
overexpression is the most common abnormality in breast cancer after TP53 mutation 
(Arnold and Papanikolaou, 2005, Hosokawa and Arnold, 1998, Buckley et al., 1993). 
Sirtuins are another example of tumour promoters in breast cancer. Their physiological 
roles have not been fully elucidated, but they appear to act as intracellular regulatory 
proteins that detect cellular stress. They have been shown to interact with many other 
proteins, including tumour suppressors such as RB1. Overexpression of members of 
this family has been associated with increased breast tumour progression (Martinez-
Pastor and Mostoslavsky, 2012, Holloway et al., 2013).   
 
Given the important role of regulation of cell cycle progression in tumour development, 
it is not surprising that a number of therapies have been developed against them. 
These therapies include inhibitors of positive signals (e.g. CDKs) and negative 
regulators (e.g. p21CIP1, p27KIP1 and INK4A), with the aim to inhibit cell growth and 
tumour formation (Kilker et al., 2004). Cell cycle inhibitors roscovitine and olomoucine 
shown to upregulate p53 and induce apoptosis in breast carcinoma cell line MCF-7 
(Wesierska-Gadek et al., 2004). A selective CDK4/6 inhibitor, LY2835219 is under 
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phase I clinical trials for patients with metastatic breast cancer shown 9 patients with 
best overall response out of 47 (Patnaik et al., 2014).  
 
1.3.2 CELL DEATH MECHANISMS 
Cell death is essential for maintaining normal cellular homeostasis and interplay with 
cell survival and proliferation. The execution of cell death is orchestrated by three 
different but interlinked death pathways: Apoptosis, Autophagy and Necrosis 
(Kroemer et al., 2009).  
The major features of these three cell death pathway are listed in table 1-2 below: 
 
Table 1-2 Morphological attributes of cell death pathways 
TRAITS APOPTOSIS AUTOPHAGY NECROSIS 
Membrane blebbing + - - 
Nuclear fragmentation + - - 
Apoptotic bodies + - - 
Cell swelling - - + 
Cell shrinkage + - - 
Cytoplasmic vacuolation - + + 
Protein degradation + Sometimes Sometimes 
Loss of organelles - + + 
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Plasma membrane rupture - - + 
Autophagosome formation - + - 
Lysosomal activity - + - 
Caspase activity  + - - 
PARP cleavage  + - - 
PARP activation - - + 
Cytochrome c release + - - 
Bcl-2 proteins + - - 
 
One of the distinctive attributes of cancer cells is their ability to evade cell death. Due 
to the fact that tumour cells are continuously mutating they develop mechanisms to 
escape programed cell death thereby providing them with more time to proliferate and 
produce more tumour cells.  
Many cancer chemotherapeutics act to cause cell death, most notably through the 
necrotic pathway. While this is sufficient to cause damage to the developing tumour, 
it does have two main disadvantages: first, these agents tend to be non-specific and 
cause necrosis in both normal and tumour cells; second, the process of necrosis is 
uncontrolled and elicits a local inflammatory reaction that can cause increase toxicity 
and side effects (Huynh et al., 2002, Vakkila and Lotze, 2004). In comparison, 
apoptotic cell death is a programmed form of cell death that, essentially, leaves no 
footprint (i.e. adverse impact on surrounding cells). Hence, there has been interest in 
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the optimisation of therapies to utilise apoptosis rather than necrotic cell death 
pathways.  
1.3.2.1 Apoptosis 
The term programmed cell death was coined in 1964 by Kerr, Curie and Wylie, who 
proposed that a series of controlled steps caused self-destruction of cells rather than 
accidental death. The term ‘apoptosis’ was used to refer to this process, translated 
from the ancient Greek for “falling of leaves” (Kerr, 2002).   
Apoptosis involves an organised series of morphological changes, including cell 
shrinkage, deformation and loose adhesive strength to neighbouring cells (Figure 1-
7). Initially, chromatin condenses and moves towards the nuclear membrane as it is 
fragmented in an ordered manner. Next, the plasma membrane begins to undergo 
blebbing or budding as its integrity is compromised, and finally apoptotic bodies are 
formed. These bodies are engulfed by the surrounding macrophages, resulting in a 
‘clean’ form of cell death that has minimal impact on surrounding cells. This latter 
process is termed as efferocytosis (Ouyang et al., 2012, Saraste and Pulkki, 2000, 
Ziegler and Groscurth, 2004). This controlled process is in contrast to necrotic cell 
death, where swelling of the cell and blebbing result in the uncontrolled release of 
cellular content, which initiates an inflammatory response (Majno and Joris, 1995).  
To control the progression through apoptosis there exists a tightly regulated molecular 
machinery for the induction and execution of apoptosis. This can be triggered by 
various stimuli from outside or inside the cell, forming the extrinsic and intrinsic 
pathways, respectively. Stimuli that can induce apoptosis include DNA damage, lack 
of survival signals, and ligation of cell surface receptors, death signals or treatment 
with irradiation or cytotoxic drugs. It should be noted that apoptosis is not only a 
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survival response system, but is also critical for developmental processes, with a 
classical example of cells undergoing apoptosis being cells dying during the embryonic 
development of fingers (Haanen and Vermes, 1996).  
  
 
 
Figure 1-7: Morphological cell changes in apoptosis 
Morphological changes during apoptosis are characterized as cell shrinkage leading to nuclear 
condensation followed by membrane blebbing. This causes nuclear collapse and membrane 
disruption creating apoptotic bodies that are finally lysed by macrophages. 
 
 
 
30 
 
 
1.3.2.1.1 Pathways of Apoptosis 
 
As noted above, apoptotic pathways can be triggered by intrinsic or extrinsic stimuli. 
The signals that trigger the intrinsic factors include heat, radiation, viral infection and 
hypoxia. In contrast, activators of the extrinsic pathway include toxins, hormones, 
growth factors, nitric oxide or cytokines, which activate (either directly or indirectly) a 
death receptor and its ligand, for example the FAS ligand and its receptor. Upon 
binding of the receptor to its ligand, a conformational change occurs, transmitting the 
signal into the cell interior. These changes expose the death signalling domain to 
various intracellular proteins such as the FAS–associated death domain protein 
(FADD) for the FAS ligand. Similarly, tumour necrosis factor (TNF) interacts with the 
TNF receptor, activating intracellular proteins that initiate the apoptotic cascade 
(Elmore, 2007, Fuchs and Steller, 2011, Jacobson et al., 1997). 
The major differences between the intrinsic and extrinsic pathways are highlighted in 
figure 1-8. As can be seen, the pathways converge in the cell with the activation of a 
group of proteins known as the caspases.  
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Figure 1-8: Pathways of programmed cell death I 
The programmed cell death I pathway initiated by two intrinsic and extrinsic factors. The binding 
of death ligand to its receptor such as FASL to its receptor starts outside the cell, whereas the 
intrinsic is mediated through mitochondria.  
(Mitochondria snapshot : adapted from www.biologycorner.com) 
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Caspases are members of the interlukin-1β-converting enzyme family of proteases. 
To date fourteen caspases have been identified, out of which twelve have been 
identified in humans. All caspases share some common properties: they are all 
aspartate-specific cysteine proteases, and their precursors are all inactive zymogens 
known as procaspases. Caspases 2, 8, 9 and 10 are classed as apoptosis activators, 
caspases 3, 6 and 7 are classed as apoptosis executioners, while all other caspases 
are inflammatory mediators. The synthesis of caspases as inactive pro-caspases 
allows them to be quickly activated through post-translation modification (cleavage). 
In addition, as one active caspase protein can cleave multiple procaspase proteins, 
this allows an activation cascade that acts to amplify the signal rapidly. The cleavage 
of procaspases to caspases occurs through interactions with specific protein domains, 
namely the Caspase activation and recruitment domain (CARD) and the death effector 
domain (DED) (Boatright and Salvesen, 2003, Cohen, 1997, Duprez et al., 2009).  
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1.3.2.1.2 Extrinsic apoptotic pathway: 
 
The extrinsic apoptosis pathway allows the capture of signals from outside of the cell, 
allowing the cell to respond to its local environment. The central groups of proteins are 
the death receptors, membrane-bound receptors that are activated by so-called death 
ligands. Association of death ligands and receptors leads to the formation of a large 
complex containing pro-caspases and adaptor proteins, which is known as the death 
inducing signalling complex (Grunert et al., 2012). Formation of Death Inducing 
Signalling Complex (Grunert et al.) ultimately leads to the activation of procaspase–8, 
which triggers the downstream caspase activation cascade that ultimately leads to 
activation of the executioner caspase and precipitation of the apoptosis (Barnhart et 
al., 2003, Boatright and Salvesen, 2003, Cohen, 1997).  
There are numerous death ligands and receptors, such as (FAS/CD95 and FASL), 
tumour necrosis factor (TNF) receptor 1 (TNFR1) and TNF-related apoptosis-inducing 
ligand – Receptor and TNF-related apoptosis-inducing ligand (TRAIL-R and TRAIL). 
Upon binding of death ligands, the intracellular death domain of the death receptor 
interacts with an adaptor molecule known as Fas-associated death domain (FADD). 
This recruits caspases-8 and -10, which completes the death-inducing signal complex 
(Elmore, 2007, Grunert et al., 2012, Kruidering and Evan, 2000).  
It should be noted that there is cross-talk between extrinsic and intrinsic pathways, 
with caspase-8 and -10 able to activate the Bcl2-interacting domain (BID), a protein 
that once activated translocates into mitochondria and induces release of cytochrome 
c, a key marker for progression of the intrinsic pathway (Duprez et al., 2009, Shamas-
Din et al., 2011, Wang and Tjandra, 2013). 
34 
 
Due to the ability of the extrinsic pathway to respond to xenobiotic and precipitate cell 
death, it is an obvious target for therapeutic agents designed to be cytotoxic. Many 
anticancer drugs with different primary intracellular targets have also been shown to 
increase CD95 expression and stimulate the death receptor pathway (Friesen et al., 
1996, Fulda et al., 1997, Muller et al., 1998).  
 
1.3.2.1.3 Intrinsic apoptotic pathway: 
 
The intrinsic pathway does not depend upon external stimuli like death factors, but 
rather acts to measure the internal health of a cell, precipitating apoptosis if certain 
physiological bounds are breached. Here, mitochondria play a vital role in the initiation 
of this pathway, with a key trigger being a malfunction in cellular energy supply. When 
these physiological bounds are breached, mitochondria release various pro-apoptotic 
proteins that are normally encapsulated within intermembrane space, such as 
cytochrome c, apoptosis inducing factor (AIF) and second mitochondria-derived 
activator of caspases (Smac).  
One of the oldest described events during apoptosis, the release of cytochrome c from 
the mitochondria, occurs following opening of the permeability transition pore (PTP), 
a protein complex formed at the contact site between the outer and inner mitochondrial 
membrane. The PTP is opened due to a loss of mitochondrial membrane potential, 
mitochondrial matrix swelling and outer membrane rupturing releasing intermembrane 
proteins (Martinou and Youle, 2011, McBride et al., 2006, van Gurp et al., 2003). 
Beyond cytochrome c, the intrinsic pathway is highly regulated by members of the Bcl-
2 family of proteins called, which are located in the outer membrane of mitochondria. 
Two groups of Bcl-2 proteins have been identified, one promoting apoptosis, and the 
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other inhibiting cell death. Members of the apoptosis promoting group include Bax, 
Bak, Bcl-X5, Bcl-Gl and Bok. In contrast, anti-apoptotic Bcl-2 family members include 
Bcl-2, Bcl-XL, Bcl-W, and Induced myeloid leukemia cell differentiation protein -1 (Mcl-
1). An example fo the role of Bcl-2 family members in precipitating apoptosis can be 
seen following DNA damage. Immediately following DNA damage, Ataxia 
telangiectasia mutated (ATM) kinase is activated, which in turn activates both Bax and 
Bak, causing cell cycle arrest. Other pro-apoptotic Bcl-2 proteins, such as Bax, then 
bind to the PTP complex and induce its opening, which leads to the release of 
cytochrome c. On the other hand, the anti-apoptotic Bcl-2 proteins normally acts to 
prevent the opening of the PTP by binding to peripheral benzodiazepine receptors, 
thus protecting the cell from dying (Adams and Cory, 2007, Bargou et al., 1995, 
Breckenridge and Xue, 2004, Cohen, 1997, Crompton, 1999, Dewson and Kluck, 
2009, Gross et al., 1999, Kuwana and Newmeyer, 2003, Narita et al., 1998, Oltvai et 
al., 1993). 
As noted above, there is cross-talk between the intrinsic and extrinsic pathways, and 
this is mediated through a Bcl-2 family member, Bid (Duprez et al., 2009, Shamas-Din 
et al., 2011, Wang and Tjandra, 2013). 
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Hence, both the pro-apoptotic and anti-apoptotic families of Bcl-2 proteins control 
outer mitochondrial membrane permeability, but with their molecular roles being in 
opposing directions (Breckenridge and Xue, 2004, Kuwana and Newmeyer, 2003, 
Newmeyer and Ferguson-Miller, 2003, Taylor et al., 2008, Tsujimoto, 1998).  
Following its release from the mitochondria, cytochrome c binds to the cytoplasmic 
protein Apaf-1 via the C-terminal WD-40 repeat domain, which results in recruitment 
of pro-caspase-9 through homophilic association of the N-terminal CARDs (caspase 
recruitment domains) of pro-caspase-9 and Apaf-1. This forms the apoptosome, a 
quaternary complex consisting of caspase 9, BCL-XL binding to Apoptotic Protease 
Activating Factor 1 (APAF-1) protein (Cain et al., 2002).  
The apoptosome further activates caspase-9 as well as the rest of the effector caspase 
cascade in an adenosine triphosphate (ATP)-dependent manner. This leads to an 
increase in the number of executioner caspase proteins (i.e. caspase-9, -3, -6, and -
7).  Once caspase-3 is activated, a series of irreversible events occur that lead to the 
death of the cell, including activation of the CAD (Caspase-Activated DNase) 
endonuclease degrading the DNA and marked by Poly-ADP ribose cleavage (Figure 
1-9) (Boatright and Salvesen, 2003, Cohen, 1997). 
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Figure 1-9. Mitochondrial dependent cell death pathway 
Pro-apoptotic stimuli or release of apoptotic proteins; BAX induces mitochondrial outer 
membrane permeability and forms transition pores. Cytochrome c, APAF1 and caspase 9 forms 
apoptosome. Apoptosome further activates executioner caspase 3/7 which cleaves poly-ADP 
ribose, finally inducing cell death.  
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1.3.2.2 Autophagy 
Autophagy, or type II programmed cell death, is a process of intra-cellular digestion of 
cell components (Yu et al., 2006). It should be noted that the existence of autophagy 
is itself a matter of debate with regard to its distinction from apoptosis and necrosis. In 
studies undertaken so far, it is depicted as a death executing process that occurs in 
the presence of defective, or insufficient, apoptosis (Maiuri et al., 2007b). Autophagy 
has a crucial role in cell survival in terms of starved cells. The cancer cells use 
autophagy as a tool for cell survival and promote tumourigenesis but only in case of 
defective apoptosis system (Degenhardt et al., 2006). In some studies it is shown to 
induce cell death via mitochondrial damage (Kanzawa et al., 2005). In terms of 
defective apoptosis and autophagy, the metabolic stress from defective cells shifts 
towards necrosis.  
 
Although the exact molecular mechanisms are still under debate, autophagy can be 
generally divided into five phase: induction, elongation, engulfment, fusion and 
degradation. Induction of autophagy starts with the engulfment of cytosolic 
components by the phagophore, or isolation membrane. This membrane is elongated, 
allowing more cytosolic material to be engulfed and the formation of the double 
membrane autophagosome. In humans this induction process is initiated through m-
TOR inhibition and formation of a multiprotein complex comprising of beclin-1, UVRAG 
(UV irradiation resistance-associated tumour suppressor gene) and p150. Next, the 
elongation process occurs, which involves two  distinct processes: first, combination 
of  Atg12 to Atg5 with the E1- and E2-like enzymes, Atg 7 and 10 respectively; second, 
the conjugation of phosphatidylethanolamine (PE) and light chain microtubule-
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associated protein 1 (LC3-1). This latter process leads to the conversion of soluble 
LC3 (LC3-I) to an autophagic vesicle form (LC3-II), which is seen as classical marker 
of autophagy.  In the next stage of the process, fusion, further autophagosomes are 
made, and these fuse with lysosomes to form the autolysosome. Finally, these 
autolysosomes are degraded due to acidic nature of their internal environment (He 
and Klionsky, 2009, Levine and Yuan, 2005). (Figure 1-10)  
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1.3.2.3 Necrosis 
In comparison to apoptosis and autophagy, necrosis can be viewed as a non-
programmed or non-controlled form of cell death. The molecular stimuli that precipitate 
necrosis are wide ranging, but often include ATP depletion upon toxic exposure or 
physical damage to the cell. Necrosis is characterised by cytoplasmic vacuolation, 
plasma membrane breakage and induction of an inflammation due to the release of 
pro-inflammatory molecules by the necrotic cell (Festjens et al., 2006, Majno and Joris, 
1995). (Figure 1-11) In common with the less controlled plasma membrane alterations, 
cells dying through necrosis do not exhibit clean chromatin condensation and DNA 
fragmentation as seen in apoptosis (Krysko et al., 2006).   
 
Figure 1-11: Morphological features of necrotic cell death. 
Upon injury or toxic stress, the organelles swells and the chromatin disassembled within 
nucleus. This then form blebs followed by nucleus dismantle. Finally the cell ruptures releasing 
the cytosolic components and inducing inflammation.   
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1.4 Nuclear Receptors:  
Nuclear receptors (NRs) are a class of proteins that act as intracellular sensors for 
vitamins, hormones, dietary lipids and various xenobiotic stimuli. They are ligand-
activated transcription factors that bind DNA, recruit auxiliary proteins, and regulate 
the expression of specific genes; the effect of this gene regulation is to alter cellular 
physiology, helping to either maintain homeostasis or respond to environmental 
challenges. In addition to their ability to maintain homeostasis and regulate cellular 
metabolism, they also control many of the stages of organismal development (Escriva 
et al., 2000).  
NRs are the largest family of transcription factors in humans, comprising 48 members 
(Mangelsdorf et al., 1995). Despite their name, NRs may be localised in either the 
nucleus or cytoplasm in the absence of ligand; upon ligand binding, the NR goes 
through conformational changes, nuclear translocation if required, binding to specific 
response elements within the DNA, resulting in alteration of gene expression for the 
target gene set (Chawla et al., 2001, Mangelsdorf et al., 1995).  
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1.4.1 Nuclear Receptor Structure 
Nearly all nuclear receptors are typical in structure and exhibit the following common 
domains: (Figure 1-12) 
 
Figure 1-12: Structure of the nuclear receptor. 
N-terminal domain (A/B), DNA binding domain (C), hinge region (D), ligand binding domain (E) 
and C-terminal domain (F). 
 
The N terminal A/B domain contains the so-called activation function-1 (AF-1), a ligand 
independent activation domain, and is highly variable in sequence between different 
NRs. The C domain contains the DNA binding region (DBD), which is a highly 
conserved region containing two zinc finger motifs that are capable of binding to 
specific DNA sequences called hormone response elements (HRE). The DBD exhibits 
a high level of sequence similarity between different NRs, reflective of the relative 
similarity between HREs. Each hormone response element is composed of two half 
sites with the consensus sequence AG[G/T]TCA or AGAACA. The exact composition 
of these half sites, their orientation and their relative spacing confer specificity for each 
NR. For example, the nuclear receptor PXR most commonly recognises AGGTCA 
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HREs as either a direct repeat separated by 4 nucleotides (DR4) or an everted repeat 
separated by a six nucleotides (ER6) (Vyhlidal et al., 2004). In contrast, FXR 
recognises AGGTCA as an inverted repeat separated by a single nucleotide IR1 
(Laffitte et al., 2000). 
 
The hinge region (domain D) functions as a bridge between the DNA binding domain 
(DBD) and ligand binding domain (LBD) regions. Domain E, the LBD, is conserved in 
the C terminus region making an amphipathic helix structure, and shows the most 
sequence variability between NRS, determining ligand specificity. The E domain also 
contains the ligand-dependent activation function -2 (AF-2), which is alpha helical in 
structure. Upon binding with ligand, conformational changes occur within domain E, 
resulting in ‘trapping’ of the ligand within the LBD; these conformational changes also 
act to reveal nuclear translocation signals (if necessary) and increase DNA binding  
(Green and Chambon, 1988, Huang et al., 2010, McKenna and O'Malley, 2002). 
 
1.4.2 Types of Nuclear Receptors  
Nuclear receptors can be divided into four subgroups depending upon their 
mechanism of action, intracellular location, and binding properties with various ligands 
and DNA half sites (Mangelsdorf et al., 1995). 
Type – I NRs are found within the cytosol in the absence of ligand. Upon activation, 
they translocate to the nucleus and bind to DNA as dimers or monomers. Their default 
HREs exist as inverted repeats, separated by different numbers of nucleotides, 
although some examples of direct HREs have been identified. Examples of type I NRs 
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include members of the steroid hormone receptors: the androgen receptor, the 
glucocorticoid receptor, the ERs and the progesterone receptors.  
Type II receptors demonstrate a nuclear localisation in the absence of ligand. They 
bind as heterodimers to DNA; in the absence of ligand in a complex with corepressor 
proteins, which are replaced by coactivator proteins upon ligand binding; for example 
steroid receptor coactivators 1, 2 and 3 (SRC-1, SRC-2 and SRC-3) that have histone 
acetytransferase (HAT) activity promoting transcription. Examples of type II nuclear 
receptors include the Retinoic Acid Receptor (RAR), the Thyroid Hormone Receptor 
(TR) from subfamily1, the Hepatocyte Nuclear Factor-4 (HNF-4), the Retinoid X 
Receptor (RXR), and the Testicular Receptor 2 and 4 (TR2/4).  
Type III nuclear receptors bind to DNA as homodimers similar to type I receptors, 
differing only in binding to direct repeat rather than inverted repeats of HREs. 
Examples of type III nuclear receptors are the Chicken ovalbumin upstream promoter 
transcription factor-1 (COUP-TFI), -2 (COUP-TFII), and V-erbA-related protein 2 
(EAR2). 
Type IV nuclear receptors bind either as monomers or as dimers to DNA, with each 
NR interacting with a single half site HRE. Examples of type IV nuclear receptors, are 
the Nerve Growth Factor IB-like (NGF-IB) and the Neuron Derived Orphan nuclear 
receptor 1 (NOR1) (Chawla et al., 2001).  
In addition to classification by their nuclear localisation and DNA binding 
characteristics, NRs are often classified by their ligands. For example, the steroid 
hormone receptors are those NRs with endogenous ligands such as estrogen 
(Estrogen receptor; ER), glucocorticoids (glucocorticoid receptor; GR) or testosterone 
(androgen receptor; AR). In contrast, NRs are called orphan receptors because their 
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endogenous ligand is unknown (Giguere, 1999). Out of 48 known members of human 
nuclear receptor superfamily, 25 were considered as orphan nuclear receptors. 
Discovery of their endogenous ligands some have been now adopted and termed as 
adopted orphan nuclear receptors. These are retinoid X receptor (RXR), farnesoid X 
receptor (FXR) and peroxisome proliferator-activated receptors (PPAR’s), pregnane 
X receptor (PXR), liver X receptor (Blumberg and Evans, 1998, Chawla et al., 2001).  
The ability of NRs to bind to specific nucleotide sequences within the promoter and 
enhancer regions of target genes allows them to regulate expression of wide range of 
genes. They can thus participate in regulating large networks of signalling pathways, 
thus maintaining cellular homeostasis. 
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1.4.3 Nuclear Receptors and Breast Cancer 
Given the role of NRs in maintaining normal cellular functioning, it is perhaps not 
surprising that their altered expression has been noted in a number of disease states, 
including cancer. Indeed, NR expression in breast cancer forms the primary basis for 
determining therapeutic treatments for non-metastatic and metastatic cancer cases; 
tumours are phenotyped for ER, PR and Her2.  
1.4.3.1 The Estrogen receptor  
The targeting of NR functionality for the treatment of breast cancer was first posited in 
the 19th century. Removal of ovaries from young women with breast cancer was shown 
to promote tumour repression by Sir Thomas Beatson in 1896. This was later shown 
to be due to the marked reduction in circulating estrogens following ovarectomy; 
estrogens are one of the most significant regulators for growth, differentiation and 
functions in most tissues, and activate two NRs, estrogen receptors (ER) α and β, 
which display specific biological functions. ERα is predominately expressed in the 
breast, uterus, cervix and vagina, while ERβ expression is limited to the ovary, 
prostate, testis, spleen, lung, thymus and hypothalamus. Estrogens also play an 
important role in fat deposition, which may explain the fact that obesity has been seen 
to play a role in increased risk of breast cancer particularly for postmenopausal women 
(Hunter and Willett, 1993, Lukanova et al., 2004). Nearly 70% of breast cancer cases 
overexpresses ERα, and are thus considered as ER-positive (Althuis et al., 2004). 
Slowing or inhibiting breast tumour growth can be achieved by interfering with the 
estrogen signalling process. Compared with ER negative tumours, ER positive 
tumours shown better clinical response and are associated with improved patient 
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prognosis (Allegra et al., 1980). The basal-like subtype of breast cancer accounts for 
15% of cases, and are estrogen, progesterone and Her-2 negative. They are 
associated with poor prognosis and are highly aggressive tumours (Diep et al., 2015, 
Livasy et al., 2006). Two treatment therapies were developed for estrogen positive 
breast cancer cases, selective estrogen receptor modulators (SERMs) and aromatase 
inhibitors (Berry et al., 2006). Tam is the archetypal SERM, and acts by inhibiting the 
binding of estrogen to the ER thus disrupting the signalling process (Jordan, 1993, 
Jordan, 2003). In contrast, aromatase inhibitors such as anastrozole prevent the 
production of estrogen in the body by blocking aromatase activity, a key step in 
estrogen biosynthesis (Mokbel, 2002).  
1.4.3.2 The Progesterone receptor  
Another important receptor that plays a role in breast cancer is the progesterone 
receptor (PR).  PR exists in humans as three isoforms (PR-A, PR-B and PR-C), with 
PR-A and PR-B the more prominent. PR controls female reproductive tract cell 
proliferation and differentiation. The exact prognosis associated with PR status is 
controversial, but lack of PR is generally seen as a poor prognosis marker. Patients 
with a low ratio of PR-A to PR-B shown higher resistance towards anti-estrogen 
treatment, due to the fact that PR-A supresses the activity of ER and dominates the 
activity of the PR-B isoform (Dowsett et al., 2001). In addition, another study showed 
that PR negative tumours also tended to have higher expression of Her-2 and EGF-1, 
which may be responsible for chemoresistance (Arpino et al., 2005). In contrast, PR 
may play a protective role as well as activation of the receptor can induce apoptosis 
in ovarian cancers (Fauvet et al., 2006) and recent reports have suggested that PR 
expression in ER negative breast cancer does not associate with poor prognosis (Hefti 
et al., 2013). 
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1.4.3.3 The Androgen receptor  
Beyond ER, PR and Her2, another NR has been associated with breast cancer 
development. The androgen receptor regulates critical pathways for development of 
male primary sex organs, but also plays role in female development and in maintaining 
the normal ovulation cycle (Walters et al., 2010).  It has been found to be 
overexpressed in nearly half of ER negative breast cancer cases and up to 90% in ER 
positive tumours (Agoff et al., 2003).  
Cortisol has been suggested to aid breast cancer cell survival and proliferation, which 
may contribute to cancer cells invasion and metastasis. Cortisol is an endogenous 
ligand for the glucocorticoid receptor (GR) and was identified first from the breast 
cancer cell line MCF-7 (Govindan et al., 1985). This receptor has five isoforms, but 
only the α isoform is worthy of note, being responsible for the majority of transcriptional 
activity. Studies have shown that nearly 50% of invasive type breast cancer express 
this receptor (Horwitz et al., 1978), as do the triple positive MCF-7 and triple negative 
MDA-MB-231 cell lines.  Glucocorticoids play a negative role in breast cancer by 
promoting cell survival and proliferation through the GR-mediated activation of anti-
apoptotic genes such as Bcl-Xl and bax. In addition, GR activation prevents cell death 
by stimulating the degradation of p53 as a further anti-apoptotic function (Moll et al., 
1992). This anti-apoptotic effect has been shown to inhibit the effects of certain cancer 
chemotherapeutics in vitro (Wu et al., 2004).  
1.4.3.4 Glucocorticoid receptor  
In contrast to the established roles of GR-mediated effects in promoting tumour 
survival and growth, glucocorticoids may also play an important therapeutic role in 
treating breast cancer: promoting chemosensitivity. Activation of GR by 
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glucocorticoids has been show to increase the cellular uptake of certain 
chemotherapeutics, including carboplatin and gemcitabine, improving anti-tumour 
response (Lu et al., 2006). The mechanism of action for this effect is down regulation 
of NF-kβ avoiding drug resistance.  Other studies have revealed the importance of a 
number of other nuclear receptors in breast cancer development and treatment. These 
include other steroid receptors, such as the retinoic acid, retinoid X receptors, and 
vitamin D receptors that bind fat soluble vitamins and orphan nuclear receptors 
(Chawla et al., 2001).  
1.4.3.5 The Retinoic acid receptor/Retinoid X receptor  
The retinoic acid receptors exist as three isoforms in humans, namely RARα, β and γ. 
They are all activated by all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid, although 
with differing affinities. Retinoid have been shown to stimulate the induction of cell 
cycle inhibitors such as p21 and p27, causing both proliferation arrest and apoptosis 
in human breast cancer cell lines (Toma et al., 1998). Likewise, studies have shown 
that 9-cis-RA induces growth arrest in ERα-positive cell lines through down-regulation 
of Cyclin D1 and D3 (Maeng et al., 2012). This is consistent with the observation that 
RAR isoforms are silenced or down regulated in most breast cancer cell lines, 
effectively removing this cellular brake on proliferation. Activation of RAR isoforms with 
ATRA has proved to be ineffective in patients having advanced metastatic breast 
cancer, suggesting that RAR isoforms are also silenced in vivo. How RAR isoforms 
are silenced during the process of carcinogenesis is still a question to be addressed 
(Widschwendter et al., 1997). RAR dimerises with RXR, another distinct family of 
retinoid receptors, the retinoid X receptors, also play an anti-proliferative role in breast 
cancer (Crowe and Chandraratna, 2004).  The RXRs (α, β and γ) are also activated 
by 9-cis retinoic acid, and act as obligate heterodimerisation partners for a range of 
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NRs, including PXR, FXR and VDR. Activation of RXR by bexarotene, a synthetic RXR 
ligand, has been shown to inhibit cancer cell growth in both estrogen positive and 
negative cell lines (Esteva et al., 2003).  
1.4.3.6 The Vitamin D receptor 
Vitamin D intake is inversely correlated to the risk of breast cancer. Vitamin D3 active 
metabolite 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is degraded in breast tissue 
through the catalysis of vitamin D 24-hydroxylase. 1,25(OH)2D3 has been shown to 
reduce breast cancer cell growth is studies done so far (Welsh et al., 2003). A study 
done by Mantell et al. (2000), showed that it inhibits angiogenesis in nude mice 
overexpressing VGEF MCF-7 xenograft. Also, the breast cancer cell lines, MCF-7 and 
BT-20 showed reduced proliferation upon 1, 25(OH)2D3 treatment (Saez et al., 1993). 
These studies showed the protective role of vitamin D in breast cancer. 
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1.5 The Farnesoid X Receptor (FXR) 
 
 The farnesoid X receptor belongs to the nuclear receptor family of ligand-activtated 
transcription factors. It is an adopted orphan NR, having been originally shown to bind 
the acyclic sesquiterpene Farnesol, which is a natural plant product, but later found to 
also be activated by endogenous bile acids (Forman et al., 1995, Makishima et al., 
1999, Parks et al., 1999). There are two FXR genes: FXRα and FXRβ. FXRβ is a 
pseudogene (non-functional) in humans, but functional in rodents, rabbits and dogs, 
representing an important species difference. For the purpose of this review, which is 
human-centric, only FXRα will be considered. 
The FXRα gene maps to 12q23.1 in humans and is composed of 11 exons and 10 
introns. It is highly conserved across the majority of mammals, and encodes a protein 
product that is highly expressed in liver, intestine, kidney and adrenal gland. Four 
isoforms of FXRα can be produced through alternative splicing; FXRα1, FXRα2, 
FXRα3 and FXRα4, with all isoforms being detected in both humans and mice (Huber 
et al., 2002, Zhang et al., 2003). These four isoforms differ at their amino terminus 
through four amino acids (MYTG) linked to the DNA binding domain region. FXRβ2 
isoform that do not contain the four amino acid insertions possess higher affinity 
binding to the FXR response elements and more strongly transactivate target genes 
such as intestinal bile acid binding protein (IBABP) (Grober et al., 1999).   
FXR is a type-II NR, in that in the absence of ligand FXR is located in the nucleus, 
where it occupies the HRE of its target genes as a heterodimer with RXR and 
complexed with corepressor proteins The FXR-RXR heterodimer binds to IR1 inverted 
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repeats in the regulatory region of target genes with high affinity (Mangelsdorf et al., 
1995). Upon activation by ligand, there is a conformational change that results in the 
release of corepressor proteins such as nuclear receptor co-repressor (NCoR) and 
recruitment of coactivator proteins such as steroid receptor coactivator (SRC-1) and 
coactivated associated arginine(R) methyl transferace-1 (CARM-1) (Pascual et al., 
2005). 
1.5.1 Activators of FXR 
As noted above, FXR is an adopted orphan NR, with bile acids being the known 
endogenous ligand. Bile acids are the end products of cholesterol metabolism, and 
can be subdivided into primary and secondary bile acids. Primary bile acids include 
chenodeoxycholic acid (CDCA) and cholic acid (CA) and are synthesized from 
cholesterol in the liver. The secondary bile acids include deoxycholic acid (DCA) and 
lithocholic acid (LCA), which are derived from primary bile acids through metabolism 
by intestinal bacteria (Chiang, 2004). The vast majority of bile acids (approximately 
70%) are reabsorbed from the ileum by the action of the apical sodium dependent bile 
acid transporter (ASBT) (Grober et al., 1999, Kramer et al., 1998), with the remaining 
30% entering the colon where they are converted to secondary and tertiary bile acids. 
To maintain the bile acid pool de novo synthesis of primary bile acids from cholesterol 
occurs in the liver (Wang et al., 1999). In the body, bile acids perform two important 
functions; first, they are the major catabolic route for the breakdown of cholesterol; 
second, the amphipathic nature of bile acids means that they form micelles in the 
intestine, which is critical for enhanced solubility of lipids during faecal elimination. 
Due to their detergent-like properties, bile acids are cytotoxic if present at high 
concentrations, have been shown to be toxic to the liver and contribute to insulin 
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resistance in vivo (Lefebvre et al., 2009, Wei et al., 2009). They cause increased 
oxidative stress, progressing the liver along a disease spectrum that can, ultimately, 
lead to hepatocarcinoma. FXR is primarily activated by primary bile acids such as 
chenodeoxycholic acid (CDCA). CDCA has been shown to be the most potent 
endogenous FXR activator with Kd nearly 14µM (Makishima et al., 1999, Parks et al., 
1999). More potent and specific synthetic ligands for FXR have been developed, such 
as GW4064 (EC50 = 90nM) (Maloney et al., 2000).  
 
1.5.2 FXR in bile acid metabolism 
 
FXR regulates the expression of genes involved in bile acid metabolism and transport 
(see Figure 1-13). 
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FIGURE 1-13. FXR regulates bile acid metabolism 
FXR plays vital role in regulating bile acid. FXR activates its target small heterodimer partner 
and downregulates the CYP7A1, a key enzyme required for cholesterol synthesis. FXR involved 
in transport of bile acids to gall bladder through BSEP and blocks the uptake by downregulating 
NTCP. Also, FXR downregulates ASBT and reduces the bile acid absorption. The bile acid pool 
is maintained via recycling of bile acids to liver through OSTα and OSTβ. In addition, FXR 
promote release of FGF19 in humans from the intestine which prevents bile acid synthesis via 
reduction in CYP7A1 expression. 
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FXR represses the cholesterol pathway indirectly by inducing gene expression of 
nuclear receptor, small heterodimer partner SHP. Activation of FXR leads to up-
regulation of small heterodimer partner (SHP) inhibiting Trans-activation of CYP7A1 
by binding to liver receptor homolog (LRH-1). Also, FXR inhibited RXR/RAR 
transactivation of NTCP promoter via SHP induction (Chiang et al., 2000, Goodwin et 
al., 2000). Activation of bile acid efflux increases expression of transporters such as 
bile salt export pump (BSEP) (Ballatori et al., 2005, Lee et al., 2006b); downregulates 
intestinal bile acid uptake transporters, including the apical sodium-dependent bile salt 
transporter (ASBT) (Landrier et al., 2006, Lee et al., 2006b). In a study in rats. FXR 
also induces fibroblast growth factor -19 (FGF-19) expression and represses CYP7A1 
via c-Jun N-Terminal kinase pathway. FXR also downregulates CYP7A1 through the 
fibroblast growth factor 15 - JUN N-terminal kinase (FGF15-JNK) cascade in mouse 
and fibroblast growth factor 17- JUN N-terminal kinase (FGF17-JNK) in humans (Kong 
et al., 2012). In addition, FXR also regulates two enzymes bile acid CoA synthase 
(BACS) and bile acid CoA-amino acid N-acetyltransferase (BAAT) that are involved in 
conversion of bile acids to bile salts before entering the gall bladder (Pircher et al., 
2003). Also, murine FXR knockout studies demonstrated that loss of the receptor 
resulted in deregulated bile acid pools and significant pathology (Sinal et al., 2000). 
Thus, indicating FXR role in bile acid homeostasis. FXR target genes regulation is 
summarized in the table 1-3.  
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Table 1-3 FXR target genes 
 
TARGET GENE  ORGAN UPREGULATION + / 
DOWNREGULATION  -   
SHP Mainly liver + 
SULT2A1 LIVER (Hepatocyte) + 
UGT2B4 LIVER (Hepatocyte) + 
CYP3A4 LIVER (Hepatocyte) + 
BACS LIVER (Hepatocyte) + 
BAAT LIVER (Hepatocyte) + 
MDR2 LIVER (Hepatocyte) + 
MDR3 LIVER (Hepatocyte) + 
CYP7A1 LIVER (Hepatocyte) _ 
CYP8B1 LIVER (Hepatocyte) _ 
OATP LIVER (Hepatocyte) _ 
NTCP LIVER (Hepatocyte) _ 
BSEP LIVER (Hepatocyte) + 
ASBT INTESTINE (Enterocyte) _ 
OSTα INTESTINE (Enterocyte) + 
OSTβ INTESTINE (Enterocyte) + 
FGF15 INTESTINE (Enterocyte) + 
FGF19 INTESTINE (Enterocyte) + 
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1.5.3 FXR in lipid and glucose metabolism  
In addition to regulation of bile acid levels in the body, FXR has been shown to be 
involved in the regulation of triglyceride and lipid metabolism. For example, a study 
undertaken by Ma et al. (2006) showed an increase in plasma cholesterol and 
triglyceride levels in FXR null mice as compared to wild type. FXR has been shown to 
regulate apoc2 expression, a cofactor for lipoprotein lipase, the enzyme responsible 
for the hydrolysis of triglycerides into fatty acids (Kast et al., 2001). Another important 
function of FXR is to induce the expression of peroxisome proliferator- activated 
receptor α (PPARα) and its target genes, which are also predominantly involved in 
fatty acid metabolism (Fiorucci et al., 2005, Pineda Torra et al., 2003). The plasma 
levels of triglycerides are maintained at their lower levels by negative regulation of 
Apoc3 via FXR (Claudel et al., 2003). However, FXR activation does negatively 
regulate the expression of other genes involved in lipid metabolism such as PLTP and 
APOE, both of which are involved in triglycerides reduction (Lee et al., 2006a, 
Watanabe et al., 2004).  
Finally, FXR has also emerged as an important factor in influencing the glucose 
metabolism (Cariou et al., 2005, De Fabiani et al., 2003). Glucose serves as an energy 
source for the body through its catabolism during glycolysis and the ultimate 
production of adenosine triphosphate (ATP). FXR shown to induce the expression of 
AKR1B7 gene that are involved in detoxification of bile acids (Schmidt et al., 2011). 
Also, activated FXR represses the transcription of glucose-6-phosphatase (G6PC) in 
vitro, involved in the transport of glucose through basolateral membrane to portal veins 
(Stumpel et al., 2001, Yamagata et al., 2004). Apart from the role in maintaining bile, 
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triglyceride and glucose metabolism, a novel role of FXR in cancer has recently been 
reported (Discussed in section 1.6).  
 
1.6 FXR and Cancer. 
Uncontrolled cell division and disruption of apoptosis is associated with a number of 
chronic liver diseases, including cholestasis, cirrhosis, and liver cancer. Hepatocellular 
carcinoma (HCC) is one of the most common forms of cancer in the world. 
Deregulated liver regeneration forms a part of a general mechanism of 
hepatocarcinogenesis, resulting from uncontrolled proliferation because of chronic 
injury. The resultant hepatocyte proliferation and liver regeneration is a trigger for 
hepatocarcinogenesis, and can be caused by an excess of bile acids (Barone et al., 
1996). The key role of FXR in this process has been shown by FXR knockout mice, 
which shown impairment of liver regeneration, have chronically high levels of 
circulating bile acids, and spontaneously develop HCC between 12-15 months of age 
(Wang et al., 2013, Yang et al., 2007).  
FXR (through its regulation of bile acids) has been demonstrated to play a role in liver 
regeneration and HCC; essentially, a lack of FXR-mediated regulation of bile acid 
metabolism can precipitate bile acid build-up, cholestasis, cell damage and repair, 
which act as non-genotoxic mechanisms for carcinogenesis. However, it is not clear if 
FXR also has a role in other cancers. The strongest evidence exists for colorectal 
cancer. Epidemiological studies have shown that a high fat diet increases the risk of 
colorectal cancer, possibly by increasing the levels of bile acids through cholesterol 
catabolism. Loss of FXR functionality has also been shown to promote colorectal 
cancer susceptibility in mice (Yang et al., 2007). The reason for this is that FXR is able 
to reduce proliferation and promote apoptosis in colorectal cancer cells through 
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increases in expression pro-apoptotic genes, including secretion of p21, Bcl-2 
antagonist killer 1 (BAK-1), FAS and FAS-associated death domain (FADD) (Lax et 
al., 2011, Modica et al., 2008). Likewise, transfection of a constitutively active form of 
FXR (AdVP16FXR) caused apoptosis in colon cancer cells (Modica et al., 2008). Such 
data, therefore, supports the potential role of FXR in a protective function in at least 
one other cancer type.  
 
1.6.1 FXR and Breast Cancer 
High fat diets and obesity have already been established as high risk factors for breast 
cancer. FXR has been shown to be expressed in normal and cancerous breast tissue 
and in human breast cancer MCF-7 and MDA-MB-468 cells (Swales et al., 2006). It 
can be hypothesised that a high fat diet may in turn lead to an increased bile acid pool, 
and thus FXR activation in breast tissue. In breast cancer cell lines, FXR activation by 
CDCA or GW4064, resulted in SHP gene transcription, inhibition of aromatase 
expression and induction of apoptosis (Swales et al., 2006). However, the molecular 
mechanisms underlying these findings are still not clear. Journe et al. (2008) on the 
other hand showed that MCF-7 cell growth was stimulated by one of the intermediates 
of mevalonate pathway, farnesol, through an FXR-dependent activation of the ER. A 
study undertaken by Giordano et al. (2011), showed that growth inhibition of tam-
resistant breast cancer cells resulted upon treatment with the FXR ligand GW4064 
and CDCA, but the mechanism is unclear. Another study suggested a mechanism by 
which FXR could promote apoptosis in HeLa cells is through regulation of miR-206 
expression and blocking of Notch3 expression, an anti-apoptotic protein (Song et al., 
2009). The findings could not delineate the exact role of FXR in cancer progression, 
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therefore it important to elucidate its role in cancer aetiology and look for prospective 
therapeutic role. 
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2.0 Hypothesis, Aims and Objectives 
2.1 HYPOTHESIS:  
The study was undertaken to test the hypothesis that activation of FXR has a cytotoxic 
ability in vitro and synergises with currently used anti-cancer agents in breast cancer. 
2.2 Objectives 
Objective 1: Study the expression of FXR in breast cancer cell lines 
 Treat breast cancer cell lines with FXR ligands and measure the expression of 
FXR. 
Objective 2: Measure the effects of FXR ligands on cell viability. 
 Treat breast cancer cell lines with FXR ligands natural CDCA and synthetic 
GW4064 for 24 hours and measure the effects of FXR activation on cell 
viability by MTT assay. 
Objective 3: Measure the effects of FXR ligands on protein levels of PARP, 
cytochrome c, Bax, Bcl2 and SHP. 
 Treating model cell lines, MDA-MB-231 and MCF-7 with FXR ligands CDCA 
and GW4064 for 24 hours and preparing protein extracts and measure them 
by Western blotting. 
Objective 4: Measure the effects of FXR ligands on caspase and ROS activity. 
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 By chemiluminescence based assay, caspase 3/7, caspase 8, caspase 9 and 
H2O2 (Reactive Oxygen Species) activity was measured upon FXR ligands 
treatment in model cell lines. 
Objective 5: Measuring the effects of FXR ligands on cell survival 
 Performing the clonogenic assay on breast cancer cell lines MCF-7 and MDA-
MB-231. Treating breast cancer cell lines with FXR agonist GW4064, tam 
alone and in combination for one hour and incubating them for 12 days and 
measure cell proliferation and synergy.   
Objective 6: Measuring the synergistic effects of FXR ligands and anti-cancer drugs 
on breast cancer cell lines. 
 Treating breast cancer cell lines with different concentrations of FXR ligands, 
tam and in combination. Measure the cell viability by MTT assay and study 
interaction between GW4064 and tam.   
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CHAPTER 3 
MATERIALS & METHODOLOGY 
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3.1. MATERIALS 
Unless otherwise stated all materials were from Sigma-Aldrich (Poole, UK) and were 
of molecular biology grade. 
Table 3-1 
Materials Supplier 
Cell Lines 
MCF-7 European Collection of Cell Cultures 
(ECACC) 
MDA-MB-231 European Collection of Cell Cultures 
(ECACC) 
HepG2 European Collection of Cell Cultures 
(ECACC) 
ARPE-19 American Type Culture Collection 
(ATCC) 
Drugs Used 
GW4064 Tocris Biosciences, Abingdon, UK 
Chenodeoxycholic Acid (CDCA) Sigma-Aldrich, Poole, UK 
Staurosporine  Calbiochem by Merck Millipore, 
Nottingham, UK 
Fas Ligand human (FasL) Sigma-Aldrich, Poole, UK 
Tamoxifen Sigma-Aldrich, Poole, UK 
Menadione Sigma-Aldrich, Poole, UK 
Caspase 3/7 Inhibitor Ac-DEVD-
CHO 
Promega, Southampton, UK 
Caspase 9 Inhibitor Ac-LEHD-CHO Sigma-Aldrich, Poole, UK 
Caspase 8 Inhibitor Ac-IETD-FMK Sigma-Aldrich, Poole, UK 
Cell Culture 
T25, T75 and T150 culture flask Sigma-Aldrich, Poole, UK 
Nunc ™ 96 Well Plate Polystyrene 
Cell Culture Clear  
Thermo scientific, IL, USA 
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Nunc™ F96 MicroWell™ White 
Polystyrene Plate 
Thermo scientific, IL, USA 
Sterile pipettes (1, 5, 10, 25 and 50 
ml) 
Sarstedt, Numbrecht, Germany 
Dulbecco’s Modified Eagle’s 
Medium 
Sigma-Aldrich, Poole, UK 
Fetal Bovine Serum Thermo Scientific, IL, USA 
Antibiotic-Antimycotic (100X) Thermo Scientific, IL, USA 
Caspase assay 
Capase 3/7 glo kit Promega, Southampton, UK 
Caspase 9 glo kit Promega, Southampton, UK 
Caspase 8 glo kit Promega, Southampton, UK 
ROS assay  
ROS-Glo H2O2  kit Promega, Southampton, UK 
Protein extraction and measurement 
Protease Inhibitor Tablets  Roche, Lewes, UK 
Mitochondria Isolation Kit for 
Cultured Cells 
Thermo Scientific,IL, USA 
bicinchoninic acid assay kit  Thermo Scientific,IL, USA 
Western Blotting  
Spectra Multicolour Broad Range 
Protein ladder 
Fermentas, Loughborough, UK 
Acrylamide stock solution 40% 
Bisacrylamide stock solution 2% 
VWR, Lutterworth, UK 
4–20% Mini-PROTEAN® TGX™ Gel Bio-Rad, Hertfordshire, UK 
Hybond-C Extra Nitrocellulose 
Membrane 
GE Healthcare, Buckinghamshire UK 
Microporous PVDF Western 
Blotting Membrane (0.45μm) 
Roche, Lewes, UK 
Dried Skimmed Milk Marvel, Dublin, Ireland 
Pierce SuperSignal West pico 
chemiluminescent Kit 
Thermo scientific, IL, USA 
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Developer, Fixer, Hardener Champion Photochemistry, Essex, 
UK 
Restore Western Blot Stripping 
Buffer 
Thermo Scientific, IL, USA 
X-Ray Film Thermo scientific, IL, USA 
Primary antibodies (anti-FXR, anti-
Cytochome C, anti-BAX, anti-Bcl2, 
anti-SHP) 
Santa Cruz Biotechnology, CA, USA 
Anti-PARP, anti-LC3 primary 
antibodies 
Cell Signalling by New England 
Biolabs, Hertfordshire, UK 
Anti β-Actin primary antibody Sigma-Aldrich, Poole, UK 
Secondary antibodies Santa Cruz Biotechnology, CA, USA 
IRDye® 800CW Goat anti-Rabbit 
IgG (H + L), IRDye® 680RD Goat 
anti-Mouse IgG (H+L) (Li-Cor #926-
68070) 
Li-Cor Biotechnology, Cambridge, UK 
  
 
TABLE 3-2 SOFTWARES USED 
SOFTWARE SUPPLIER 
Image J Wayne Rasband, NIH, Maryland, 
USA 
GraphPad PRISM v6.0 GraphPad Software Inc. California, 
USA 
Image Studio™ Software v5.0 LI-COR Inc.  Lincoln, US 
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3.1.1. Reagents Used in this study: 
Solutions and Buffers: 
 
Phosphate Buffer Saline (PBS): 
To prepare 1X PBS, one tablet of 5 X was dissolved in 100 ml of RO water and 
autoclaved. Kept at room temperature. 
Cell culture medium: 
Dulbecco’s Modified Eagles Medium (DMEM) was supplemented with 10% (v/v) Fetal 
Bovine Serum (Thermo Scientific) and 1 X antibiotic/antimycotic (Thermo Scientific). 
Stored at 4OC. 
 Cell dissociation medium: 
Trypsin EDTA (0.5 % trypsin, 0.2 % EDTA) 10 X was diluted to 1 X with PBS. This is 
then used in cell culture for trypsinization. Stored at 4OC. 
Cell Viability assay solution: 
To perform MTT assay, 0.002g tetrazolium dye MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide was dissolved in 1ml of DMEM without Fetal Bovine 
Serum or antibiotic. Prepared fresh each time. 
Radio immunoprecipitation assay buffer: 
Radio immunoprecipitation buffer (RIPA) is a general buffer used for the extraction of 
proteins from biological samples. To prepare, 200μl Igepal CA-630, 100mg sodium 
deoxycholate, and 20mg SDS were dissolved in 20ml PBS. One protease inhibitor 
tablet (Roche) was added to 10ml RIPA, which was aliquoted into eppendorf tubes 
and stored in -20OC.  
Tris Buffer Saline 10x (concentrated): 
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Tris base (24.23g) and NaCl (80.06 g) was mixed in 800 ml RO water. The pH was 
adjusted to 7.6 with pure HCl and finally topped up to 1L. Stored at 4OC. 
10% SDS: 
One times SDS was prepared by dissolving 1g of SDS to 10 ml of RO water. Kept at 
room temperature. 
PBS-T: 
Phosphate buffer saline-Tween was prepared by mixing 720µl of Tween-20 to 200ml 
of PBS. Kept for stirring and stored at room temperature. 
10X SDS-PAGE electrophoresis running buffer: 
Ten times stock was prepared by mixing Tris-HCl (30.28g of 250mM), Glycine (144g 
of 1.92M) and 10g of 1%SDS dissolved in 1L RO water. Adjusted to pH 8.3. Kept at 
RT. 100ml of 10X running buffer added to 900ml of RO water to prepare 1X running 
buffer, and stored at 4OC. 
Transfer buffer: 
Ten times stock was prepared by adding 18.8g Tris base (Fisher Scientific) and 90g 
Glycine (Fisher Scientific) 90g to 1L water. The resultant solution was corrected to 
pH 6.8 with HCl and then stored at room temperature. One times transfer buffer was 
prepared by mixing 100ml of 10X transfer buffer, 200ml methanol and 700ml water. 
10% Blocking Solution: 
Dissolve 1g Marvel dry milk powder to 10ml PBST. Prepared fresh each time. 
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The drugs are reconstituted as given in table 3-3. 
TABLE 3-3 Drug Reconstitution 
 
 
 
 
 
 
 
 
 
 
Antibodies used in this study are given in table 3-4 
TABLE 3-4 Antibodies with their respective concentrations used: 
 
Primary Antibodies Used 
Concentration 
(dissolved in PBST) 
FXR Rabbit polyclonal IgG (Santacruz 
biotechnology #sc-1204) 
1:500 
PARP Rabbit polyclonal IgG (Cell Signaling #9542)  1:1000 
Cytochrome C Rabbit polyclonal IgG (Santacruz 
biotechnology #sc-7159) 
1:500 
Bax Rabit polyclonal IgG (Santacruz biotechnology 
#sc-493) 
1:250 
Drugs used Stock solution 
GW4064 (Tocris Biosciences) 30mM in DMSO 
CDCA  300Mm in DMSO 
Staurosporine (Calbiochem) 1mM in DMSO 
FASL 10mM in DMSO 
Tamoxifen 10mM in Ethanol 
Menadione  10mM in DMSO 
Doxorubicin Hydrochloride (Abcam) 1mM in DMSO 
Caspase 3/7 Inhibitor Ac-DEVD-CHO (Promega) 10mM stock 
Caspase 9 Inhibitor Ac-LEHD-CHO 10mM in DMSO 
Caspase 8 Inhibitor Ac-IETD-FMK 10mM in DMSO 
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Bcl-2 Mouse monoclonal IgG (Santacruz 
biotechnology #sc-7382) 
1:250 
LC3 antibody (Cell Signaling #2775) 1:1000 
SHP antibody (Santacruz biotechnology #sc-15283) 1:100 
Anti-β-actin mouse monoclonal IgG (Sigma-Aldrich 
#A2228) 
1:1000 
 
Secondary antibodies used Concentration 
(dissolved in PBST 
with 5% non-fat 
milk) 
Goat anti-mouse IgG-HRP (Santacruz 
biotechnology # sc-2031) 
1:10000 
Goat anti-rabbit IgG-HRP (Santa-cruz biotechnology 
#sc-2030)  
1:10000 
IRDye® 800CW Goat anti-Rabbit IgG (H + L) (Li-
Cor #926-32211) 
1:10000 
IRDye® 680RD Goat anti-Mouse IgG (H+L) (Li-Cor 
#926-68070) 
1:10000 
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3.2 METHODS 
 
3.2.1 Freezing and Thawing of cell lines: 
Mammalian cell lines can be stored in liquid nitrogen for many years without loss in 
viability. To ensure cell integrity, cells are stored in solutions containing anti-freezing 
chemicals such as Dimethyl sulfoxide (DMSO). To store cells in liquid nitrogen, cells 
were spun down at 300 x g in medium for 3 minutes at room temperature. Medium 
was then aspirated from the pelleted cells and resuspended in freezing medium (90% 
medium and 10% DMSO) and transferred to cryovials. These cryovials were then kept 
in -80OC for at least 24 hours before transferring to liquid nitrogen. 
To recover frozen cells from cryostorage, the cell suspension was defrosted at room 
temperature. Next, cells were decanted into 10ml of fresh medium to dilute the DMSO 
in the storage solution. Finally, cells were centrifuged at 300 x g for 3 minutes and the 
resultant pellet re-suspended in fresh complete medium and transferred to appropriate 
cell culture plasticware for incubation. 
3.2.2 In-vitro cell culture: 
The breast tumour cell lines MCF-7 (Catalog no. 86012803) and MDA-MB-231 
(Catalog no. 92020424) Hepatocarcinoma cell line: HepG2 (Catalog no. 85011430) 
were purchased from the European Collection of Cell Cultures (ECACC). ARPE-19, a 
human retinal pigment epithelial cell line was a gift from Dr. Axel Nohturfft (St. 
George’s University of London). Frozen vials of each cell line were rapidly thawed in 
a 37oC water bath with gentle agitation, and placed immediately in 10 ml of fresh, pre-
warmed growth medium. 
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3.2.2.1 Maintenance of cell lines: 
MCF-7 (passage 12-35), MDA-MB-231 (passage 11-30), HepG2 (passage 18-24) and 
ARPE-19 (passage 6-10) cell lines were grown and maintained in DMEM, 
supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin, 0.1mg/ml 
streptomycin sulphate, and 0.25μg/ml amphotericin B. Cell lines were grown at 37 OC 
in a humidified 95% air and 5% CO2 atmosphere in appropriate sized tissue culture 
plasticware. 
When cells reached approximately 70-80% confluence, they were passaged: Medium 
was removed, and cells harvested by trypsinization with 1X Trypsin (0.1% trypsin–
0.02%EDTA) for approximately 5 minutes at 37OC. Cell detachment and 
disaggregation into single cells was checked by light microscopy; once complete, cells 
were resuspended in an appropriate volume of complete medium and sub-cultured 
into new plasticware as required. Under standard conditions MCF-7 cells were 
passaged at the ratio of 1:4, MDA-MB-231 at the ratio of 1:7, HepG2 at the ratio of 1:3 
and ARPE-19 at the ratio of 1:8 every four days. 
3.2.3 Cell viability assay:  
 MTT or cell viability assay is based on the reduction of the tetrazolium salt by the 
mitochondrial dehydrogenase in a viable cell. MTT is reduced to purple formazan 
crystals which are insoluble in water. Therefore, they are dissolved in organic solvents 
such as DMSO and measured colorimetrically (Puck and Marcus, 1955, Scudiero et 
al., 1988, Twentyman and Luscombe, 1987). To undertake the MTT cell viability 
assay, breast cancer cell lines were seeded in 96-well plates at an initial density of 5 
x 104 cells per well. The cells were allowed to attach overnight, and then serum-starved 
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for 24 hours by replacing complete medium with medium lacking FBS. Next, cells were 
treated with different concentrations of test chemical (GW4064, CDCA; Staurosporine; 
Tam and Doxorubicin), plus appropriate controls for 24 hours. The drugs were 
reconstituted in DMSO with final concentration not exceeding over 0.1 percent. Both 
the compounds, GW4064 and CDCA used in this study are lipophilic in nature, with 
LogP values 4.5 and 8.3 respectively and to avoid protein binding, serum free 
conditions are used (Wishart et al., 2013). For the final hour of incubation, MTT 
solution (2mg/ml) serum-free was added. At the end of the incubation period, 100% of 
DMSO was added to each well to dissolve the formazan salt produced by metabolic 
conversion of MTT in viable cells, and absorbance read at 490 nm. Cell viability was 
presented as percentage of controls. 
Cell viability was normalised between the range 100% viable (untreated cells) and 0% 
viable (0.1% v/v TX100-treated). All experiments were performed in triplicates to 
account for technical variability, and undertaken on three independent occasions to 
account for biological variability. Data is presented as the mean (±SEM) of the three 
independent experiments, with each experimental value being the mean of the 
technical repeats (i.e. n=3) 
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3.2.4 Protein Isolation and measurement:  
 
3.2.4.1 Isolation of total protein: 
Breast cancer cells were added to 6-well plates at a concentration of 1.2x106 cells/well 
and incubated overnight at 37OC to allow attachment. Cells were exposed to chemicals 
(GW4064, CDCA or Staurosporine) at the appropriate concentration, or vehicle, for 
the required amount of time. 
To isolate total protein, medium was removed and the plate washed with 1xPBS to 
remove cellular debris and residual medium. Next, cells were harvest by scarping and 
triplicate wells combined. The cell suspension was pelleted by centrifugation at 800g 
for 3 min, and then the pellet re-suspended in 100μl RIPA buffer (including protease 
inhibitors) and kept on ice for 30 minutes. A final centrifugation step (300g for 3 min) 
was undertaken, and then supernatant collected and stored at – 20OC. 
3.2.4.2 Isolation of Mitochondria and cytosol: 
For isolation of cytosolic and mitochondrial protein fractions, a mitochondrial isolation 
kit (Thermo Scientific) was used according to the manufacturer’s instructions. A brief 
protocol is given below. 
Breast cancer cell lines were treated as described previously (section 3.2.3.1 protein 
isolation). At the end of the incubation period, cells were harvested by trypsinization 
and re-suspended in fresh medium. The cell suspension was centrifuged at 850 x g 
for 3 minutes to pellet and medium discarded. The pellet was resuspended in 800µL 
of Reagent A and vortexed at medium speed for 5 seconds. The Eppendorf was then 
incubated on ice for exactly 2 minutes. After that, 10µL of Reagent B was added to the 
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suspension and vortexed at maximum speed for 5 seconds. This was then incubated 
on ice for 5 minutes, vortexing every 1 minute. Finally, 800µL of Reagent C was added 
and mixed by rotating upside down, without vortexing.  
Eppendorf tubes were then centrifuged at 700 x g for 10 minutes at 4OC, and the 
supernatant then transferred to fresh Eppendorf tubes. These were centrifuged at 
12,000 x g for 15 minutes at 4OC, with the resultant supernatant stored as the cytosolic 
fraction. To the pellet, 500 µL of the mitochondrial isolation Reagent C was added, the 
pellet re-suspended, and the sample centrifuged at 12,000 x g for 5 minutes. Finally, 
the mitochondrial pellet was resuspended in 100µL of mitochondrial lysis buffer, 
vortexed for 1 minute and then centrifuged at high speed for 2 minutes. The 
supernatant (soluble mitochondrial extract) was used for protein determination. Of 
note, the composition of reagents A, B and C are not mentioned by the manufacturer 
(Thermo FisherScientific #89874).   
 
3.2.4.3 Determination of protein concentration: 
 
The bicinchoninic acid (BCA) assay was performed to determine protein 
concentration. The test is a dye-binding assay based on the differential colour change 
of a dye in response to protein concentration. To perform the assay, 10μl of protein 
samples were pipetted in triplicate into a 96-well plate. Next, 10µl of Bovine Serum 
Albumin (BSA) standards (0 to 1 mg/ml of bovine γ globulin) were pipetted into a 96-
well plate. BCA working reagent (100µl) was added per well for 30 minutes. At the end 
of the incubation period, absorbance was measured at OD595 using 
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spectrophotometer, and sample protein concentration calculated against the standard 
curve. 
 
 
3.2.5 Western Blotting: 
 
3.2.5.1 Gel Preparation:  
 
Acrylamide resolving gels of 10% (10% acrylamide, 0.3% bis-acrylamide, 0.1% SDS, 
0.4M Tris-HCL pH8.8, 0.16% APS and 0.16% of TEMED) and 12% and 20% (w/v) for 
lower molecular weight proteins were prepared to detect different proteins. To prepare, 
320µl of 10% ammonium persulfate (freshly prepared each time) and 32µl of TEMED 
were added to 20ml of resolving stock, mixed gently and immediately poured between 
the gel casting plates (Bio-Rad, USA). Isopropanol was poured on top and kept at 
room temperature for 30 minutes to allow polymerisation to occur.  
Next, isopropanol was removed, and a 4% (4% acrylamide, 0.1% bis-acrylamide, 0.1% 
SDS, 0.2M Tris-HCl pH6.8, 0.24% APS and 0.4% TEMED) or 6% stacking gel (240µL 
Ammonium persulphate and 40µl TEMED to 10ml of stacking stock) was poured on 
the top of the resolving gel. The comb was inserted and left for 30 minutes to 
polymerise.  
For cytochrome C, SHP, Bcl-2, BAX and LC3 expression precast gels 4-20% (Bio-rad) 
were used.  
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3.2.5.2 Sample loading: 
Protein samples (30-60µg) were prepared by mixing with equal amounts of loading 
buffer (60mM Tris-HCl pH6.8, 12% glycerol, 2% SDS, 0.003% pyronin Y, 0.7M β-
mercaptoethanol). Samples were heat denatured for 5 minutes in a thermal cycler at 
90OC. Samples were then loaded onto the prepared SDS gel, alongside Spectra 
Multicolor Broad Range Protein Ladder (Thermo Scientific), and separated at 150mA 
until the dye reaches the bottom nearly 40 – 80 minutes. (Figure 3-1) 
 
 
FIGURE 3-1: SDS PAGE electrophoresis (running) 
(A) SDS-PAGE Apparatus consists of lid with anode and cathode points, (B) gel apparatus 
to load samples to gel and (C) buffer tank (D) filled with running buffer. At the end of 
running cycle, (E) the gel will have marked multicolour ladder and the sample with the 
loading dye at the end.  
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3.2.5.3 Transfer of Proteins: 
 
Following separation of proteins using gel electrophoresis, they are transfered onto a 
more robust material (nitrocellulose membrane) for subsequent antibody detection. 
The nitrocellulose membrane, blotting papers and scotchbright pads were soaked in 
a tray containing transfer buffer (16mM Tris, 120mM glycine, 20% methanol) for 10 
minutes. To assemble the transfer apparatus, Whatmann 3MM filter paper, the 
acrylamide gel and nitrocellulose membrane were sandwiched between scotchbrite 
pads avoiding any air bubble and placed in Bio-Rad transfer tank alongside an ice-
pack. (Figure 3-2). The transfer tank was filled with transfer buffer and then transfer 
carried out at constant 0.3A for 90 minutes.   
 
 
FIGURE 3-2: SDS PAGE electrophoresis (wet transfer) 
 
(A) Transfer Apparatus consists of cassette that holds the gel, membrane, filter paper and 
scrotchbrite pad sandwich with black and white surface, (B) transfer apparatus to load 
this gel-membrane sandwich, keeping sides facing similar colour and (C) buffer tank 
filled with (D) transfer buffer. (E) At the end of cycle, nitrocellulose membrane will have 
marked multicolour ladder and the protein loaded onto it. 
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3.2.5.4 Blocking and Immunoblotting membrane: 
 
To reduce non-specific binding of antibodies, membranes are ‘blocked’ using an 
albumin-containing solution, most commonly milk powder. The nitrocellulose 
membrane was blocked in 10% (w/v) blocking solution, comprising of non-fat milk 
powder dissolved in TBS-T. The membrane was placed in 50ml falcon tube with 
protein side facing inwards, along with 10ml of blocking solution, and incubated at 
room temperature for 1-2 hours on a rotary roller. The blocking solution was discarded 
& washed three time with 5ml PBS-tween for 5 minutes. The membrane was then 
incubated with the primary antibody, diluted to a suitable concentration in PBST 
(mentioned in table 3-4). Incubations with primary antibody were always carried out in 
a cold room temperature (4-8OC) overnight on a rotary roller.  
Following incubation with primary antibody, membranes were washed three times in 
PBS-T for 10 minutes with rolling. Next, the membrane was incubated with the 
secondary antibody for one hour at room temperature on a bold roller. All secondary 
antibodies were used at a dilution of 1:10,000 in 5% Milk PBS-T.  
Following incubation with the secondary antibody, membranes were washed again 
three times for 10 minutes with PBS-T on a roller, and then once with PBS only. 
Detection was either through chemiluminescence or infrared. For chemiluminescence, 
the detection reagent was prepared by mixing equal amounts of the stable peroxide 
solution and the luminol/enhancer solution from the Pierce SuperSignal West pico 
chemiluminescent Kit. The mix was added onto the membrane and incubated for 5 
minutes at room temperature. Excess reagent was drained and the membrane 
transferred to a film cassette, protein side face up. The membrane was apposed to X-
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ray film for 5 minutes to 1 hour in safe light/dark. Next, the film was transferred to the 
developing solution and incubated until bands were sufficiently visible. The film was 
then washed with water for few seconds and transferred into fixation solution for 5 
minutes. The film was rinsed with cold water and hung up to dry.  
For infra-red detection, IRDye secondary antibodies were used. After the final wash 
with PBS, these wet membranes transferred into an Odyssey Infrared Imaging System 
and scanned in both the 700 and the 800 nm channels, which give rise to the red and 
green signal simultaneously. 
 
3.2.5.5 Membrane stripping for re-probing 
 
To enable membranes for re-probing with different antibodies on the same membrane, 
existing antibody should be removed to avoid false protein expression. To do so, the 
membranes were chemically stripped. The membranes were placed in 50ml falcon 
tube protein side facing inwards with 5ml of Restore™ Western Blot Stripping Buffer 
to remove primary and secondary antibodies and incubated for 30 minutes on rotary 
roller. After incubation, the membrane was washed three times with PBS-T for 5 
minutes. Then the membrane was blocked as mentioned in 3.3.4. Membranes are not 
stripped for more than three times as it could lead to loss of protein. 
3.2.5.6 Densitometry of western blots: 
Western blots are analysed for quantification. The x-ray films are scanned with Gene 
Genius BioImaging System and analysed using Image J. ODYSSEY® CLx was used 
to scan membranes probed with fluorescence antibodies and analysed using Li-Cor 
Image Studio software. 
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3.2.6 CASPASE ASSAY: 
 
Breast cancer cells were seeded in a white-walled 96-well plate at a density of 1 X 104 
cells per well in complete medium and left to attach overnight. Next, the medium was 
removed and cells washed once with PBS. The PBS was discarded and treatments, 
dissolved in serum-free medium plus vehicle, were added to triplicate wells. 
Staurosporine (1µM) was used as a positive control, while the caspase inhbitiors Ac-
DVED-CHO (caspase 3/7), Z-LEHD-FMK (caspase 9), and Z-IETD-FMK (caspase 8) 
were used as negative controls. Z-DEVD-aminoluciferin (Caspase 3/7), Z-LEHD-
aminoluciferin (Caspase 9) and Z-LETD-aminoluciferin (Caspase 8) used as a 
luminogenic substrate. The aminoluciferin are liberated upon substrate cleavage by 
respective active caspase produces light in a luminescence reaction which is read 
through luminometer (O’Brien et al., 2005). 
Following exposure of cells to test chemicals, 100µl of Caspase-Glo® 3/7 or 9 reagent 
was added to each well of a white-walled 96-well plate containing 100µl of blank, 
negative control and treatments.  
The plate was then incubated for 1 hour at room temperature and luminescent read 
through a Luminometer.  
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3.2.7 ROS ASSAY: 
Various reactive oxygen species such as superoxide anion, hydrogen peroxide and 
hydroxyl radical are generated by the mitochondrial metabolism occurring due to 
oxidative stress (Andreyev et al., 2005). Among various ROS, the hydrogen peroxide 
(H2O2) has better stability with longer half-life making it ideal for studying in cell culture 
(Giorgio et al., 2007). Breast cancer cell lines were seeded in a 96-well plate at 1 X 
104 cells per well in complete medium, and allowed to attach overnight. The next 
morning, the medium was removed and cells washed with PBS. The PBS was then 
discarded and treatments plus the H2O2 substrate were added to the wells in triplicate 
using serum-free medium. After 6 hours of incubation, 100µl of ROS glo detection 
solution was added to the wells. The presence of the H2O2 substrate reacts directly 
with the H2O2 present in the system generating the luciferin precursor which is 
converted by D-cysteine to produce luminescent signal. The amount of signal 
produced is directly proportional to the amount of H2O2 present in the cell culture 
system, as mentioned by the manufacturer. The plate was then incubated for 20 
minutes at room temperature, and luminescence detected using a Luminometer 
(Fluostar Omega).  
 
3.2.8 Colony Formation Assay: 
 
Developed in 1955 by Puck TT and Marcus PI, colony formation or clonogenic assay 
is a standard protocol to assess the proliferative and survival effects of drug on tumour 
cells. Hence it is been widely used in cancer research. The most prominent feature of 
this technique is to examine the long term effects in model cell lines, thereby examining 
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drugs potential role in clinic. Single or combination of drugs can be used to study the 
dose-survival relationship on various tumour cell lines (Franken et al., 2006). 
 
Breast cancer cell lines were seeded in 6-well plates at varying concentrations in 
complete medium, and allowed to attach overnight. Next, the complete medium was 
removed and replaced with 1 ml of serum-free medium containing test chemical at the 
desired concentration or vehicle. Following one hour of incubation at 37OC, the 
medium was removed and replaced with complete medium. Plates were the incubated 
in a humidified incubator for 12 days, at the end of which the number of colonies was 
manually counted.  
 
For colony counting, cells were washed twice with PBS, and then fixed using 100% 
methanol for 10 minutes on ice. Finally, cells were stained with crystal violet solution 
0.5% (w/v) for 10 minutes to enhance visibility, and air dried for storage until counting 
could be undertaken. 
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3.3 Statistical Analysis: 
 
All data are given as means +/- SEM. The concentrations are transformed into log and 
fitted using non-linear regression with log (inhibitor) vs normalised response. The 
slope runs from 100% to 0% to determine the IC50 of the inhibitor used in this study. 
Comparison of treatments against controls was made using Dunnett’s t-test. For 
multiple comparisons one-way or two-way ANOVA (as appropriate) was used, with 
Bonferroni’s multiple comparisons test to determine the significance between the 
group treatments. * p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 were considered 
statistically significant. The statistical tests were performed using GraphPad Prism 
software v6.0. The statistical analysis was carried out using GraphPad Prism 6.0 
software package.  
Combination Index: The type of interaction between chemicals in a binary mixture 
(synergism, additivity, antagonism) was assessed using the combination index 
isobologram method, which is based on the median-effect (Chou, 2010). Analysis was 
undertaken using the CompuSyn software package. 
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CHAPTER 4 
Characterisation of FXR agonists on breast 
cancer cell lines 
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4.1 INTROUCTION 
  
To study breast cancer in-vitro, it is important to choose the right model, and to 
demonstrate that it is grown under the correct conditions to ensure that it maintains 
these characteristics throughout the experimental period (i.e. phenotypic robustness). 
Breast cancer is a very complex and heterogeneous disease exhibiting wide molecular 
expression. To study breast cancer, various cell lines have been established, each of 
which has different characteristics, allowing the study of these different molecular 
and/or cellular backgrounds. The first carcinoma cell line developed, and indeed one 
of the first cell lines of all, was the HeLa cell line (Scherer et al., 1953). The cell line 
was named after Henrietta Lacks, an African-black women suffering from cervical 
carcinoma, and was developed in the Baltimore laboratory of Dr George O. Gey over 
50 years ago (Masters, 2002). This development heralded the isolation of many 
different cancer cell lines, with the first breast cancer cell line being BT-20, which was 
isolated in 1958 (Lasfargues and Ozzello, 1958). Following this, perhaps the most 
widely used cell line, MCF-7, was isolated by the Michigan Cancer Foundation in 1973 
(Lee et al., 2015). Due to its hormone sensitivity towards estrogen, due to the fact that 
it retains expression of the ER, this cell lines was an ideal model to study what would 
subsequently be classified as ER+ breast cancer in vitro (Soule et al., 1973, Levenson 
and Jordan, 1997). As noted in the introduction, breast cancer is a complex disease 
encompassing several cell types and a wide variety of molecular profiles (Holliday and 
Speirs, 2011). This, therefore, necessitated the development of other cell lines that 
could be used to study these different cellular phenotypes. Over the past 40 years a 
large number of cell lines have been developed to mimic breast cancer; for example, 
a search of the European Cell and Animal Culture Collection (ECACC) for ‘breast 
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cancer’ returns twenty-four different cell lines (Lacroix and Leclercq, 2004, Vargo-
Gogola and Rosen, 2007). For any study on breast cancer it is thus important to utilise 
this diversity in in vitro models, allowing the study of how mechanisms may differ 
between cellular phenotypes. At the same time it also makes it vital that the nature of 
the cell line being used is fully established, such that the relevance of studies to breast 
cancer, and to the work of others, can be clearly established. 
Phenotyping of cell lines has traditionally been undertaken using a combination of 
phenotypic and molecular profiling (Prat et al., 2013). In recent years, the advent of 
DNA microarray technology, and latterly deep sequencing, has allowed this 
categorisation and an unparalled level (Trevino et al., 2007). Despite this, the most 
commonly used markers are those that relate directly to tumour phenotype, namely 
the expression of important receptors such as ER , progesterone receptor  and human 
epidermal growth factor receptor 2 (HER2) (Conzen, 2008, Vienonen et al., 2003, 
Lakhani et al., 2002). This combination of these characterisation approaches has 
allowed the development and categorisation of breast cancer cell lines with regard to 
their relationship to important breast cancer sub-types. This involves characterisation 
based firstly upon markers determining histological type, tumour grade, lymph node 
status, expression of the ER, PR and HER2 (Kao et al., 2009). This phenotypic 
profiling has been augmented by molecular profiling, and allowed the classification of 
breast cancer cell lines into the five subtypes of breast cancer: Luminal A, Luminal B, 
HER2, basal and normal (Perou et al., 2000). Table 4-1 lists a number of common 
breast cancer cell lines, their tumour type, and immunoprofile for ER, PR andHER2 
status, and the breast cancer subtype they most closely model. 
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TABLE 4-1 Breast tumour subtypes 
Cell Line Immunoprofile Cancer Type Reference 
 
MCF-7  ER+ PR+ HER- Luminal A (Soule et al., 1973) 
MDA-MB-231 ER- PR- HER- BASAL 
(Claudin-low) 
(Cailleau et al., 1974) 
MDA-MB-468 ER- PR- HER- BASAL (Cailleau et al., 1974) 
SkBr3 ER- PR- HER+ HER2 (Trempe, 1976) 
T-47D ER+ PR+ HER-- Luminal A (Sher et al., 1981) 
BT-474 ER+ PR+ HER+ Luminal B (Lasfargues et al., 1979, 
Lasfargues et al., 1978) 
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4.2 RESULTS 
 
4.2.1 Morphological characterisation of MCF-7 and MDA-MB-231 as 
model cell lines.  
 
As discussed in introduction section 1.6, the Farnesoid X receptor is expressed 
primarily in liver and intestine, regulates the bile acid synthesis (Eloranta and Kullak-
Ublick, 2008). FXR activation in breast cancer cells have shown to be both pro-
proliferative (Journe et al., 2009, Journe et al., 2008) and anti-proliferative (Giordano 
et al., 2011, Swales et al., 2006). Due to the discrepancies between studies it is 
important to delineate its role in breast cancer. To examine FXR activation effects in 
breast cancer, it is important to study breast tumour models. For this study I have 
selected MCF-7 and MDA-MB-231 cell line as the model due to their phenotypic 
variability. MCF-7 (Soule et al., 1973) being estrogen and progesterone responsive, 
non-invasive subtype whereas MDA-MB-231 (Cailleau et al., 1974) being triple 
negative breast cancer (TNBC) and highly metastatic subtype associated with poor 
prognosis.  
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FIGURE 4-1: Morphological depiction of MCF-7 cells. 
(A) MCF-7 cells were cultured in medium containing 10% FBS and 1X antibiotics for 3-5 
days. Photographs were taken at the confluence nearly around 70 percent. The 
photographs were taken by digital camera at a magnification of 10x. (B) MCF7 image 
accessed from European Collection of Cell Cultures ECACC #86012803.   
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FIGURE 4-2: Morphological depiction of MDA-MB-231 cells 
(A) MDA-MB-231 cells were cultured in medium containing 10% FBS and 1X antibiotics for 
3-5 days. Photographs were taken at the confluence nearly around 70 percent. The 
photographs were taken by digital camera at a magnification of 10x. (B) MDA-MB-231 
image accessed from European Collection of Cell Cultures ECACC #92020424. 
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The microscopic images clearly depict the morphological differences between two cell 
lines. MCF-7 cells have a more round-like phenotype with strong cell-cell adhesion 
(Figure 4-1; A), whereas MDA-MB-231 cells have more of an elongated fibroblast-like 
morphology with membrane protrusion (Figure 4-2; A) unlike tight cell-to-cell 
connection as in MCF-7.   
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4.2.2 Expression of FXR in the model cell lines: 
 
In search of new targets for treating breast cancer, recent work has highlighted the 
potential of the adopted orphan nuclear receptor, the Farnesoid X Receptor (Giordano 
et al., 2011, Swales et al., 2006). Its adopted status is due to the identification of 
primary bile acids such as chenodeoxycholic acid (CDCA) as ligands for FXR (Han et 
al., 2010, Makishima et al., 1999). Importantly, recent research has demonstrated the 
over-expression of FXR in a range of cancerous tissues, including liver, kidney and 
small intestine (Claudel et al., 2003, Huang et al., 2006, Ma et al., 2013, Modica et al., 
2008). As FXR activation has been shown to induce cell death, it is thus a potential 
target for novel anti-cancer therapeutics. For example, CDCA-dependent activation of 
FXR has been shown to induce cell death in liver tumours through the activation of the 
tumour suppressor gene N-myc downstream-regulated gene 2 (NDRG2) (Deuschle et 
al., 2012). In another study, (Guan et al., 2013) showed that inhibition of FXR could 
promote cell death in esophageal cancer, suggesting that the relationship between 
FXR activation status and cell death may be context dependent (Gadaleta et al., 
2015).  With regard to breast cancer, studies have shown that FXR is highly-expressed 
in breast tumours, and specifically in the ductal and epithelial lining of breast 
carcinoma tissues, thus raising the possibility of FXR-targeted therapy as an option in 
breast cancer (Giordano et al., 2011, Swales et al., 2006). The molecular rationale for 
the increased expression in tumours is unclear, but it is interesting to note that 
postmenopausal women with breast cancer have been demonstrated to possess high 
concentrations of bile acids, the endogenous ligands of FXR, in cysts (Costarelli and 
Sanders, 2002, Javitt et al., 1994, Mannello et al., 1997).  
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In this experiment, FXR expression was confirmed in MCF-7 and MDA-MB-231 breast 
cancer cell lines used in this project. In addition, the human retinal pigment epithelial 
cell line (ARPE-19) was used as a negative control for FXR expression, by western 
blotting as discussed in Methods section 3.3. The efficiency of total protein transfer 
was assessed by anti-β-actin antibodies see Figure 4-3.  
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Figure 4-3: FXR expression in MCF-7 and MDA-MB-231. 
 
MCF-7, MDA-MB-231 and ARPE-19 cell lines were seeded in 6 well plate at 6 X 105 cells per well. 
The plates are kept at incubator 37OC and allowed to grow. When nearly 70 percent confluent 
the plates were ready for protein isolation as described under Methods. Protein measurement 
was carried out using bicinchoninic acid assay (BCA) and each lane contained 30 micrograms. 
The protein was separated by SDS-PAGE and immunoblotted for Farnesoid X Receptor (FXR); 
top and Beta-Actin (bottom). Each lane represents a biological replicate. In the blot for FXR, a 
negative control ARPE-19 was included. 
 
  
 
 
 
 
97 
 
 
4.2.3 Effect of FXR on SHP expression in breast cancer cell lines. 
 
Having demonstrated that both MCF-7 and MDA-MB-231 cell lines express FXR, it is 
important to demonstrate that the signalling cascade in these cells is also functional. 
To achieve this, the expression of a classical FXR target gene was examined following 
exposure of both cell types to the FXR ligands GW4064 and CDCA. Small 
Heterodimer Partner (SHP) is an orphan nuclear receptor that is a target for FXR (Seol 
et al., 1996). SHP is expressed in various tissues in humans, including liver, heart, 
kidney, small intestine, adrenal gland and stomach in humans, paralleling the 
expression of FXR (Sanyal et al., 2002, Goodwin et al., 2000). SHP is a non-classical 
nuclear receptor, containing a ligand binding domain, but lacking the conserved DNA 
binding domain (Lee et al., 1998). SHP functions to silence the activity of other nuclear 
receptors by forming non-DNA binding complexes (Lee et al., 1998): For example, 
SHP has been shown to interact with liver receptor homologue-1 (Li et al., 2005), c-
jun (Park et al., 2008), hepatocyte nuclear factor 4α (Lee et al., 2000), liver X receptor 
α (Brendel et al., 2002), pregnane X receptor (Ourlin et al., 2003), peroxisome 
proliferator activated receptor γ (Nishizawa et al., 2002), androgen and estrogen 
receptor α/β (Johansson et al., 1999) and the Farnesoid X receptor (Goodwin et al., 
2000).  
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Figure 4-4: SHP expression in MCF-7 cell lines 
MCF-7 and HepG2 cells were treated with DMSO (Control; C), FXR ligands GW4064 (GW) and 
CDCA. The protein extracts were separated on SDS-PAGE and immunoblotted as described in 
Methods and Materials. (A) Western blot analysis and quantitative densitometry of the protein 
expressions of the SHP-1 under baseline conditions and treated conditions in HepG2 and MCF-
7 cell line. (B) In HepG2 cells, SHP is expressed at 26KDa with GW4064 treatment. MCF-7 cells 
showed SHP expression at 26KDa with GW4064 treatment but no expression with CDCA. The 
loading control β-actin was detected at 45KDa. The blot is representative image of N=3 repeats, 
bars; mean + SE.    
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Figure 4-5: SHP expression in MDA-MB-231 
MDA-MB-231 and HepG2 cells were treated with DMSO (Control; C), FXR ligands GW4064 (GW) 
and CDCA. The protein extracts were separated on SDS-PAGE and immunoblotted as described 
in Methods and Materials. (A) Western blot analysis and quantitative densitometry of the protein 
expressions of the SHP-1 under baseline conditions and treated conditions in HepG2 and MDA-
MB-231 cell line. (B) In HepG2 cells, SHP is expressed at 26KDa with GW4064 treatment. MDA-
MB-231 cells showed SHP expression at 26KDa with GW4064 treatment but no expression with 
CDCA. The loading control β-actin was detected at 45KDa. The blot is representative image of 
N=3 repeats, bars; mean + SE.  
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The human hepatoma cell line HepG2 was used as a positive control, as it has been 
previously demonstrated to show SHP induction following activation of FXR (Goodwin 
et al., 2000). As can be seen in figure 4-4 and 4-5, exposure of HepG2 cells with 30µM 
GW4064 for 24 hours resulted in a statistically significant increase in SHP protein of 
5.9-fold. In contrast, exposure of HepG2 cells to 300µM CDCA had no impact on SHP 
protein levels in either cell line. 
A similar effect was observed when MCF-7 (figure 4-4) and MDA-MB-231 (figure 4-5) 
cells were exposed to FXR agonists. In both cell lines, exposure to 35 and 22µM 
GW4064 for 24 hours resulted in a statistically significant increase in SHP protein 
levels, being 3.8- and 4.6-fold above control levels for MCF-7 and MDA-MB-231 cells, 
respectively. However, in both cell lines no effect on SHP protein levels were observed 
following 24 hours exposure to 245 and 210µM CDCA.   
The Farnesoid X Receptor has been shown to participate in controlling the bile acid 
pool. Activation of FXR leads to the down-regulation cholesterol 7 alpha-hydroxylase 
(CYP7A1) levels, the key enzyme in cholesterol synthesis (Goodwin et al., 2000, Seol 
et al., 1996, Makishima et al., 1999, Wang et al., 1999). However, FXR does not 
directly bind to the CYP7A1 gene, but rather works via an SHP-LRH-1 interaction 
(Goodwin et al., 2000). SHP itself has been linked to the apoptotic cascade, both as 
an inhibitor and inducer of apoptosis. For example, monocytic cells evade etoposide-
induced apoptosis through the cytoplasmic mobility of p21WAF1, which is dependent 
upon SHP activation (LaBaer et al., 1997). On the other hand, activation of SHP by 6-
[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid AHPN has been 
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show to induce apoptosis in the breast cancer cell line MDA-MB-468 (Farhana et al., 
2007).  
4.2.5 Effect of FXR on the viability of MCF-7 and MDA-MB-231 cell 
lines 
 
After demonstrating that model cell lines expressed FXR and its target gene SHP, the 
next research point was to study the impact of FXR ligands on these cell lines. As 
noted above, activation of FXR seems to have a context-dependent effect, with 
different studies detailing an induction of either cell death of cell growth/tumour 
metastasis (Gadaleta et al., 2015, Guan et al., 2013, Deuschle et al., 2012, Journe et 
al., 2008, Journe et al., 2009). Swales et al. (2006) previously reported that the FXR 
activation induces cell death in the breast cancer cell lines MCF-7 and MDA-MB-468, 
although the MDA-MB-231 cell line was not studied, nor was any molecular 
mechanism of cell death delineated. The novelty of this thesis is to provide in depth 
analysis of cell death on these cell lines and the mechanism it follows. 
Two FXR agonists were utilised in this study: first, the primary bile acid 
Chenodeoxycholic acid (CDCA) was used as it represents a classic endogenous 
ligand for FXR (Makishima et al., 1999, Maloney et al., 2000, Parks et al., 1999); 
second, the synthetic but more potent activator GW4064 was also chosen (Maloney 
et al., 2000). The use of the GW4064 is important as it has a Kd for interaction with 
FXR in the nanomolar range (approximately 10nM: (Maloney et al., 2000)), compared 
to the micromolar range observed with CDCA 50 µM (Maloney et al., 2000, Han et al., 
2010). This designed selectivity of GW4064, allows concentrations to be used that will 
activate FXR significantly with minimal off-target interactions that would alone 
confound the data interpretation. By comparison, at the concentrations required to 
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activate FXR significantly, CDCA is expected to demonstrate a number of off-target 
effects, including effects mediate by other nuclear receptors such as PXR and LXR, 
and signalling cascades such as MAPK (Staudinger et al., 2001, Talukdar et al., 2007).  
MCF-7 cells were seeded in 96 well plate for 24 hours. Cells were serum starved for 
24 hours before use. In serum free medium, cells were treated with increasing 
concentrations of FXR ligands (CDCA 10, 30, 100, 300μM, and GW4064 1, 3, 10, 
30μM), or vehicle control (0.1% DMSO) for 24 hours. MTT solution is added and 
absorbance was measured. The concentrations selected are equal to or more than 
the kD (i.e. 10nM for GW4064 and 50µM for CDCA) to achieve 50 to nearly 100 
percent fractional occupancy to get the sigmoidal curve (Makishima et al., 1999 
Maloney, 2000 #220).   
The inhibitory concentration (IC50) for each drug is given below in table 4-3. 
  TABLE- 4-2 Inhibitory concentrations of drugs  
DRUG IC50 (µM) MCF-7 MDA-MB-231 
GW4064 35 ± 1.2 22 ± 1.2 
CDCA 245.2 ± 1.0 210 ± 1.4 
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Figure 4-6:  FXR activation induces MCF-7 cell death 
Concentration dependent effects of bile acids CDCA and synthetic ligand GW4064 on MCF-7 
after 24 hours. Points, mean viability as a percentage of control (i.e., vehicle-treated cells = 
100%). Mean ± SEM, n=9, * p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 compared to control by 
one-way ANOVA (Dunett’s multiple comparison test). 
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Figure 4-7:  FXR activation induces MDA-MB-231 cell death 
Concentration dependent effects of bile acids CDCA and synthetic ligand GW4064 on MDA-MB-
231 after 24 hours. Points, mean viability as a percentage of control (i.e., vehicle-treated cells = 
100%). Mean ± SEM, n=9, * p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 compared to control by 
one-way ANOVA (Dunett’s multiple comparison test). 
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4.3 DISCUSSION 
The Farnesoid X receptor is an adopted orphan nuclear receptor, for which bile acids 
are the endogenous ligand. More specifically, primary bile acids have been shown to 
activate FXR at physiological levels (Makishima et al., 1999, Han et al., 2010, Lefebvre 
et al., 2009). This is part of an important negative feedback mechanism within the body 
to limit the concentrations of bile acids, as elevated levels of bile acids have been 
associated with acute liver injury, driving cholestasis and hepatocarcinoma (Lefebvre 
et al., 2009). Metabolism of excess cholesterol in the body (classically within the liver) 
leads to the formation of bile acids. These activate FXR, which acts to negatively 
regulate expression of CYP7A1, a central enzyme in cholesterol metabolism. This has 
the effect of switching cholesterol clearance to alternative routes (predominantly 
increased transport), and prevents the build-up of potentially toxic bile acids within the 
cell (Staels and Fonseca, 2009). While this phenomenon has been classically 
associated with the liver, bile acids are present within the blood at micromolar 
concentrations (Gustafsson et al., 2006, Smith et al., 2004, Tadano et al., 2006), and 
due to their lipophilic nature (logP >3) are likely to be concentrated in fatty tissues. 
Such is indeed the case, with bile acids identified in normal breast tissue (Costarelli 
and Sanders, 2002, Javitt et al., 1994), and at elevated levels in the cysts of women 
with breast cancer (Costarelli and Sanders, 2002, Mannello et al., 1997). The potential 
for increased levels of bile acids in tumours, coupled with reports of increased FXR 
expression in these tissues raises important questions with regard to both their 
biological role, and their potential as therapeutic targets. At present, the answers to 
these questions remain unclear, with different reports suggesting different 
physiological effects of FXR activation in tumours, including both enhanced cell death 
and proliferation/invasion (Giordano et al., 2011, Guan et al., 2013, Journe et al., 2008, 
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Swales et al., 2006). It is thus the aim of this thesis to fully examine this area in a single 
tumour type: breast tumours.     
In this study, two breast cancer cell lines have been used: MCF-7 and MDA-MB-231. 
Their choice reflects their disparate phenotypes, for example, different ER status, with 
the former being ER positive and the latter being ER negative. Overall, the two cell 
lines represent significantly different phenotypes, with MCF-7 representing a non-
invasive, slowly dividing tumour, while MDA-MB-231 cells represent rapidly dividing, 
invasive phenotype.  
As the main topic of this thesis is the role of FXR in breast cancer, it was important to 
first establish that both cell lines express FXR at levels that would allow significant 
pharmacological intervention. The Western blot analysis showed that FXR is 
expressed in both cell lines, but absent from the negative control cell line ARPE-19  
Such data is consistent with expectations, both in vitro and in vivo. Previous work by 
Swales et al. (2006) demonstrated FXR expression in vitro in both the MCF-7 cell line 
and the invasive cell line MDA-MB-468 cells. In vivo, FXR has been shown to be 
expressed in normal breast tissue, and highly-expressed in some breast tumours 
(Swales et al., 2006, Wang et al., 2008, Modica et al., 2008). FXR target gene SHP, 
expressed in both MCF-7 and MDA-MB-231. SHP, as mentioned in section 4.2.3 is a 
target gene of FXR, repress the cholesterol catabolic pathway. It heterodimerize with 
liver receptor homolog 1 (LRH-1), downregulate CYP7A1 and thus decreases the bile 
acids production (Goodwin et al., 2000). As such, these data support the use of MCF-
7 and MDA-MB-231 cells as suitable models for examining the impact of FXR 
activation in non-invasive and invasive breast cancer models, respectively. 
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After demonstrating the suitability of the chosen model cell lines, the impact of FXR 
activation on cell viability was next examined. To address this, the FXR agonists 
GW4064 and CDCA been used to treat cells, and viability of cells were determined 
through the MTT assay. In the MCF-7 breast cancer cell line both FXR ligands, 
GW4064 and CDCA, elicited a dose dependent cytotoxicity. In case of the low affinity 
endogenous ligand CDCA, a 70% significant reduction in viability was observed after 
24h exposure at the maximal concentration used (300μM; figure 4-5). The high affinity 
FXR ligand GW4064 elicited a maximal significant reduction in viability of 
approximately 40% and 60% after 24 hours of treatment at 10µM and 30µM 
concentrations respectively (Figure 4-6). The cells were treated with concentrations of 
CDCA and GW4064 expected to cause differing levels of receptor occupancy. Table 
4-2 shows the expected fractional receptor occupancy for each drug concentration 
used. The lower the kD the higher the fractional occupancy as evident from GW4064.  
 
TABLE 4-3 Fractional Occupancy 
GW4064 (µM)  EXPECTED FO CDCA (µM) EXPECTED FO 
0.3 96% 3 6% 
1 99% 10 16% 
3 99% 30 38% 
10 99% 100 67% 
30 99% 300 86% 
 
It is important to note that these concentrations cover a wide range of fractional 
occupancies. In addition, the highly selective nature of GW4064 against FXR means 
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that FXR-dependent effects alone can be studied (Maloney et al., 2000). In contrast, 
CDCA demonstrates considerable promiscuity with regards to its sub-cellular targets, 
and it is expected that as the fractional occupancy rises, so will be level of 
(confounding) off-target interactions. For both GW4065 and CDCA there as a 
concentration-dependent decrease in cell viability over the 24h exposure period. From 
the generated concentration-response curves, an IC50 value can be calculated, 
equating to the concentration of each drug required to elicit a 50% decrease in cell 
viability: these are presented in table 4-3. 
The study showed that both in MCF-7 and MDA-MB-231 cell lines could induce cell 
death, and hence was irrespective of ER, PR and HER2 status. This data would 
support the examination of FXR as a potential therapeutic target against breast 
cancer. Having demonstrated that in breast cancer cell lines FXR activation leads to 
decreased cell viability, it is now important to delineate the molecular mechanism(s) 
that underlie this effect, such that the potential of this as a therapeutic approach can 
be further evaluated. 
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CHAPTER 5 
 
FXR AND APOPTOSIS 
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5.1 INTRODUCTION 
 
The balance between cell proliferation and cell death is tightly regulated to maintain 
cell number within a tissue. Dysregulation of apoptosis has been associated with 
various human diseases including cancer (Bold et al., 1997, Lowe and Lin, 2000, 
Wallace-Brodeur and Lowe, 1999). Oncogenes and tumour suppressor proteins have 
been linked with cancer. The first identified oncogene Bcl2 studied was shown to block 
apoptosis. To date 13 Bcl-2 family members are identified some promoting apoptosis 
and some blocking it (Cleary et al., 1986, Gross et al., 1999, Tsujimoto et al., 1984). 
Overexpression of bcl-2 anti-apoptotic protein blocks the cytochrome c release 
disrupting apoptosis and have been linked with various tumour types (Berchem et al., 
1995, Del Bufalo et al., 1997, McDonnell et al., 1992, Miyashita et al., 1994, Tron et 
al., 1995). Bcl-2 overexpression has been linked to tumour metastasis, proliferation 
and unresponsiveness towards chemotherapy (Del Bufalo et al., 1997, Krajewski et 
al., 1995, Yang et al., 2013, Yunis et al., 1989). Apoptosis is distinguished between 
intrinsic and extrinsic pathway as mentioned in the introduction chapter. The extrinsic 
pathway governed by initiation of the death receptors such as FAS. Upon binding to 
their ligands they recruit the death domain forming death inducing signalling complex, 
which further activates the cell death protease caspase 8 that results in apoptotic cell 
death (Fulda and Debatin, 2006, Kischkel et al., 1995, Muzio et al., 1996). On the other 
side, the death signals modulates the bcl-2 family of proteins and disrupt the 
mitochondrial potential. The release of pro-apoptotic bcl-2 family members facilitates 
the opening of mitochondrial pores resulting in release of cytochrome c and caspase 
9. The caspase 9 along with apaf-1 and cytochrome c initiates the executioner 
caspase cascade resulting in apoptotic cell death (Elmore, 2007, Green and Reed, 
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1998, Gross et al., 1999, Wyllie et al., 1980). Mutations have been found in caspases 
that are linked with tumorigenesis due to their ability to deregulate apoptosis. Both 
intrinsic and extrinsic caspases have been linked with certain cancers. Caspase 8 
mutations have been linked with gastric and colorectal cancers also in hepatocellular 
carcinomas with frameshift mutations (Ando et al., 2013, Kim et al., 2003, Li et al., 
2014, Soung et al., 2005). Caspase 9 although not frequently mutated in cancer but 
the inability of apoptosome formation lead to oncogenic transformation in some cases 
(Jia et al., 2001, Liu et al., 2002, Wolf et al., 2001). In case of breast cancer, it has 
been shown that nearly 75% of breast tumour samples have deficient caspase 3 
expression (Devarajan et al., 2002). Also breast cancer cell line MCF-7, has been 
shown to be deficient in caspase 3 (Kurokawa et al., 1999). The caspase 7 with 
missense mutations has been linked with colorectal and head-neck cancers (Soung 
et al., 2003). Therefore these studies have shown the involvement of apoptotic 
regulatory proteins in tumourigenesis. Recent researches provide evidences of the 
role of nuclear receptor FXR in induction of apoptosis (Deuschle et al., 2012, Giordano 
et al., 2011, Modica et al., 2008). FXR agonists GW4064 and CDCA are involved in 
the activation of mitochondrial permeability transition pore (MPTP) and release of 
cytochrome c following apoptosis induction (Pu et al., 2013). Another study suggested 
that FXR activation enhances apoptosis in ovarian cancer cells (Alberts et al., 2001). 
Swales et al. (2006) showed that FXR activation induces apoptosis in breast cancer 
cells. However the mechanism of cell death was unknown. The present study 
demonstrated that FXR activation in breast cancer cell lines MCF-7 and MDA-MB-231 
induces cell death (Chapter 4). Next, I examined the molecular mechanism of FXR 
mediated cell death in breast cancer cell lines MCF-7 and MDA-MB-231. To study this, 
the effect of staurosporine, was used as positive control in this study to induce 
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apoptosis in breast cancer cell lines. Next, the proteins involved in apoptosis pathways 
were studied (Figure 5-1).   
 
 
 
Figure 5-1: Apoptosis Pathway 
The intrinsic and extrinsic pathway. Intrinsic pathway mediated by Bcl-2 family of proteins. 
Translocation of Bax and release of cytochrome c to cytosol. Cytochrome c combines with 
APAF-1 and procaspase 9 forming apoptososme. Apoptosome activates caspase 9, further 
activating executioner caspase 3 resulting in PARP cleavage. Extrinsic pathway is FAS mediated 
pathway. Once activated forms the death inducing signalling complex. This further activates the 
caspase 8 and further activating caspase 3 followed by PARP cleavage and cell death.  
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5.2  RESULTS 
 
5.2.1 Effect of staurosporine on MCF-7 and MDA-MB-231 cells. 
 
To study apoptosis, staurosporine was used to induce apoptosis in breast cancer cell 
lines MCF-7 and MDA-MB-231. Staurosporine has been shown in studies to blocks 
the protein kinase activity and was used in this study as positive control (Meggio et al., 
1995, Omura et al., 1995, Tamaoki et al., 1986). It has been used as one of the 
classical cell death inducer by activating Caspase 3 (Chae et al., 2000, Jacobsen et 
al., 1996, Yue et al., 1998). Both cells lines were treated with Staurosporine and cell 
viability was assessed with MTT assay as described in Methods. The result shows 
that staurosporine induces concentration dependent cell death in both MCF-7 (Figure 
5-2) and MDA-MB-231 (Figure 5-3) cell lines. 
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Figure 5-2: Staurosporine induce cell death in MCF-7 
  
 
Concentration dependent effects of staurosporine on MCF-7 after 24 hours. MCF-7 cells 
were treated with different concentrations of STS (0, 0.1, 0.3, 1 and 10 µM) showed decreased 
cell viability with increasing concentration at 24 hours. Points, mean viability as a 
percentage of control (i.e., vehicle-treated cells = 100%) from n=9 replicates from five 
separate experiments; bars, SE.  
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Figure 5-3: Staurosporine induce cell death in MDA-MB-231 
  
Concentration dependent effects of staurosporine on MDA-MB-231 after 24 hours. MDA-MB-
231 cells were treated with different concentrations of staurosporine (0, 0.1, 0.3, 1 and 10 
µM) showed decreased cell viability with increasing concentration at 24 hours. Points, mean 
viability as a percentage of control (i.e., vehicle-treated cells = 100%) from n=9 replicates 
from five separate experiments; bars, SE. 
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5.2.2 Effect of FXR on Poly ADP-ribose polymerase (PARP): 
 
 One the classical early markers of apoptotic cell death is cleavage of the Poly-ADP 
ribose polymerase 1 protein (PARP). PARP plays an important role in functioning of 
cell, acting as one of the gatekeeper of DNA damage. PARP is one of a family of 
enzymes that demonstrates a high level of conservation in nature, with orthologues 
being present in genera as diverse as mammals (Uchida and Miwa, 1994). Its major 
biological function is the detection of, and subsequent binding to, single strand breaks 
in DNA. Following detection of DNA damage, PARP is integral to single strand repair 
through the PARP-dependent synthesis of a poly (ADP-ribose) chain, which acts as a 
signal to recruit repair enzymes such as DNA ligase III and DNA polymerase beta. 
Once this complex has successfully repaired the single strand break, the poly (ADP-
ribose) chain is degraded through the action of a poly (ADP-ribose) glycohydrolase 
(Davidovic et al., 2001, Herceg and Wang, 2001, Soldani and Scovassi, 2002). An 
important step in the apoptotic cascade is the inactivation of this repair mechanism 
through the action of caspase-dependent cleavage of PARP, with caspase-3 the most 
common executioner caspase catalysing this reaction (Chaitanya et al., 2010, 
D'Amours et al., 2001). In the previous chapter, it was demonstrated that activation of 
FXR by either GW4064 or CDCA resulted in a concentration-dependent decrease in 
cell viability. To examine if apoptosis was a potential mechanism underlying this effect, 
the impact of FXR activation on PARP cleavage was studied. In addition to treatment 
with the FXR agonists (GW4064; 30µM and CDCA; 245µM), both breast cancer cell 
lines (MCF-7 and MDA-MB-231) were also exposed to 1 µM staurosporine as a 
positive control for apoptosis. The protein extracts were prepared as stated in the 
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methods (section 3.2.3), and samples were separated by SDS-PAGE and probed with 
PARP-1 antibody (section 3.3). 
Full length PARP protein has a molecular mass of 116 KDa. Cleavage occurs at the 
Asp and Gly residues at 214 and 215 respectively, producing fragments of 85 KDa 
and 24 KDa (Lazebnik et al., 1994). The results indicate that FXR agonists GW4064 
and CDCA, as well as the positive control staurosporine were able to induce PARP 
cleavage (Figure 5-4 and 5-5).  
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Figure 5-4: PARP cleavage induced by FXR agonists in MCF-7. 
MCF-7 cells treated for 24 hr with GW4064 (35µM), CDCA (245µM) and positive control 
Staurosporine (1µM). (A) Bar graph shown as the ratio of cleaved PARP to actin control of 3 
independent repeats. (B) Representative blot image (upper panel) of PARP uncleaved and 
cleaved with corresponding β actin loading control (lower panel). The cell lysates analysed by 
Western using anti-PARP, which detects both intact PARP (116 KDa) and the apoptotic marker 
PARP cleavage fragment (85 KDa). The loading control β-actin was detected at 45KDa.  Data 
analysed by one way ANOVA. Data represented as mean ± SE. of 3 samples (N=3); P<0.05 was 
considered as significant and indicated as **** P<0.01 as higher significance.  
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Figure 5-5: PARP cleavage induced by FXR agonists in MDA-MB-231. 
 
MDA-MB-231 cells treated for 24 hr with FXR agonists GW4064 (22µM) CDCA (210µM) and 
positive control Staurosporine (1µM). (A) Bar graph shown as the ratio of cleaved PARP to actin 
control of 3 independent repeats. (B) Representative blot image (upper panel) of PARP 
uncleaved and cleaved with corresponding β actin loading control (lower panel). The cell lysates 
analysed by Western using anti-PARP, which detects both intact PARP (116 KDa) and the 
apoptotic marker PARP cleavage fragment (85 KDa). The loading control β-actin was detected 
at 45KDa.  Data analysed by one way ANOVA. Data represented as mean ± SE. of 3 samples 
(N=3); P<0.05 was considered as significant and indicated as **** P<0.01 as higher significance 
and P<0.05 indicated as not significant and marked as NS. 
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Having demonstrated that FXR activation was able to stimulate cell death through 
apoptosis, the concentration dependence of this effect was next examined. As can be 
seen in figure 5-6 and 5-7, FXR agonists and staurosporine induces PARP cleavage 
in a dose-dependent manner.   
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Figure 5-6: Dose-dependent PARP cleavage in MCF-7 
 
MCF-7 cells treated for 24 hr with different doses of GW4064, CDCA and Staurosporine. (A) Bar 
graph shown as the ratio of cleaved PARP to actin control of 3 independent repeats. (B) 
Representative blot image (upper panel) of PARP uncleaved and cleaved with corresponding β 
actin loading control (lower panel). The cell lysates analysed by Western using anti-PARP, which 
detects both intact PARP (116 KDa) and the apoptotic marker PARP cleavage fragment (85 KDa). 
The loading control β-actin was detected at 45KDa. Data analysed by one way ANOVA. Data 
represented as mean ± SE. of 3 samples (N=3), SE; P<0.05 was considered as significant and 
indicated as **** P<0.01 as higher significance and P<0.05 indicated as not significant and 
marked as NS. 
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Figure 5-7: Dose-dependent PARP cleavage in MDA-MB-231 
MDA-MB-231 cells treated for 24 hr with different doses of GW4064, CDCA and Staurosporine. 
(A) Bar graph shown as the ratio of cleaved PARP to actin control of 3 independent repeats. (B) 
Representative blot image (upper panel) of PARP uncleaved and cleaved with corresponding β 
actin loading control (lower panel). The cell lysates analysed by Western using anti-PARP, which 
detects both intact PARP (116 KDa) and the apoptotic marker PARP cleavage fragment (85 KDa). 
The loading control β-actin was detected at 45KDa. Data analysed by one way ANOVA. Data 
represented as mean ± SE. of 3 samples (N=3); P<0.05 was considered as significant and 
indicated as **** P<0.01 as higher significance and P<0.05 indicated as not significant and 
marked as NS. 
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5.2.3 FXR induces intrinsic pathway activity in MCF-7 and MDA-MB-
231. 
 
5.2.3.1 Effect of FXR on caspase 3/7 activity in MCF-7 and MDA-
MB-231. 
 
In the previous section, the FXR ligands were shown to induce PARP cleavage in both 
MCF-7 and MDA-MB-231 breast cancer cell lines. Such PARP cleavage is usually 
taken as a strong indicator for the activation of apoptotic cascade; however, it has 
been reported that PARP cleavage can be independent of caspase cleavage of 
apoptotic pathway (Jones et al., 1999, Liu et al., 2001, Masdehors et al., 2000). 
Essentially, as the degree of single-strand DNA breaks increases so does the 
activation of PARP. As PARP requires the energy source nicotinamide adenine 
dinucleotide (NAD+) to create the poly (ADP-ribose) chain, this can lead to depletion 
in intracellular NADH stores, leading to necrotic cell death (Berger, 1985, Carson et 
al., 1986, Gobeil et al., 2001, Oleinick and Evans, 1985). On this basis, it is important 
to use a second, complimentary, measurement for activation of the apoptosis cascade 
to exclude this possibility. 
Apoptosis is governed by two pathways, the intrinsic or mitochondrial dependent 
pathway and extrinsic or death receptor pathway. Both of these pathways are 
controlled by members of the cysteine protease family of enzymes, called caspases. 
Hence, activation of caspases is seen as evidence of apoptotic mode of cell death.   
Given the two modes of apoptotic cell death, intrinsic and extrinsic pathways, the 
choice of caspase to study is important as it will determine which pathway is studied. 
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While effector caspases such as caspase 8 and caspase 9 are pathway dependent 
(Acehan et al., 2002, Boatright et al., 2003, Cain et al., 2002, Chang et al., 2003, Li et 
al., 1997, Muzio et al., 1998, Peter and Krammer, 2003, Shiozaki et al., 2002), the 
executioner caspases 3 and 7 are at the ends of both pathways and hence their 
activation is indicative of apoptosis through either pathway (Boatright and Salvesen, 
2003, Nunez et al., 1998, Porter and Janicke, 1999, Riedl and Shi, 2004, Salvesen 
and Riedl, 2008, Slee et al., 2001). Caspase 3 in particular is of interest with respect 
to breast cancer, and has been studied extensively (Blanc et al., 2000, Devarajan et 
al., 2002, Mandlekar et al., 2000, O'Donovan et al., 2003, Yang et al., 2001).  
MCF-7 and MDA-MD-231 cells were cultured as previously described and then 
exposed for 20 hours to vehicle, IC50 concentrations of GW4064 or CDCA, or 1µM 
staurosporine as a positive control. In addition, treatments were also undertaken in the 
presence of 50µM Ac-DEVD-CHO, a competitive caspase 3/7 inhibitor, as a negative, 
control.   
As can be seen from figure 5-8 (MCF-7) and figure 5-9 (MDA-MB-231), staurosporine 
was able to increase caspase 3/7 activity in both cell lines. The fold-activation was 
different between the two cell lines, with MCF-7 cells exhibiting a lower (7-fold relative 
to vehicle control) increase compared to MDA-MB-231 cells (11 fold). This is 
consistent with the published literature, where MCF-7 cells are reported to undergo 
apoptotic cell death to a lower extent than MDA-MB-231 cell lines (Janicke et al., 
1998a, Janicke et al., 1998b, Jia et al., 2014, Syed Alwi et al., 2012). In both cases, 
addition of the caspase 3/7 inhibitor Ac-DEVD-CHO completely ablated activity, 
supporting the conclusion that the observed activity is specific to caspase 3/7 
activation. 
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Having demonstrated the ability of staurosporine to induce apoptosis in both cell lines, 
albeit to differing degrees, the impact of FXR activation by GW4064 and CDCA were 
next examined. In both MCF-7 (figure 5-7) and MDA-MB-231 (figure 5-8) cell lines, 
caspase 3/7 activity was significantly increased by FXR activation. The specificity of 
this increase was demonstrated through the use of Ac-DEVD-CHO, where co-
incubation caused a complete loss of caspase 3/7 activity. GW4064 caused a greater 
fold-activation than CDCA in both cell lines, being 4-fold and 7-fold versus 1-fold and 
2-fold in MCF-7 and MDA-MB-231 cell lines, respectively. It is important to note, 
however, that these values are not directly comparable, due to the concentrations 
used. Concentrations were selected to represent the IC50 values for cell viability, but 
when related to the Kd between each compound and FXR are equivalent to 99% and 
68% occupancy for GW4064 and CDCA, respectively. To conclusively determine if the 
relative potency of each ligand to stimulate caspase 3/7 activation, an expanded 
concentration-response curve would be required.  As was seen with staurosporine, 
activation of caspase 3/7 activity was lower in MCF-7 cells than MDA-MD-231 cells, 
being on average 4-fold lower for both drugs. 
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Figure 5-8: GW4064 and CDCA induces caspase 3/7 activity in MCF-7 
 
MCF-7 (1 x 104) cells per well seeded in 96 well plate for 24 hours. The cells were treated with 
Staurosporine (1µM), GW4064 (35µM) and CDCA (245µM) for 20 hours. DMSO was used as 
control.  Cellular caspase 3/7 activity was determined by Caspase-Glo assay kit (Promega) and 
expressed as percentage of the treated cell to the untreated control cell. A negative control 
group which received Caspase inhibitor Ac-DEVD-CHO treatment (50 µM) was included in each 
cell line to assess whether the Caspase-Glo assay kit is specific for Caspase 3/7. Caspase 
activity was represented as the percentage (%) to untreated control group, and data represented 
as mean ± SE. of 3 samples (n=3). Data analysed by one-way ANOVA. P<0.05 was considered as 
significant and indicated as ** P<0.01 as higher significance and indicated as *** P<0.05 as not 
significant and marked as NS.  
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Figure 5-9: GW4064 and CDCA induces caspase 3/7 activity in MDA-MB-231 
 
MDA-MB-231 (1 x 104) cells per well seeded in 96 well plate for 24 hours. The cells were treated 
with Staurosporine (1µM), GW4064 (22µM) and CDCA (210µM) for 20 hours. DMSO was used as 
control.  Cellular caspase 3/7 activity was determined by Caspase-Glo assay kit (Promega) and 
expressed as percentage of the treated cell to the untreated control cell. A negative control 
group which received Caspase inhibitor Ac-DEVD-CHO treatment (50 µM) was included in each 
cell line to assess whether the Caspase-Glo assay kit is specific for Caspase 3/7. Caspase 
activity was represented as the percentage (%) to untreated control group, and data represented 
as mean±SE of 3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as 
significant and indicated as ** P<0.01 as higher significance and indicated as *** P<0.05 as not 
significant and marked as NS.  
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5.2.3.2 Effect of FXR on caspase 9 activity in MCF-7 and MDA-
MB-231.  
 
Having demonstrated that activation of FXR by GW4064 and CDCA elicited a 
statistically significant increase in executioner caspase activity, the next logical 
question is whether this is due to activation of the extrinsic or intrinsic apoptotic 
cascades, or both. To examine this, the levels of caspase 9 and caspase 8 were 
examined. As depicted in figure 5-1, the intrinsic pathway is dependent on the 
formation of the apoptosome, a complex that included caspase 9 along with apaf-1 
and cytochrome c (Cain et al., 2002, Li et al., 1997). Dysregulation of apoptosome 
formation has been observed in certain cancers, with failure of apoptosome formation 
leading toward tumour cell survival (Jia et al., 2001, Liu et al., 2002, Wolf et al., 2001). 
In contrast, the extrinsic apoptotic cascade is driven through activation of cell surface 
receptors such as FAS ligand, a member of tumour necrosis factor family (Ashkenazi 
and Dixit, 1998, Boatright and Salvesen, 2003, Elmore, 2007, Krammer, 1998, 
Magnusson and Vaux, 1999). Activation of the Apo-1 or CD95 by FAS then triggers 
activation of caspase 8, formation of the death inducing signalling complex (Grunert 
et al.) and activation of the apoptotic cascade (Figure 5-1).  
Under basal conditions both MCF-7 and MDA-MB-231 cell lines showed a low level of 
caspase 9 activity, which was significantly increased by exposure to staurosporine: 
64-fold and 70-fold in MCF-7 and MDA-MB-231 cells, respectively (Figure 5-10 and 5-
11). This activation could be ablated by addition of an excess of the caspase 9 
competitive inhibitor Ac-LEHD-FMK (Ekert et al., 1999).    
The FXR agonists GW4064 and CDCA were also able to increase caspase 9 activity 
in both cell lines, and these effects were also ablated by the competitive caspase 9 
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inhibitor Ac-LEHD-FMK. 35µM and 22µM GW4064 caused a 50-fold and 65-fold 
increase of caspase 9 activity in MCF-7 and MDA-MB-231 cells, respectively, while 
245µM and 210µM CDCA elicited 25-fold and 40-fold increases in these cell lines, 
respectively. As noted previously, comparison between the effects of the two 
compounds in the absence of full concentration-response curves is limited. However, 
it is important to note that as with caspase 3/7, the degree of activation was 
significantly less in MCF-7 cells compared to MDA-MB-231, being 15-fold lower for 
both GW4064 and CDCA lower. The results are consistent with the observed cell 
death occurring via the intrinsic apoptotic pathway.  
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Figure 5-10: GW4064 and CDCA induces caspase 9 activity in MCF-7 
 
MCF-7 (1 x 104) cells per well seeded in 96 well plate for 24 hours. The cells were treated with 
Staurosporine (1µM), GW4064 (35µM) and CDCA (245µM) for 9 hours. DMSO was used as control. 
Cellular caspase 9 activity was determined by Caspase-Glo assay kit (Promega) and expressed 
as percentage of the treated cell to the DMSO control cell. A negative control group which 
received Caspase inhibitor Ac-LEHD-CHO treatment (50 µM) was included in each cell line to 
assess whether the Caspase-Glo assay kit is specific for Caspase 9. Caspase activity was 
represented as the percentage (%) to DMSO control group, and data represented as mean±SE 
of 3 samples (n=3). P<0.05 was considered as significant and indicated as ** P<0.01 as higher 
significance and indicated as *** P>0.05 as not significant. 
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Figure 5-11: GW4064 and CDCA induces caspase 9 activity in MDA-MB-231 
 
MDA-MB-231 (1 x 104) cells per well seeded in 96 well plate for 24 hours. The cells were treated 
with Staurosporine (1µM), GW4064 (22µM) and CDCA (210µM) for 9 hours. DMSO was used as 
control. Cellular caspase 9 activity was determined by Caspase-Glo assay kit (Promega) and 
expressed as percentage of the treated cell to the DMSO control cell. A negative control group 
which received Caspase inhibitor Ac-LEHD-CHO treatment (50 µM) was included in each cell line 
to assess whether the Caspase-Glo assay kit is specific for Caspase 9. Caspase activity was 
represented as the percentage (%) to DMSO control group, and data represented as mean±SE 
of 3 samples (n=3). P<0.05 was considered as significant and indicated as ** P<0.01 as higher 
significance and indicated as *** P>0.05 as not significant. 
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5.2.3.3 FXR and caspase 8 activity in MCF-7 and MDA-MB-231. 
 
Activation of the extrinsic apoptotic pathway was next examined. First, the ability of 
the classical activator of the extrinsic pathway, FAS ligand, to increase caspase 8 
activity was examined. In both MCF-7 and MDA-MB-231 cell lines, 10µM FAS ligand 
induced a significant increase in caspase 8 activity, being 1.8-fold and 1.9-fold above 
vehicle control, respectively. In contrast, neither of the FXR agonists elicited any 
significant increase in caspase 8 activity in either MCF-7 or MDA-MB-231 cell lines 
(Figure 5-12 and 5-13). These results are consistent with the conclusion that FXR 
agonists do not activate extrinsic apoptotic pathway, but rather act only through the 
intrinsic apoptotic pathway. 
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Figure 5-12: Caspase 8 activity in MCF-7 
 
MCF-7 (1 x 104) cells per well seeded in 96 well plate for 24 hours. The cells were treated with 
FAS (50µM), GW4064 (35µM) and CDCA (245µM) for 9 hours. DMSO was used as control. Cellular 
caspase 8 activity was determined by Caspase-Glo assay kit (Promega) and expressed as 
percentage of the treated cell to the DMSO control cell. A negative control group which received 
Caspase inhibitor Z-IETD-FMK treatment (50 µM) was included in each cell line to assess 
whether the Caspase-Glo assay kit is specific for Caspase 8. Caspase activity was represented 
as the percentage (%) to DMSO control group, and data represented as mean±SE of 3 samples 
(n=3). P<0.05 was considered as significant and indicated as ** P<0.01 as higher significance 
and indicated as *** P>0.05 as not significant and marked as NS. 
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Figure 5-13: Caspase 8 activity in MDA-MB-231 
 
MDA-MB-231 (1 x 104) cells per well seeded in 96 well plate for 24 hours. The cells were treated 
with FAS (10µM), GW4064 (22µM) and CDCA (210µM) for 9 hours. DMSO was used as control. 
Cellular caspase 8 activity was determined by Caspase-Glo assay kit (Promega) and expressed 
as percentage of the treated cell to the DMSO control cell. A negative control group which 
received Caspase inhibitor Z-IETD-FMK treatment (50 µM) was included in each cell line to 
assess whether the Caspase-Glo assay kit is specific for Caspase 8. Caspase activity was 
represented as the percentage (%) to DMSO control group, and data represented as mean±SE 
of 3 samples (n=3). P<0.05 was considered as significant and indicated as ** P<0.01 as higher 
significance and indicated as *** P>0.05 as not significant and marked as NS. 
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5.2.3.4 Effect of FXR on mitochondrial disruption and 
cytochrome c release 
  
The intrinsic apoptotic pathway is mitochondrial dependent, with disruption of the 
mitochondrial membrane a key feature of the apoptotic cascade. This triggers the 
release of pro apoptotic proteins from mitochondria to cytosol activating the initiator 
caspase 9 and forming the apoptosome (Acehan et al., 2002, Green and Reed, 1998, 
Cain et al., 2002). One of the key proteins that is released is cytochrome c, which 
resides in the mitochondrial inter-membrane where it is a part of the electron transport 
chain (Rohlena et al., 2013, Pramanik et al., 2011, Green and Reed, 1998, Jiang and 
Wang, 2004, Gao et al., 2001, Matsuyama et al., 2000). 
In order to investigate mitochondrial cytochrome c release, cell fractionation into 
cytosolic and mitochondrial pools was undertaken as described under Methods. 
Successful fractionation was assessed by Western blot analysis for lactate 
dehydrogenase (LDH), an enzyme expressed solely in the cytosol (Williams et al., 
1985, Zhong and Howard, 1990). Cytochrome c levels in these pools was assessed 
by Western blot following exposure of cells to 1µM staurosporine, 35 and 22µM 
GW4064 or 245 and 210 µM CDCA for MCF-7 and MDA-MB-231,respectively for 
times between 2 hours and 8 hours.  
In blots from untreated samples (time zero), cytochrome c was detected predominantly 
in the mitochondrial fraction, although a low level of cytochrome c was detected in the 
cytosolic fraction (figures 5-14 – 5-19). LDH expression was observed only in the 
cytoplasmic fraction, consistent with an efficient separation of the two fractions. 
However, without the use of a mitochondrial marker it is not possible to determine if 
the cytosolic cytochrome c observed in the untreated cells is due contamination of the 
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cytosolic fraction with mitochondrial extract, or representative of the background 
apoptosis observed previously (Figure 5-14). 
As a positive control for cytochrome c release, the effect of staurosporine was first 
examined.  As seen in figure 5-14, 1µM staurosporine causes a time-dependent 
release of cytochrome c from mitochondria.  
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Figure 5-14: Staurosporine induces cytochrome c release in MCF-7 
MCF-7 cells were treated at different time points with Staurosporine and mitochondrial/cytosolic 
fractions were prepared, as described in Methods. The mitochondrial and cytosolic proteins 
were separated by SDS-PAGE and immunoblotted for cytochrome c (Cty C) and lactate 
dehydrogenase (LDH). From 2 to 8 hours cytochrome c was completely expressed into cytosol. 
(A) Relative band intensities expressed as percentage. (B) Top; Western blot expression of 17-
kDa cytochrome C protein translocation to cytosol, Bottom; LDH expression of 35-kDa in the 
cytosolic fraction. Image is representative blot of N=3 repeats. Data represented as mean±SE of 
3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as significant and 
indicated as ** P<0.01 was considered significant and indicated as *** P<0.0001 as higher 
significance and indicated as **** P>0.05 as not significant and marked as NS. 
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This effect is very rapid in MCF-7, with nearly 100% of cytochrome c being found in 
the cytosolic fraction after only 2 hours of exposure. In contrast, exposure of MDA-
MB-231 cells to 1µM staurosporine elicits a much slower translocation, which is 100% 
complete following only after 8 hours of exposure (Figure 5-15).  The rationale for the 
difference in timings between these two cell lines is unclear, but is consistent with 
literature reports for a rapid (low hours) translocation in both cell lines (Punj et al., 
2004, Rudy et al., 2008, Mooney et al., 2002).  
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Figure 5-15: Staurosporine induces cytochrome c release in MDA-MB-231 
 MDA-MB-231 cells were treated at different time points with Staurosporine and 
mitochondrial/cytosolic fractions were prepared, as described in Methods. The mitochondrial 
and cytosolic proteins were separated by SDS-PAGE and immunoblotted for cytochrome c (Cty 
C) and lactate dehydrogenase (LDH). From 6 to 8 hours cytochrome c was completely expressed 
into cytosol. (A) Relative band intensities expressed as percentage. (B) Top; Western blot 
expression of 17-kDa cytochrome c protein translocation to cytosol, Bottom; LDH expression 
of 35-kDa in the cytosolic fraction. Image is representative blot of N=3 repeats. Data represented 
as mean±SE of 3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as 
significant and indicated as ** P<0.01 was considered significant and indicated as *** P<0.0001 
as higher significance and indicated as **** P>0.05 as not significant and marked as NS.   
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Next, the effect of the FXR agonists GW4064 and CDCA on cytochrome c localisation 
was examined. Both 35 and 22µM GW4064 and 245 and 210µM CDCA in MCF-7 and 
MDA-MB-231 respectively, were able to cause a time-dependent release of 
cytochrome c from the mitochondria (figure 5-16, 5-17, 5-18 and 5-19). GW4064 
caused 100% release of cytochrome c into the cytoplasm by 6 hours in both cell lines, 
while CDCA achieved only 25±1.2% and 34±2.4% in MCF-7 and MDA-MB-231 cell 
lines after 8 hours, respectively.  
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Figure 5-16: GW4064 induces cytochrome c release in MCF-7 
 MCF-7 cells were treated at different time points with GW4064 (35µM) and 
mitochondrial/cytosolic fractions were prepared, as described in Methods. The mitochondrial 
and cytosolic proteins were separated by SDS-PAGE and immunoblotted for cytochrome c (Cty 
C) and lactate dehydrogenase (LDH). From 6 to 8 hours cytochrome c was completely expressed 
into cytosol. (A) Relative band intensities expressed as percentage. (B) Top; Western blot 
expression of 17-kDa cytochrome c protein translocation to cytosol, Bottom; LDH expression 
of 35-kDa in the cytosolic fraction. Image is representative blot of N=3 repeats. Data represented 
as mean±SE of 3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as 
significant and indicated as ** P<0.01 was considered significant and indicated as *** P<0.0001 
as higher significance and indicated as **** P>0.05 as not significant and marked as NS. 
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Figure 5-17: GW4064 induces cytochrome c release in MDA-MB-231 
 MDA-MB-231 cells were treated at different time points with GW4064 (22µM) and 
mitochondrial/cytosolic fractions were prepared, as described in Methods. The mitochondrial 
and cytosolic proteins were separated by SDS-PAGE and immunoblotted for cytochrome c (Cty 
C) and lactate dehydrogenase (LDH). From 6 to 8 hours cytochrome c was completely expressed 
into cytosol. (A) Relative band intensities expressed as percentage. (B) Top; Western blot 
expression of 17-kDa cytochrome c protein translocation to cytosol, Bottom; LDH expression 
of 35-kDa in the cytosolic fraction. Image is representative blot of N=3 repeats. Data represented 
as mean±SE of 3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as 
significant and indicated as ** P<0.01 was considered significant and indicated as *** P<0.0001 
as higher significance and indicated as **** P>0.05 as not significant and marked as NS. 
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Figure 5-18: CDCA induces cytochrome c release in MCF-7 
 MCF-7 cells were treated at different time points with CDCA (245µM) and 
mitochondrial/cytosolic fractions were prepared, as described in Methods. The mitochondrial 
and cytosolic proteins were separated by SDS-PAGE and immunoblotted for cytochrome c (Cty 
C) and lactate dehydrogenase (LDH). No significant cytochrome c release was measured into 
cytosol. (A) Relative band intensities expressed as percentage. (B) Top; Western blot expression 
of 17-kDa cytochrome c protein translocation to cytosol, Bottom; LDH expression of 35-kDa in 
the cytosolic fraction. Image is representative blot of N=3 repeats. Data represented as mean±SE 
of 3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as significant 
and indicated as ** P<0.01 was considered significant and indicated as *** P<0.0001 as higher 
significance and indicated as **** P>0.05 as not significant and marked as NS. 
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Figure 5-19: CDCA induces cytochrome c release in MDA-MB-231 
MDA-MB-231 cells were treated at different time points with CDCA (245µM) and 
mitochondrial/cytosolic fractions were prepared, as described in Methods. The mitochondrial 
and cytosolic proteins were separated by SDS-PAGE and immunoblotted for cytochrome c (Cty 
C) and lactate dehydrogenase (LDH). No significant cytochrome c release was measured into 
cytosol. (A) Relative band intensities expressed as percentage. (B) Top; Western blot expression 
of 17-kDa cytochrome c protein translocation to cytosol, Bottom; LDH expression of 35-kDa in 
the cytosolic fraction. Image is representative blot of N=3 repeats. Data represented as mean±SE 
of 3 samples (n=3). Data analysed by one way ANOVA. P<0.05 was considered as significant 
and indicated as ** P<0.01 was considered significant and indicated as *** P<0.0001 as higher 
significance and indicated as **** P>0.05 as not significant and marked as NS 
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5.2.3.5 Effect of GW4064 and CDCA on BAX and Bcl-2 
expression. 
 
Cytochrome c release is an important step in the intrinsic apoptotic cascade. Its 
release is mainly regulated by the complement of anti-apoptotic and pro-apoptotic 
proteins within the cell (Dewson and Kluck, 2009, Landes and Martinou, 2011). More 
specifically, it is the relative amount of pro-apoptotic proteins to anti-apoptotic proteins 
that determines mitochondrial membrane integrity and, therefore, cytochrome c 
localisation (Dewson and Kluck, 2009, Kluck et al., 1997, Gross et al., 1998). For 
example, studies have demonstrated that mutations in the pro-apoptotic BAX gene 
are associated with altered cell growth and tumour survival (Del Bufalo et al., 1997, 
Miquel et al., 2005, Ouyang et al., 1998, Rampino et al., 1997), while inadequate or 
insufficient activation of pro-apoptotic proteins can lead to tumour formation in breast 
cancer (Bargou et al., 1995, Bargou et al., 1996, Krajewski et al., 1995). 
Since the primary function of the Bcl-2 family of proteins is to regulate apoptosis, it 
raises the question as to whether FXR agonists are able to alter the expression of 
these family members, thus shifting the pro-apoptotic: anti-apoptotic ratio and affecting 
mitochondrial function and cytochrome c release. To examine this, the ratio of 
BAX:Bcl2 was examined in MCF-7 and MDA-MB-231 cells following exposure to 
GW4064 and CDCA. 
As can be seen from figure 5-20, in MCF-7 cells, the expression level of Bcl2 was 
significantly decreased following exposure to 35µM GW4064 or 245µM CDCA for 24 
hours. In contrast, BAX expression was significantly increased in MCF-7 cells following 
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exposure to GW4064, with an increasing trend also observed following treatment with 
CDCA. When these expression levels are presented as the BAX:Bcl-2 ratio, which is 
a determinant of apoptotic cascade activation (Oltvai et al., 1993, Gross et al., 1999), 
it can be seen that this is elevated by both treatments, although this only reaches 
statistical significance with GW4064. Exposure of MDA-MB-231 cells to 22µM 
GW4064 or 210µM CDCA for 24 hours elicited a broadly similar result (figure 5-21). 
Bcl-2 expression was decreased by GW4064 exposure, while CDCA elicited no 
significant effect.   
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Figure 5-20: Effects of FXR ligands on BAX & Bcl2 in MCF-7 
MCF-7 cells were treated with DMSO (Control), GW4064 (35µM) and CDCA (245µM). The protein 
extracts were separated on SDS-PAGE and immunoblotted as described in Materials & Methods. 
(A) In MCF-7 cells the level of BAX expression increases, while Bcl-2 expression decreases with 
the treatments. (B) Densitometric analysis of Bax and Bcl2 protein expression levels in MCF-7 
cells treated with GW4064 and CDCA. (C) Bax and Bcl2 ratio was significantly higher only in 
MCF-7 treated with GW4064 over control. Data analysed by two-way ANOVA. N=3; ** p<0.001, 
**** p<0.0001vs. control; bars, mean ±SE 
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Figure 5-21: Effects of FXR ligands on BAX and Bcl2 in MDA-MB-231 
 
MDA-MB-231 cells were treated with DMSO (Control), GW4064 (22µM) and CDCA (210µM). The 
protein extracts were separated on SDS-PAGE and immunoblotted as described in Materials & 
Methods. (A) In MDA-MB-231 cells the level of BAX expression increases, while Bcl-2 expression 
decreases with the treatments. (B) Densitometric analysis of Bax and Bcl2 protein expression 
levels MDA-MB-231 cells treated with GW4064 and CDCA. (C) Bax and Bcl2 ratio was 
significantly higher only in MCF-7 treated with GW4064 over control. Data analysed by two-way 
ANOVA. N=3; ** p<0.001, **** p<0.0001vs. control; bars, mean ±SE 
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5.2.4 Cell death with autophagy features 
5.2.4.1 MCF-7 cells exhibits autophagy response 
 
The work described in the previous section clearly demonstrates that activation of FXR 
results in activation of apoptotic cascade in both MCF-7 and MDA-MB-231 cell lines. 
However, while the IC50 values derived for FXR-mediated cell death do not differ 
greatly between cell lines (chapter 3), the extent of apoptosis appears to. For example, 
caspase 3/7 activation by FXR agonists is on average 3-fold higher in MDA-MB-231 
cell line compared to MCF-7 cells. In addition, the positive control agent staurosporine 
elicits a 200% greater response in MDA-MB-231 cells. Together these data support 
the observation that MCF-7 cells do not commit to the apoptotic pathway as strongly 
as other cell line, which is consistent with the published literature. Apoptosis cannot 
be solely responsible for cell demise in MCF-7 cells, and recent research provides 
ample evidence that autophagy has a cross talk with apoptosis in deciding the cells 
fate (Luo and Rubinsztein, 2010, Bursch et al., 1996, Liang et al., 1999b, Akar et al., 
2008, Paglin et al., 2005). Thus, it is an important factor to resolve the disparity 
between observed cell death and apoptotic activation in MCF-7 cells.  
To investigate autophagic response, MCF-7 and MDA-MB-231 cells were exposed to 
35 or 22µM GW4064 or 245 or 210µM CDCA respectively, for 24 hours.Following 
exposure, total protein was extracted, and immunoblotted against microtubule-
associated protein 1 light chain 3 (LC3). LC3 is a well-recognised marker of 
autophagy, with cleavage of LC3 to LC3 II a marker of autophagosome formation 
(Tanida et al., 2008, Tanida and Waguri, 2010). The ratio of LC3-II/LC3-I is directly 
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proportional to the number of autophagosomes, and hence an indirect measure of 
autophagy (Karim et al., 2007, Kadowaki and Karim, 2009).  
The present study used the LC3-II:LC3-I ratio to assess the effect of GW4064 and 
CDCA on LC3 protein expression; a larger ratio indicating enhanced autophagy. In 
MCF-7 cells, exposure to GW4064 induced a statistically significant 2-fold increase in 
the LC3-II-I:LC3-I ratio; however, exposure to the less potent FXR agonist CDCA did 
not increase this ratio above control levels. In contrast, in the MDA-MB-231 cell line, 
neither GW4064 or CDCA exposure was able to increase the LC3-II:LC3-I ratio. 
Together, these data are consistent with FXR activation inducing autophagy in the 
MCF-7 cell line, but not in MDA-MB-231 cell line. As such, this provides a possible 
explanation for the disparity between loss of cell viability and increase in apoptosis 
observed in the MDA-MB-231 cell line. 
 
 
 
 
 
 
 
 
151 
 
 
Figure 5-22: LC3 expression in MCF-7 
LC3 has two subtypes, LC3-I and LC3-II. Upon autophagy induction, the conversion from LC3-I 
to LC3-II is significantly increased. (A) Immunoblotting of LC3-I and LC3-II. The conversion from 
LC3-I to LC3-II is apparent in the GW4064 group, but was not evident in CDCA group. (B) LC3-II 
band density normalized to LC3-I, showing the conversion rate of LC3-I to LC3-II. This indirectly 
shows the autophagy rate of the MCF-7 cells treated with FXR ligands. HepG2 was used as a 
negative control. There was no significant difference in the conversion of LC3-I to LC3-II 
between the CDCA and control groups. Data analysed by one-way ANOVA. N=3; * p<0.05 vs. 
control; bars, mean ±SE 
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Figure 5-23: LC3 expression in MDA-MB-231 
 LC3 has two subtypes, LC3-I and LC3-II. (A) Immunoblotting of LC3-I and LC3-II. The conversion 
from LC3-I to LC3-II was not evident in GW4064 or in CDCA group. (B) LC3-II band density 
normalized to LC3-I, showing the conversion rate of LC3-I to LC3-II. HepG2 was used as a 
negative control. There was no significant difference in the conversion of LC3-I to LC3-II 
between the GW4064, CDCA and control groups. Data analysed by one-way ANOVA. N=3; * 
p<0.05 vs. control; bars, mean ±SE 
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5.3 DISCUSSION 
Given that both FXR ligands were seen to cause a clear concentration-dependent 
toxicity on MCF-7 and MDA-MB-231 cells, the next step was to determine the 
mechanism of cell death such as programmed cell death type I and II, apoptosis and 
autophagy respectively (see Chapter 4). To investigate the potential of breast cancer 
cell lines MCF-7 and MDA-MB-231 to undergo apoptosis, staurosporine was used in 
this study as apoptotic inducer (Meggio et al., 1995, Omura et al., 1995, Tamaoki et 
al., 1986, Chae et al., 2000, Jacobsen et al., 1996, Yue et al., 1998). Staurosporine 
induces concentration dependent cell death in both MCF-7 and MDA-MB-231 cells, 
indicative of apoptotic stimuli. Therefore the next step was to study proteins involved 
in the apoptotic pathway. PARP recognises the DNA ends and strand breaks and 
recruits the excision repair proteins such as XRCCI, APE 1, and DNA ligase III, to 
perform the DNA repair (Berger, 1985, Carson et al., 1986, Virag, 2005). The 
evidences support the role of PARP in execution of cell death pathway such as 
apoptosis (Chaitanya et al., 2010, D'Amours et al., 2001, Davidovic et al., 2001, 
Soldani and Scovassi, 2002). PARP ribosylating activity is inhibited during late stage 
apoptosis by proteolytic cleavage.  This cleavage is governed by the caspase family 
of proteins. The caspase family of proteins are executioner proteins in the apoptotic 
pathways, with PARP being a classical target of activated caspases; hence, cleaved 
PARP is a classical surrogate marker for apoptosis (Berger, 1985, Davidovic et al., 
2001, Germain et al., 1999, Lazebnik et al., 1994, Oleinick and Evans, 1985, Nunez 
et al., 1998, Soldani and Scovassi, 2002). Western blot analysis was performed with 
untreated control MCF-7 cells and cells exposed for 24 hours to GW4064, CDCA or 
staurosporine at their predetermined IC50 concentrations. Uncleaved PARP (116KDa) 
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was observed in all lanes, although the concentration appeared reduced following 
Staurosporine, GW4064 and CDCA treatment. Cleaved PARP, indicative of active 
caspase-3 (Soldani and Scovassi, 2002, Kaufmann et al., 1993, Lazebnik et al., 1994, 
Nicholson et al., 1995, Los et al., 1997, Los et al., 1999), was observed at 89KDa only 
in those cells exposed to staurosporine (positive control for apoptosis) or the FXR 
agonists GW4064 and CDCA as shown in figures 5-4 and 5-5. This PARP cleavage 
observed was dose dependent with increasing concentration of GW4064, CDCA and 
staurosporine as shown in figures 5-6 and 5-7. These data are in agreement with the 
findings of Catalano et al. (2013) who showed that FXR agonists GW4064 and CDCA 
induce PARP cleavage in leydig tumour cells. The present study, to the best of our 
knowledge, is the first to show PARP cleavage in breast cancer cell line MCF-7 and 
MDA-MB-231 upon GW4064 and CDCA treatment. Although a time dependent study 
is required to fully determine the minimum and maximum time required for PARP 
cleavage exposure, as PARP cleavage is regarded as a hallmark of apoptosis it can 
be seen as further confirmation that activation of FXR results in apoptotic cell death. 
Some studies provide evidence suggesting PARP cleavage could possibly lead to 
necrotic cell death, and although these are in the minority, this possibility cannot be 
disregarded (Ha and Snyder, 1999, Gobeil et al., 2001, Park et al., 2014, Eguchi et 
al., 1997, Bhaskara et al., 2009). Also, PARP cleavage is observed in TNF-induced 
necroptosis independently of caspase activation (Laster et al., 1988, Lemaire et al., 
1998, Los et al., 2002, Aikin et al., 2004, Vercammen et al., 1998, Chan et al., 2003). 
PARP over-activation been observed in Hl60 cells with necrosis inducing agent 
treatment, cytochalasin B (Morris et al., 2009). Necroptosis via PARP-1 over activation 
leads to the increased synthesis of poly (ADP-ribose) from nicotinamide adenine 
dinucleotide (NAD+) further decline in NAD+ resulting in abrogation of adenosine-5′-
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triposphate (ATP) energy pools (Leist et al., 1997, Vandenabeele et al., 2010, 
Feoktistova and Leverkus, 2015).  Recent evidence supports the hypothesis that ATP 
levels determine the mode of cell death, with low levels resulting in necrosis, while 
high intracellular levels initiate apoptosis (Leist et al., 1997, Tsujimoto, 1997, Eguchi 
et al., 1997). Therefore, study is required to determine the ATP levels upon FXR 
agonist’s treatments on MCF-7 and MDA-MB-231 cell lines to determine necrotic cell 
death, if present.  
In an attempt to characterise the molecular mechanisms of apoptosis induced by 
GW4064 and CDCA, the activity of caspases (3/7, 8 and 9) were determined by 
luminescent assay. Caspase family of proteins regulates the apoptosis pathway as 
mentioned in introduction chapter (Boatright and Salvesen, 2003, Elmore, 2007, Los 
et al., 1999, Nunez et al., 1998, O'Donovan et al., 2003). The executioner caspases, 
Caspase 3 and 7 cleaves the 116KDa fragment of PARP-1 into two fragments (89KDa 
and 24KDa) at the DVED site (Lazebnik et al., 1994, Soldani and Scovassi, 2002, 
Margolin et al., 1997). The results in this study indicate that both GW4064 and CDCA 
induces caspase3 and 7 activity in MCF-7 and MDA-MB-231 cell lines. However, it is 
noteworthy that GW4064 elicit 3 fold higher caspase 3 activity in MDA-MB-231 
compared to MCF-7. This discrepancy could be due to caspase 3 loss in MCF-7 cell 
line (Kurokawa et al., 1999, O'Donovan et al., 2003). The PARP cleavage observed in 
MCF-7 and MDA-MB-231 cells resulted due to caspase 3 activation in these cell lines. 
Next, I examined two distinct pathways of apoptosis, the intrinsic and extrinsic 
pathway. As mentioned earlier caspase 8 and 9 are the distinguishing caspases of 
these two pathway, the activation of these caspases were studied (Acehan et al., 
2002, Blanc et al., 2000, Boatright et al., 2003, Boatright and Salvesen, 2003, Cain et 
al., 2002, Fulda and Debatin, 2006). Both MCF-7 and MDA-MB-231 elicit significant 
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caspase 9 activity with GW4064 for 9 hour exposure at their respective IC50 
concentrations. Whereas, the CDCA elicits significant activation only in MCF-7 cell 
lines after 9 hour exposure at IC50 concentration; though, the time-course study is 
required to determine minimum and maximum time required for caspase activity. On 
the contrary, FXR agonists GW4064 and CDCA do not induce significant caspase 8 
activity in MCF-7 and MDA-MB-231 cell lines; whereas the positive control (FAS) elicit 
significant caspase 8 activity. FAS was used as a positive control to elicit caspase 8 
activation in these cell lines (Waring and Mullbacher, 1999, Barnhart et al., 2003). Of 
note, there exists a cross talk between two pathways. Bid a pro-apoptotic protein is a 
member of Bcl family of proteins, that activates BAX and facilitates cytochrome c 
release (Roy and Nicholson, 2000). To elucidate possibility of this cross-talk, Bid 
activation needs to be studied in these cell lines. The results in this study indicate that 
FXR agonists could induce the activation of intrinsic apoptotic pathway.  
Alteration in the mitochondrial function has been implicated as the vital process in 
programed cell death I or apoptosis (Dewson and Kluck, 2009, Elmore, 2007, Fesik, 
2000, Green and Reed, 1998). As mentioned earlier the Bcl-2 family of proteins and 
cytochrome c translocation are the key markers of the mitochondrial dependent 
intrinsic apoptosis pathway (Gross et al., 1998, Gross et al., 1999, Jiang and Wang, 
2004). Therefore, next I examined the effects of FXR agonists GW4064 and CDCA on 
cytochrome c , pro and anti-apoptotic proteins BAX, Bcl-2 expression in breast cancer 
cell lines MCF-7 and MDA-MB-231. The upregulation of BAX and downregulation of 
Bcl2 proteins were observed in both cell lines. As both cell lines showed significantly 
higher caspase 9 activity and no significant caspase 8 activity with GW4064, this 
indicates the intrinsic pathway activation. Further it was proved as GW4064 induces 
complete cytochrome c release within 8 hours of treatment. CDCA, on the other hand, 
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neither significantly induces, caspase 9 activity nor induces significant cytochrome c 
release or BAX upregulation. The rationale for CDCA being not effective could be due 
to its less selectiveness and potency as an activator of FXR (Maloney et al., 2000). 
These results of this study are in agreement with another study that showed FXR 
activation induces caspase 3, 9 activity, cytochrome c release and bax upregulation in 
neonatal rat ventricular myocytes (NRVMs) (Pu et al., 2013). On the contrary, De 
Gottardi et al. (2006) showed gugglesterone, a FXR antagonist, induces caspase 3 
activation and apoptosis in BE-derived cells (CP-18821). The present study for the 
first time established that the FXR agonist GW4064 induces mitochondrial mediated 
apoptosis in breast cancer cell lines MCF-7 and MDA-MB-231. However, the reason 
for the contradictions between published works and the data presented here remain 
unclear. One possible rationale for this discrepancy could be the tissue-specific 
responses of FXR (Gadaleta et al., 2015).  
The Bcl-2 family of proteins also play a role in another cell death pathway called 
autophagy (Decuypere et al., 2012, Marquez and Xu, 2012, Tanida and Waguri, 2010, 
Yang et al., 2011). Unlike apoptosis, autophagy could serve as cell survival in case of 
defective apoptosis signalling, especially in hypoxic conditions (Cui et al., 2007, 
Degenhardt et al., 2006, Liu et al., 2002). Recent studies provide evidences of 
autophagy inhibiting tumourigenesis. The beclin-1, an autophagy gene, has been 
shown to inhibit MCF-7 cell growth (Liang et al., 1999a). In mouse models, studies 
have shown that deletion in Beclin-1 promotes liver carcinogenesis (Qu et al., 2003). 
On the other hand, beclin-1 +/+ mouse mammary epithelial cells show resistance 
towards cell death in apoptosis defective cells (Karantza-Wadsworth et al., 2007). 
Beclin-1 cleavage appeared to promote apoptosis compromising the autophagic 
response (Wirawan et al., 2010). Studies have also shown that autophagy could 
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promote cell death in MCF-7 when treated with chemotherapeutic drugs such as tam 
(Hwang et al., 2010). Beclin-1 has been shown to bind BH3 homolog of the Bcl-2 
protein. It has been shown that increased expression of beclin-1 facilitates the release 
of Bax protein, promoting apoptosis. On the contrary, the deceased expression of Bcl-
2 promotes autophagy (Gordy and He, 2012, Mukhopadhyay et al., 2014, Zhou et al., 
2011). Thus, it is evident from studies so far, that both apoptosis and autophagy 
together play role in cancer. Autophagy is marked by the formation of 
autophagosomes. Microtubule-associated protein 1A/1B-light chain 3 (LC3) the 
cytosolic form bind to the phosphatidylethanolamine to form LC3-
phosphatidylethanolamine conjugate (LC3-II). The degradation of LC3-II upon 
lysosomal engulfment is the key marker for autophagic activity (Kadowaki and Karim, 
2009, Karim et al., 2007, Tanida et al., 2008). In this study, LC3 expression was seen 
in MCF-7 cells treated with GW4064, indicating autophagic cell death. Due to lack of 
caspase 3 activity, it is evident from the results that only MCF-7 shows autophagic 
response not MDA-MB-231. To confirm this autophagic activity in MCF-7 cells, other 
important autophagy regulatory proteins need to be studied such as Beclin-1 and 
p62/SQSTM1. The focus, in the next chapter, will be on the mechanism of cell death.  
The present study shows FXR activation induces mitochondrial mediated apoptosis in 
breast cancer cell lines MCF-7 and MDA-MB-231 and thus, it could possibly be a 
therapeutic alternative to treat breast cancer. As mentioned in the introduction chapter, 
endocrine therapy is the classical way of treating patients with breast cancer. Next, 
the interaction between FXR agonists and traditional chemotherapeutics was studied 
on breast cancer cell lines. 
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CHAPTER 6 
 
FXR mechanism of action and potential role as 
chemotherapeutic drug 
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6.1 INTRODUCTION 
 
 
In the previous chapter, the results showed that FXR agonists induced 
mitochondrial dependent apoptosis in breast cancer cell lines MCF-7 and MDA-
MB-231. However, the mechanism need to be identified. Mitochondria, the power 
house of the cell, are the source of the reactive oxygen species (ROS) generation 
(McBride et al., 2006, Murphy M 2009). At physiological levels, ROS maintain the 
normal cellular homeostasis, while excess production leads to activation of specific 
cellular response pathways (Brookes et al., 2004, Simon et al., 2000). In cancer, 
tumour cells rely on mitochondrial aerobic glycolysis for ATP source due to failed 
oxidative phosphorylation, termed as the Warburg effect (Warburg, 1956). The 
mitochondrial oxidative phosphorylation pathway involves generation of 
superoxide through electron leakage (Cadenas, 2004). These reactive oxygen 
species (ROS) are the toxic by-products of cellular metabolism, some of which are 
hydrogen peroxide (H2O2), superoxide (O2−), hydroxyl radical (OH.), nitric oxide 
(NO), singlet oxygen (1O2), ozone/trioxygen (O3) (Valko et al., 2005, Valko et al., 
2007). The formation of the mitochondrial permeability transition pore (PTP) plays 
an important role in ROS mediated mitochondrial dysfunction (Batandier et al., 
2004, Crompton, 1999, Marchi et al., 2012, Storz, 2006). Upon an apoptotic 
stimulus, stimulated by ROS there occurs an electrochemical gradient shift. Recent 
research suggests that aquaporin family involves the transmembrane drifting of 
hydrogen peroxide and water (Bienert et al., 2007, Lee and Thevenod, 2006). This 
shift results in the disruption of the mitochondrial potential and swelling of the 
mitochondrial matrix. This opens the mitochondrial pores and releases the 
downstream proteins involved in intrinsic pathway (Kaasik et al., 2007, Lee and 
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Thevenod, 2006). The release of cytochrome c from mitochondria activates the 
downstream caspase cascade (Cadenas, 2004, Madesh and Hajnoczky, 2001, 
Sabharwal and Schumacker, 2014, Sauer et al., 2001, Simon et al., 2000, 
Takahashi et al., 2004, Wu and Bratton, 2013). Thus, ROS generation has been 
considered one of the major activators for intrinsic apoptotic pathway. The existing 
literature provides evidence that ROS initiates the caspase cascade and induction 
of apoptosis via mitochondria (Ahmad et al., 2004, Madesh and Hajnoczky, 2001, 
Migliaccio et al., 1999). Also recent research has shown that many anti-cancer 
drugs induces DNA damage by generation of ROS (Chung et al., 2003, Donadelli 
et al., 2007, Loaiza-Perez et al., 2004, McLean et al., 2008, Qanungo et al., 2005, 
Siedlakowski et al., 2008, Zhang et al., 2008). ROS production induces activation 
of the AKT pathway and inhibits tumour angiogenesis in ovarian cancer cells (Liu 
et al., 2006). In breast cancer cell lines ROS production reduces the metastatic 
potential by phosphorylating p38 MAPK (Zhou et al., 2008). Also, in MCF-7 cells 
reduced ERK phosphorylation by zinc or copper induces ROS mediated 
mitochondrial apoptosis (Ostrakhovitch and Cherian, 2005).  Thus, a bioactive 
reagent of medicinal plant induces ROS mediated apoptosis in breast carcinoma 
cell line via p53 activation and inducing mitochondrial depolarization (Saha et al., 
2014). It has been evident from studies that ROS generation plays an important 
role in mitochondrial mediated apoptosis. Therefore, I next examined whether 
GW4064 and CDCA mediated mitochondrial apoptosis is associated with ROS 
generation.   
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6.2 RESULTS 
 
6.2.1 Effect of FXR on ROS production in MCF-7 and MDA-MB-231. 
 
Oxygen metabolism in cells leads to the generation of reactive oxygen species (Apel 
and Hirt, 2004). These ROS play a dual role, with low concentrations being important 
to cell survival, defence and signalling, while higher concentrations induce cell death 
(Liou and Storz, 2010, Waris and Ahsan, 2006). In this thesis, the production of ROS 
and its link to cell death will be examined. Excess ROS production has been 
associated with necrotic cell death (Cho et al., 1999, Morgan et al., 2008), but as it is 
a marker of mitochondrial damage or dysfunction, then it can also trigger apoptotic cell 
death, (Zamzami et al., 1995). As previously described, the mitochondrial-dependent 
cell death pathway is mediated by members of the Bcl-2 class of proteins, which act 
to control mitochondrial membrane integrity (Adams and Cory, 2007, Gross et al., 
1999, Jourdain and Martinou, 2009, Narita et al., 1998). Higher intracellular ROS 
levels  lead to mitochondrial membrane depolarization and release of the effector 
proteins from mitochondria through formation of mitochondrial transition pore 
permeability (Green and Reed, 1998). These effector proteins include cytochrome c 
and apaf1, which complex with pro-caspase 9 to form the apoptosome and activate 
the intrinsic apoptotic pathway (Green and Reed, 1998, Hampton et al., 1998, 
Martinou and Youle, 2011).  
The previous chapter demonstrated that activation of the nuclear receptor FXR by 
either GW4064 or CDCA was able to induce cell death in breast cancer cell lines. In 
addition, the mode of cell death was demonstrated to be (mainly) apoptosis via 
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activation of the intrinsic pathway. To investigate upstream regulatory mechanisms 
that could lead to mitochondrial dysfunction, we examined the effect of GW4064 and 
CDCA on intra-cellular ROS level by a luminescent reporter assay.  
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Figure 6-1: GW4064 and CDCA induces ROS in MCF-7 
MCF-7 cells were plated at 10,000 cells/well in a 96-well assay plate and incubated overnight. 
After overnight incubation at 37°C in 5% CO2, medium was removed from all wells. Eighty 
microliters of DMEM medium with 20µl of H2O2 Substrate Dilution Buffer containing 125µM 
Substrate was added to wells with and without cells. Other wells with and without cells were 
treated with menadione (100µM), GW4064 (35µM) and CDCA (240µM) for 4 hours and incubated 
at 37°C in 5% CO2 humidified incubator. After incubation, 100μl of ROS-Glo™ Detection Solution 
was added to the wells. The plate was incubated for 20 minutes at room temperature. 
Luminescence was determined with a FLUOstar Omega Luminometer. The average RLU and 
standard deviation of triplicate samples were calculated. Results of two-way ANOVA are 
representative of n=3 repeats. Two-way ANOVA showed significant effect of treatments in H2O2 
production (F3, 64 = 264.8, P < 0.0001) and cells verses medium (F1, 64 = 558.8, P < 0.0001). 
Menadione **** P < 0.0001, GW4064 **** P < 0.0001 and CDCA *** P < 0.001 showed significant 
ROS production from cells compared with medium alone. 
 
 
165 
 
 
 
 
Figure 6-2: GW4064 induces ROS in MDA-MB-231 
MDA-MB-231 cells were plated at 10,000 cells/well in a 96-well assay plate and incubated 
overnight. After overnight incubation at 37°C in 5% CO2, medium was removed from all wells. 
Eighty microliters of DMEM medium with 20µl of H2O2 Substrate Dilution Buffer containing 
125µM Substrate was added to wells with and without cells. Other wells with and without cells 
were treated with Menadione, GW4064 and CDCA for 4 hours and incubated at 37°C in 5% CO2 
humidified incubator. After incubation, 100μl of ROS-Glo™ Detection Solution was added to the 
wells. The plate was incubated for 20 minutes at room temperature. Luminescence was 
determined with a FLUOstar Omega Luminometer. The average RLU and standard deviation of 
triplicate samples were calculated. Results of two-way ANOVA are representative of n=3 repeats. 
Two way ANOVA showed significant effect of treatments in H2O2 production (F 3, 64 = 219.7, P < 
0.0001) and cells verses medium (F 1, 64 = 462.3, P < 0.0001). Menadione **** P < 0.0001 and 
GW4064 **** P < 0.0001 showed significant ROS production from cells compared with medium 
alone. 
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Menadione (100µM) was used as a positive control, as it is a cytotoxic quinone that 
induces ROS-mediated cytotoxicity in cell lines when used at concentrations greater 
than 100µM (Nutter et al., 1992, Marchionatti et al., 2009). As shown in figure 6-1 and 
figure 6-2, 100µM MD elicited a statistically significant increase in H2O2 in both cell 
lines: 3.4-fold and 9.3-fold above vehicle control in MCF-7 and MDA-MB-231 cells, 
respectively.  
Both GW4064 and CDCA were able to induce a statistically significant increase in 
H2O2 production in MCF-7 cells, with fold inductions above vehicle control of 6.3 and 
2.6, respectively (figure 6-1). Similarly, exposure of MDA-MB-231 cells to GW4064 
produced a 6.3-fold, statistically significant increase in H2O2 levels compared with 
vehicle control. This fold increase is on a par with that seen with MCF-7 cells, 
suggesting a similar response to GW4064 in the two cell lines. While exposure of 
MDA-MB-231 cells to CDCA elicited a 2.5-fold increase in H2O2 levels, which is similar 
to that observed in MCF-7 cells, this did not reach statistical significance.  
Reactive oxygen species play an important role in maintaining the normal 
NADH/NAD+ pool (Seo et al., 2006). In addition, they are important in host defence 
mechanisms, acting to remove pathogens (Sauer et al., 2001), and over-expression 
can be associated with pathology (Apel and Hirt, 2004, Sabharwal and Schumacker, 
2014, Waris and Ahsan, 2006). For example, an increase in ROS has been shown to 
contribute to cellular damage, including cell death. Generation of ROS triggers 
apoptosis through the disruption of the mitochondrial membrane and release of 
cytochrome c (Gogvadze et al., 2009). The presented data reveal that activation of 
FXR in the breast cancer cell lines MCF-7 and MDA-MB-231 is associated with an 
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increase in ROS. Data presented in chapter 5 also show that activation of FXR results 
in apoptotic cell death in these cell lines, including cytochrome c loss from the 
mitochondria. Such data are consistent with the hypothesis that increased ROS 
production caused by FXR activation results in mitochondrial dysfunction and 
apoptotic cell death in breast cancer cell lines. Further work using, for example, 
antioxidants or FXR knock-downs would be required to demonstrate a causal 
relationship. 
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6.2.2 GW4064 synergises with tamoxifen and enhance apoptosis in 
breast cancer cell lines; MCF-7 and MDA-MB-231. 
 
Chemotherapy has been a mainstay of treating patients with breast cancer for many 
years. However, such an approach is not without its drawbacks, and over time many 
patients develop resistance towards either one or a combination of drugs, which is 
referred to as multi drug resistance (Gottesman et al., 2002, Hassan et al., 2010, Ring 
and Dowsett, 2004). Therefore, it is imperative that alternative/complimentary 
approaches are explored to ensure the continued efficacious treatment of breast 
cancer patients.  
An example of such a complementary approach is adjuvant therapy, whereby patients 
with advanced breast cancer are given a secondary treatment following the primary 
chemotherapy regimen to reduce the potential for recurrence (Bergh et al., 2001, 
Hassan et al., 2010). An example of an alternative approach is the rapidly expanding 
area of biologicals, including breast cancer treatments such as Herceptin (Baselga et 
al., 2006, Garnock-Jones et al., 2010). 
 
As described in the introduction (section 1.4.3), one of the key characteristics of a 
breast tumour is the expression (or lack thereof) of the nuclear receptors ER, PR and 
Her2 (Clarke et al., 2001, Hall and McDonnell, 1999). As such, these receptors have 
also become prime targets to treat breast cancer. Over the last 30 years, selective ER 
modulators (SERMs) have been particularly effective in the treatment of ER positive 
breast cancer: Tam is one of the classical SERMs (Fan and Craig Jordan, 2014, Lerner 
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and Jordan, 1990, Osborne et al., 2003). The mode of action of tam is through 
metabolism to form 4-hydroxytamoxifen, followed by competitive inhibition of the ER 
(Coezy et al., 1982). As activation of ER can be an important step in breast tumour 
growth, tam thus acts to slow tumour growth and prevent cancer relapse (Fisher et al., 
1981). Tam has been widely used since its regulatory approval in the 1970s, and is 
still a highly effective medicine and the standard therapy for the treatment of breast 
cancer in post-menopausal women along with aromatase inhibitors (Gottardis et al., 
1989). It is present on the WHO list of essential medicines (Love and Koroltchouk, 
1993). Despite these important positives, there are limitations to the use of tam: first, 
it has become evident that patients develop resistance to this treatment (Gonzalez-
Angulo et al., 2007); second, it can cause adverse side effects, including endometrial 
cancer, hepatosteatosis and reduced cognition (Jordan, 1993). The use of 
combination treatments allows a reduction of tam dose, reducing the negative impacts, 
while maintaining therapeutic efficacy.   
Activation of FXR through its selective ligand GW4064 has been shown to induce 
mitochondrial dependent apoptosis in the breast cancer cell lines MCF-7 and MDA-
MB-231. As these cells are ER-positive and ER-negative, respectively this 
demonstrates that this effect is not dependent on ER status. The current study further 
investigates the anticancer effects of GW4064, examining its combination with tam on 
the breast cancer cell lines, MCF-7 and MDA-MB-231. The potential for synergistic 
efficacy was examined by both MTT assay and clonogenic assay. 
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Figure 6-3: Combinational effects of GW4064 and Tamoxifen on MCF-7 
MCF-7 cells were treated with (A) GW4064 (0 to 90µM; 0.25, 0.5,1,2 and 4 times IC50 from 
previous result) and (B) Tam (0 to 15µM) showed cell death in a concentration dependent manner 
for 24 hours. MCF-7 cell lines were treated with different concentrations of (C) GW4064 and Tam 
(3 µmol/L; IC50) combination induced cell death (24 hours). MTT assay was performed to detect 
cell viability. Points, mean viability as a percentage of control (i.e., vehicle-treated cells = 100%), 
from n = 9 replicates from three separate experiments; bars, SEM 
 
 
 
 
 
171 
 
 
 
 
 
Figure 6-4: Combinational effects of GW4064 and Tamoxifen on MDA-MB-231 
MDA-MB-231 cells were treated with (A) GW4064 (0 to 112µM; 0.25, 0.5,1,2 and 4 times IC50 from 
previous result) and (B) Tam (0 to 60µM) showed cell death in a concentration dependent manner 
for 24 hours. MDA-MB-231 cell lines were treated with different concentrations of (C) GW4064 
and Tam (10 µmol/L; IC50) combination induced cell death (24 hours). MTT assay was performed 
to analyse cell viability. Points, mean viability as a percentage of control (i.e., vehicle-treated 
cells = 100%), from n = 9 replicates from three separate experiments; bars, SEM 
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In MCF-7 cells (Figure 6-3) and MDA-MB-231 cells (Figure 6-4) GW4064, tam and 
combination elicited concentration dependent decrease in cell viability. Of note, the 
combination elicited nearly 90 percent cell death with combination at lowest 
concentrations used of GW4064, 7 and 7.5 µM for MCF-7 and MDA-MB-231 
respectively. Although, the viability tends to increase at the highest concentrations of 
GW4064 with combination of tam in MDA-MB-231 (Figure 6-4), the reason remains 
unclear. However, it could be argued that at these concentrations, the effect could be 
additive rather synergistic, but it requires further study to completely establish the 
reason for this discrepancy.  
To formally investigate whether the combination of tam and GW4064 shows additivity, 
synergy or antagonism compared to the individual treatments, a Chou-Talalay plot 
was constructed (Chou, 2010), using a non-constant ratio of the two components. The 
drug combination is shown to have a synergistic interaction if the combination index is 
greater than one (CI < 1); an additive interaction when the CI = 1; and an antagonistic 
interaction when the CI > 1. In addition, a dose reduction (DR) metric can be 
calculated, which reflects the reduction in individual dose concentrations that can be 
used in combination to achieve the same magnitude of effect. 
The derived plots are presented in figure 6-5, with the respective CI and DR values 
presented in tables 6-1 and 6-2.  
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Figure 6-5: Synergistic evaluation of tamoxifen and GW4064 on MCF-7 
(A) MCF-7 cells with increasing log doses of GW4064 and tam (IC 50) with its respective 
effect was plotted for dose response curve generated using compusyn. For combination 
studies, six dose of GW4064 and tam were used covering the IC50 of GW4064 and tam. 
Percentage growth inhibition was calculated and the results plotted according to the 
median effect equation, (B) fa/fu = (D/Dm)m, where fa is the fraction affected by dose D, 
fu is the fraction unaffected, D is the dose and Dm is the dose required for 50% growth 
inhibition and m is the coefficient of sigmoidicity . (C) Combination index (CI) was 
determined from the CI-isobologram method using the computer program compusyn. 
The three possibilities: CI < 1, CI = 1, and, CI > 1, indicated synergy, additive effect, and 
antagonism, respectively. (D) The dose reduction (DR) measures how much the dose in 
combination reduced to produce similar effect comparing with the doses of each drug 
alone. Thereby allowing to determine the reduction in toxicity levels of doses in 
combination. Dose reduction index (DRI) when equals 1 indicated no reduction, whereas 
DRI >1 is favourable and DRI < 1 is non-favourable. 
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Table 6-1: Combination Index values of GW4064 and tamoxifen for MCF-7 
 
 
                   
 
Table 6-2: DRI of GW and Tamoxifen combination on MCF-7 
 Fa  Dose 
TAM  
Dose 
GW  
DRI 
TAM  
DRI 
GW 
0.235 0.58 0.26 0.63 2.57 
0.634 4.45 0.98 5.31 5.48 
0.784 5.34 1.81 5.92 12.12 
0.879 7.47 2.44 8.28 3.88 
0.936 10.49 3.286 11.61 4.05 
0.983 12.40 5.89 20.58 6.67 
0.989 18.24 7.10 25.96 8.98 
 
 
For MCF-7 cells, a clear synergistic interaction can be seen between tam and GW4064 
(figure 6-5). Using a fixed concentration of tam (3.3µM, the IC50 value), combination 
indexes were derived for GW4064 (0 to 112µM GW4064; 0.25, 0.5,1,2 and 4 times 
IC50 from previous result). At the lowest concentration of GW4064 examined (7µM), 
the interaction with tam was determined to be strongly antagonistic, with a combination 
index of 2.6.  However, at concentrations greater than 17.5µM GW4064 there was 
strong synergistic interaction with 3.3µM tam, producing CI values in the range 0.3 to 
0.1.This synergistic interaction led to a significant potential dose reduction for both 
Dose TAM  Dose GW  Effect  CI 
0.903       0.1       0.035       2.65  
0.903       0.301       0.784       0.32  
0.903       0.602       0.879       0.32  
0.903       0.903       0.936       0.27 
0.903       1.0       0.983       0.12  
0.903       1.301       0.989       0.11  
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compounds, with maximal DRI values of 25.9 and 8.9 for tam and GW4064, 
respectively. 
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Figure 6-6: Synergistic evaluation of tamoxifen and GW4064 on MDA-MB-231 
(A) MDA-MB-231 cells with increasing log doses of GW4064 and tam (IC 50) with its 
respective effect was plotted for dose response curve generated using compusyn.  (B) 
For combination studies, six dose of GW4064 and tam were used including the IC50 of 
GW4064 and tam. Percentage growth inhibition was calculated and the results plotted 
according to the median effect equation, fa/fu = (D/Dm)m, where fa is the fraction 
affected by dose D, fu is the fraction unaffected, D is the dose and Dm is the dose 
required for 50% growth inhibition and m is the coefficient of sigmoidicity. (C) 
Combination index (CI) was determined from the CI-isobologram method using the 
computer program compusyn. The three possibilities: CI < 1, CI = 1, and, CI > 1, indicated 
synergy, additive effect, and antagonism, respectively. (D) The dose reduction (DR) 
measures how much the dose in combination reduced to produce similar effect 
comparing with the doses of each drug alone. Thereby allowing determination of the 
reduction in toxicity levels of doses in combination. Dose reduction index (DRI) when 
equals 1 indicated no reduction, whereas DRI >1 is favourable and DRI < 1 is non-
favourable. 
 
177 
 
 
Table 6-3: Combination Index of GW4064 and TAM for MDA-MB-231 
                     
 
 
 
Table 6-4: DRI of GW and Tamoxifen combination on MDA-MB-231 
 
 
For MDA-MB-231 cells, a similar pattern was observed, with a clear synergistic 
interaction between tam and GW4064 (figure 6-6). At all concentrations of GW4064 
examined a strong synergistic interaction was observed with 10µM tam, producing CI 
values in the range 0.12 to 0.5.This synergistic interaction led to a significant potential 
dose reduction for both compounds, with maximal DRI values of 90 and 9.1 for tam 
and GW4064, respectively. 
 
 
Dose TAM Dose GW Effect CI 
0.477      0.1      0.065      0.50 
0.477      1.0      0.875      0.24 
0.477      1.301      0.933      0.22  
0.477      1.602      0.966      0.18 
0.477      1.903      0.982      0.15 
0.477      2.204      0.991      0.12 
Fa  Dose 
TAM  
Dose 
GW  
DRI 
TAM  
DRI 
GW 
0.465       1.917       0.41     4.02       4.10      
0.675       13.42     4.70  28.14     4.70      
0.833       17.94      6.76      37.62       5.20      
0.966       22.24       9.85     50.82      6.15      
0.982       31.92      13.91      66.93      7.31     
0.991       41.94      20.16      90.02      9.15       
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6.2.3 GW4064 and Tamoxifen synergistically reduce MCF-7 and 
MDA-MB-231 cell proliferation 
 
To confirm, and further examine, the synergistic effect of tam and GW4064, a 
complimentary experimental system, the clonogenic assay, was performed on MCF-7 
and MDA-MB-231 breast cancer cell lines. In this assay, cells are seeded at low 
density and allowed to grow for 14 days with and without treatment. Due to the low 
plating density, cells form ‘colonies’, representing division from a single progenitor cell 
(Franken et al., 2006). These colonies were stained for easy visualisation and then 
colony number counted. PF and SF were calculated as per the formula given below.   
Plating efficiency was calculated by: 
 
Survival Fraction was calculated by: 
                               
To investigate the potential for a synergistic interaction between GW4064 and tam, 
the effect of GW4064 and tam alone and in combination on cell proliferation and 
clonogenic survival were assessed in MCF-7 (Fig 6-7) and MDA-MB-231 (Fig 6-8) 
cells. GW4064 and tam inhibited cell growth in both cancer cell lines in a 
concentration-dependent manner. In addition, clonogenicity of both cancer lines was 
also reduced in a concentration-dependent manner.  
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Figure 6-7: Clonogenic survival analysis of GW4064 and tamoxifen 
combination on MCF-7 
(A) Influence of GW4064, tam alone and combination of treatments on MCF-7 cells by the 
number of colony-forming cells, as evaluated by clonogenic assay. Representative 
dishes by colony-forming assay. (B) Cells were incubated for 2h with increasing doses 
of GW4064, tam and 3µM tam-GW4064 combination. After 2h, fresh medium added and 
plates were incubated for 12 days & the clonogenic survival was determined. All data 
points are means of 3 independent experiments mean±SE 
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                Figure 6-8: Clonogenic survival analysis of GW4064 and tamoxifen 
combination on MDA-MB-231. 
(A)Influence of GW4064, tam alone and combination of treatments on MDA-MB-231 cells by the 
number of colony-forming cells, as evaluated by clonogenic assay. Representative dishes by 
colony-forming assay. (B) Cells were incubated for 2h with increasing doses of GW4064, tam 
and 10µM tam-GW4064 combination. After 2h, fresh medium added and plates were incubated 
for 9 days & the clonogenic survival was determined. Control set to 100%. All data points are 
means of 3 independent experiments mean±SE 
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6.3 DISCUSSION 
The previous result (chapter 4 and 5) depicts that FXR induces the activation of 
intrinsic apoptotic pathway in breast cancer cell lines MCF-7 and MDA-MB-231. 
However, the exact mechanism how it happens was unclear. As mentioned in section 
6.1, ROS or the reactive oxygen species has been studied in various cancers and 
linked with activation of intrinsic pathway (Chung et al., 2003, Donadelli et al., 2007, 
Loaiza-Perez et al., 2004, McLean et al., 2008, Qanungo et al., 2005, Siedlakowski et 
al., 2008, Zhang et al., 2008). To further identify the mechanism, the effects of FXR 
agonists on generation of reactive oxygen species was studied. Both MCF-7 and 
MDA-MB-231 cell lines were treated with positive control menadione, which is a 
cytotoxic quinone. Menadione used at cytotoxic concentration elicited the maximum 
H2O2 activity within MCF-7 and MDA-MB-231 cells. MD shown to be cytotoxic and 
reduce cell viability of MCF-7 cells (Nutter et al., 1992). MD shown to induce reactive 
oxygen species (ROS) in MDA-MB-231 and MCF-7 irrespective of their estrogen 
status (Wang et al., 2009). Of note, the H2O2 levels in the medium alone does not 
depict the same effect eliminating the chances of H2O2 production due to medium. In 
case of MCF-7, GW4064 and CDCA both significantly induce H2O2 activity, whereas 
only GW4064 induce significant hydrogen peroxide activity within the cells. CDCA has 
no significant H2O2 activity as the production from cells and medium shown similar 
effect. This could be due to generation and elimination of H2O2 from cells at nearly 
similar rates. Also as mentioned earlier, GW4064 is more potent activator of FXR than 
CDCA (Maloney et al., 2000). GW4064 elicited similar ROS activity with both MCF-7 
and MDA-MB-231 despite being different phenotypic characteristics. The proposed 
mechanism of FXR activity in this study on breast cancer cell lines MCF-7 and MDA-
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MB-231 is the ROS mediated formation of the permeability transition pore. However, 
mitochondrial related parameters such as the cellular ATP levels, NADP+/NADPH 
ratio and mitochondrial potential Δψm needs further investigation (Jang et al., 2008). 
Mitochondrial transition pore leads to cytochrome c release and activation of intrinsic 
apoptotic cascade (Green and Reed, 1998, Hampton et al., 1998, Martinou and Youle, 
2011). Both cytochrome c release and caspase 9 activation was observed in MCF-7 
and MDA-MB-231 cell lines upon FXR activation. These results indicate that FXR-
ROS mediated mitochondrial dependent caspase activation in breast cancer cell lines 
MCF-7 and MDA-MB-231.  
These results indicate positive effects of FXR and its potential as a therapeutic. As 
mentioned earlier in Introduction chapter, despite the efforts of endocrine treatment to 
combat breast cancer, resistance to chemotherapeutic drugs remains major setback 
(Bergh et al., 2001, Gonzalez-Angulo et al., 2007, Lehnert, 1998, Raguz and Yague, 
2008). Tam has been widely used as an endocrine treatment for patients. But there 
are a few hurdles encountered by clinicians, first tam ineffectiveness due to loss of 
ER, secondly the resistance developed during treatment and disease relapse 
(Dorssers et al., 2001, Grana, 2004, Lykkesfeldt, 1996, O'Driscoll and Clynes, 2006, 
Shastry and Yardley, 2013). Therefore, there is vast ongoing search for alternatives 
that can be used to treat patients. Our results so far, showed FXR activation induces 
mitochondrial mediated apoptosis in both MCF-7 and MDA-MB-231 despite being 
phenotypically different. Next, we studied the effect of tam in MCF-7 and MDA-MB-
231 cells. As expected, MCF-7 cells were responsive towards tam and showed 
concentration dependent cell death. However, MDA-MB-231 could inhibit 50% cells at 
3 times the concentration required for MCF-7. This difference is expected as MDA-
MB-231 is a triple negative cell line, thus slower response as compared to MCF-7 
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being estrogen-progesterone positive (Chavez et al., 2010). This is in agreement with 
studies showing tam induces cell death in MCF-7 and MDA-MB-231, however high 
concentrations are required to elicit death in case of MDA-MB-231 (Al-Akoum et al., 
2007, Bollig et al., 2005, Ferlini et al., 1997, Fisher et al., 1998, Fisher et al., 2005, 
Ferlini et al., 1999). Moreover, it has been reported that tam can induce cell death 
independent of ER status in breast cancer cell lines (Obrero et al., 2002, Perry et al., 
1995). Also, tam has shown to induce ROS mediated apoptosis in breast cancer cell 
lines (Kallio et al., 2005). To study the interaction between tam and FXR, I examined 
whether tam and combination of GW4064 could: firstly, induce cell death, secondly, 
the effects are estrogen dependent and thirdly, the effects are synergistic, additive or 
antagonist. The data showed that treatment with tam and GW4064 as a single or in 
combination resulted in decreased cell viability. At lowest concentration of GW4064 
alone, it inhibited only about nearly 30% and 10% cell viability in MCF-7 and MDA-
MB-231, whereas in combination with tam inhibit 90% cell viability in both cell lines for 
24 hours. To check if the effect was additive or synergistic, the combination index was 
calculated using Chou-Talay method (Chou, 2010). The results indicate strong 
synergism between tam and GW4064. However, the non-fixed dose study is required 
to obtain maximum effect at lowest dose possible of both drugs at pharmacological 
concentrations. The lowest concentration of GW4064 synergistically induces 
approximately 80% cell death in MCF-7 (Figure 6-3) and MDA-MB-231 (Figure 6-4) in 
combination with tam compared to ~20% when applied alone. Both ER-positive and 
ER-negative breast cancer cells were sensitive to this combination therapy. To assess 
the long term effects of this combination, clonogenic assay (Franken et al., 2006) was 
performed with combination of tam and GW4064. Both MTT and cell proliferation 
assays markedly showed synergistic effect of tam when combined with GW4064. 
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MCF-7 and MDA-MB-231 cell lines were subjected to single dose of tam and various 
doses of GW4064 for 12 days to consider long term effects. The potent cytotoxic effect 
of GW4064, tam and combination was assessed. The results are consistent with the 
cell viability assay performed, as shown in Figures 6-7 and 6-8. The combination 
indexes are presented in table 6-1 and 6-3 for MCF-7 and MDA-MB-231 respectively. 
These data strongly indicate a synergistic effect for the interaction between GW4064 
and tam, with a CI less than one. Interestingly, MDA-MB-231 shown synergism with 
the lowest concentration of GW4064, unlike MCF-7. The results indicate that GW4064 
possibly could be a good alternative therapeutic irrespective of their estrogen status. 
However, the mechanism of action needs further investigation. The results are in 
agreement with other reports indicating GW4064 induces cell death in tam resistant 
MCF-7 cell line (Giordano et al., 2011). Thus, GW4064 could possibly be incorporated 
in chemotherapy to treat breast cancer especially the metastatic profile categorised 
with poor prognosis.   
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CHAPTER 7 
DISCUSSION 
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7.1  Characterisation of breast cancer cell lines: 
 
The study undertaken examined the hypothesis that activation of FXR has a 
cytotoxic effect in-vitro and synergises with currently used anti-cancer agents in 
breast cancer. FXR is a member of the ligand dependant transcription factor 
nuclear receptor superfamily (Makishima et al., 1999, Parks et al., 1999, Wang et 
al., 1999) and has been demonstrated to play a protective role against number of 
cancers, such as intestinal (Maran et al., 2009, Modica et al., 2008), liver (Kim et 
al., 2007, Lee et al., 2010), colon (Lax et al., 2012) and prostate (Choi et al., 2003, 
Kaeding et al., 2008) cancers. In contrast to these studies, FXR has been shown 
to have a negative impact promoting cell proliferation in other studies (Journe et 
al., 2009, Journe et al., 2008, Lee et al., 2011). Also, FXR has been previously 
shown to be over-expressed in some breast tumours (Swales et al., 2006). Also, 
the FXR ligand CDCA was shown to induce apoptosis in a tam-resistant cell line 
(Giordano et al., 2011). These reports would support that development of FXR 
agonists as cancer therapeutics with breast cancer as potential target for 
treatment. Most importantly these mixed evidence of pro-apoptotic and anti-
apoptotic effect of FXR in breast cancer made it imperative to fully understand and 
establish its potential therapeutic role. To obtain its therapeutic efficacy, it should 
be pro-apoptotic (kill tumour cells) and anti-proliferative. Therefore, FXR activation 
in breast tumour cell lines was studied. 
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7.2  Establishing the pro-apoptotic role 
 
The primary objective was to confirm cytotoxic ability of FXR agonists on two 
breast cancer cell lines. The choice of cell lines used in this study is based 
independently of their estrogenic status and different phenotype, being low (MCF-
7) to high (MDA-MB-231) invasive character. FXR endogenous (CDCA) and 
synthetic (GW4064) ligands were used to confirm the expression of FXR in breast 
tumour cell lines and a negative control (ARPE-19) included to confirm its 
specificity. FXR was expressed in both tumour cell lines and as expected no 
expression observed in ARPE-19. Both ligands were tested for effect on cell 
viability using the MTT assay, under serum-free conditions for 24 hours exposure. 
The activation of FXR caused concentration dependent cell death in both cell lines. 
Although cytotoxicity was seen in both cell lines, the level of effect differed. 
GW4064 elicited approximately 60% cell death while CDCA nearly 70% cell death 
at their highest concentration after 24 hours exposure in MCF-7 tumour cell line. 
While in the case of MDA-MB-231, both GW4064 and CDCA elicited 
approximately 50% cell death. As GW4064 is a selective FXR agonist at the 
concentrations used, these effects should be due to activation of FXR and not to 
non-specific activation(s). This effect is supported by the work that demonstrated 
that GW4064 and CDCA induced cell death in MDA-MB-468 and MCF-7 breast 
tumour cell lines, whereas glycol-CDCA does not, which is not a FXR agonist 
(Swales et al., 2006). Another study supported the fact that FXR agonists inhibit 
tam-resistant MCF-7 breast cancer cell growth (Giordano et al., 2011). In addition 
to these studies, (Baker et al., 1992, Im et al., 2001) it has been shown that CDCA 
inhibits MCF-7 and MDA-MB-231 cell growth. In contrast, to these findings, 
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(Journe et al., 2008) shown that CDCA induced MCF-7 cell proliferation. The data 
presented in this study suggests that FXR activation is cytotoxic to breast tumour 
cell lines, in line with previous published literature. The published literature so far 
concluded both cytotoxic and pro-proliferative effects of FXR agonists in breast 
tumour models, a clearly contradictory situation. Therefore, given these 
contradictions, it was decided to examine further the potential mechanisms by 
which FXR activation could lead to cell death in breast cancer cells. Caspases are 
a family of cysteine proteases that regulate apoptosis, or programmed cell death 
(Cox et al., 2007, Devarajan et al., 2002, Frank et al., 2006, Kischkel et al., 2001, 
Nakopoulou et al., 2001) Therefore, I decided to study the activation of the initiator 
and executioner caspases that are closely related to induction of apoptosis. Of its 
family, the caspase 3 activation is regarded critical for the apoptotic cascade. It is 
often referred as an ‘executioner’ caspase, as it executes the final process of 
apoptotic cell death such as cleavage of PARP (Janicke et al., 1998b, 
Oberhammer et al., 1993, Samali et al., 1999). A luminescence-based assay was 
used to detect cleavage of the reporter peptide Z-DEVD in MCF-7 and MDA-MB-
231 cells, which is a substrate for both caspase 3 and the highly related caspase 
7. The activation of caspase 3/7 was demonstrated with GW4064 (30 µM) and 
CDCA (240 µM) treatments at 20 hours. Notably, MDA-MB-231 cells induced two 
folds higher activation of caspase 3/7 as compared to MCF-7 cells. This effect 
could be due to the caspase 3-deficient status in MCF-7 cells, a recognised 
phenomenon (Janicke et al., 1998b), meaning that only the activation of caspase 
7 is possible in MCF-7 cell line. This is in agreement with literature suggesting that 
in absence of caspase 3, caspase 7 can lead to apoptosis (Cohen, 1997, Fraser 
and Evan, 1996). In addition, caspase activation was inhibited when cells were 
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treated with Z-DEVD-FMK used as a negative control (Ekert et al., 1999). Thus, 
FXR agonists activate executioner caspases indicating apoptotic cell death in 
breast cancer cell lines. Furthermore, the cleavage of poly-ADP ribose 
polymerase in these cell lines suggested the caspase mediated cell death. The 
cleavage of PARP by caspases leads to formation of two fragments, 89KDa and 
24KDa (Fischer et al., 2003, Kaufmann et al., 1993, Lazebnik et al., 1994). 
Staurosporine used in this study as a positive control induced complete PARP 
cleavage, resulting in the 89KDa cleaved PARP. Full length PARP (118 KDa) and 
cleaved PARP (89KDa) were detected in both cell lines when treated with 
GW4064 and CDCA. In addition, the PARP cleavage observed was dose 
dependent in both cell lines.  
Activity of the initiator caspases 8 and 9 can be used to distinguish the different 
routes of activation for the apoptotic cascade. Intrinsic or mitochondrial-mediated 
caspase activation is dependent upon the activation of caspase 9, whereas the 
extrinsic pathway mediated through caspase 8 (Duprez et al., 2009, Elmore, 2007, 
Fulda and Debatin, 2006, Gorczyca et al., 1993). Therefore, I next explored 
whether FXR agonists mediate extrinsic or intrinsic cell death in MCF-7 and MDA-
MB-231 cells. A luminescence-based assay was performed on breast cancer cell 
lines to study the activity of caspase 8 and 9. In both cancer cell lines, caspase 9 
is significantly induced upon FXR agonist’s treatment, but no significant caspase 
8 activation measured compared to the vehicle. This indicates the intrinsic 
apoptotic pathway activation. In addition, this is supported by the western blotting 
data, with FXR activation inducing cytochrome c release in time dependant 
manner and significantly high BAX/Bcl-2 ratio treated up to 8 hours as compared 
to vehicle. Cytochrome c release from mitochondria is regulated by the apoptosis-
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promoting and apoptosis-inhibiting Bcl-2 proteins in the outer membrane (Jiang 
and Wang, 2004). In this study, staurosporine induces cytochrome c release to 
cytoplasm as early as within 2 hours of treatment and complete release by 6 hours 
in both cell lines whereas, both GW4064 and CDCA induce cytochrome c release 
within 4-8 h treatment. In MCF-7 and MDA-MB-231 cells, BAX protein levels are 
higher after 8 h treatment with GW4064 and CDCA, also much lower expression 
of anti-apoptotic protein Bcl-2 was observed, which was subsequent to 
cytochrome c release. It is therefore possible that, in these cells, BAX upregulation 
and Bcl-2 downregulation induce cytochrome c release, although MCF-7 cells 
shown lesser BAX expression as compared to MDA-MB-231. FXR agonists 
GW4064 and CDCA induce the expression of the FXR target gene small 
heterodimer partner (SHP) in MCF-7 and MDA-MB-231 cells and regulate 
apoptosis via FXR-SHP interaction. SHP inhibits the production of aromatase, an 
enzyme for local estrogen production (Kovacic et al., 2004). Zhang et al. (2010) 
reported that SHP induces mitochondrial membrane permeability and releases 
cytochrome c, leading to further activation of the caspase cascade. An important 
concept is the continuum of cell death mechanisms, ranging from the fully 
programmed apoptotic cascade to uncontrolled necrosis. Along this continuum, it 
is often the case that more than one mode of cell death is occurring at any one 
time. In addition, the mechanisms are not isolated, but impinge on central 
molecular pathways; for example, there is a good body of evidence to demonstrate 
cross talk between apoptosis and autophagy (Cho et al., 2009, Cui et al., 2007, 
Decuypere et al., 2012, Gordy and He, 2012). Autophagy type cell death 
coordinates with apoptosis shown in some studies done so far. Beclin-1 regulates 
autophagy by binding to phosphoinositide 3-kinase (PI3K) and formation of 
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autophagosomes. Beclin-1 interacts with the Bcl-2 family of proteins, inhibiting the 
Bcl-2/Bcl-XL and activates pro-apoptotic proteins such as BAX (Maiuri et al., 
2007a, Wirawan et al., 2010). One of the markers for autophagy is Microtubule-
associated protein 1A/1B-light chain 3 (LC3). The cytosolic form of LC3 (LC3-I) is 
then conjugated with phosphatidylethanolamine, forming the LC3-
phosphatidylethanolamine conjugate (LC3-II), which is present at the 
autophagosomal membranes and seen as a marker of autophagy. These 
autophagosomes fuse with lysosomes, forming the autolysosomes. LC3-II is 
degraded and this change over from LC3-I to LC3-II marks the autophagic activity 
which could be induced through starvation and are detected through western 
blotting. Also, it has been shown that autophagic proteins act as substrates for 
caspase dependent apoptosis. In particular, ATG5, required for formation of 
autophagosomes when cleaved by caspases, induces mitochondrial dependent 
apoptotic pathway (Betin and Lane, 2009, Galonek and Hardwick, 2006, Wirawan 
et al., 2010, Yousefi et al., 2006). Therefore, I next studied the expression of LC3, 
the marker of autophagy in MCF-7 and MDA-MB-231 cells. The cells were treated 
with FXR agonists and immunoblotted for LC3. The results indicate autophagic 
activity in MCF-7 cells with GW4064 treatment induces LC3 expression but not 
with CDCA. The explanation could be that, GW4064 is more potent cell death 
inducer as evident from previous results. In case of MDA-MB-231 there is no 
autophagic activity observed. The results are in agreement with previous literature 
stating that MCF-7 cells are more prone to autophagic cell death than apoptosis 
(Bursch et al., 1996). However, it is matter of debate whether the crosstalk 
between autophagy and apoptosis is mutualistic or not (Carew et al., 2007, 
Kanzawa et al., 2003, Oh et al., 2011, Ropolo et al., 2012, Turcotte et al., 2008).   
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The key findings are presented in the figure 7.1. 
 
 
Figure 7-1: FXR induces mitochondrial mediated apoptosis in breast cancer  
GW4064 and CDCA (agonists) activates FXR and its target gene small 
heterodimer partner (SHP) expression and induces ROS. SHP activates apoptosis 
by translocating to mitochondria. There it binds to the anti-apoptotic protein Bcl-2 
and causes the activation of BAX, a pro-apoptotic protein. This causes the release 
of cytochrome c. The caspase 9 along with cytochrome c forms the apoptosome. 
This then further activates downstream effector caspases caspase 3 and caspase 
7 followed by PARP cleavage resulting in cell death.  
 
 
193 
 
 
7.3  GW4064 as a potential chemotherapeutic 
 
The current study establishes the cytotoxicity of GW4064 on breast cancer cell 
lines MCF-7 and MDA-MB-231 and anti-proliferative effects. In contrast, GW4064 
has been shown to have limited cytotoxicity on the normal breast cell line MCF-
10A (Noura Alasmael, personal communication), indicating a potential 
discrimination between normal and tumour breast cells. On other hand, some 
studies have suggested GW4064 inhibitory effects on cell proliferation in MCF-
10A cells, but this could be due to difference of presence of serum in the medium 
in this latter study (Giordano et al., 2011). The differences in toxicity levels in 
cancer vs. non-cancerous phenotype still needs to be addressed, and a wider 
screen of the impact of GW4064 on breast cancer cell line viability is warranted. 
However, the potential cytotoxic effect of GW4064 on breast cancer cells makes 
it a promising therapeutic in the case of breast cancer. Endocrine treatments are 
widely employed to treat patients with breast cancer, such as classical use of tam. 
However, it is well understood that over time patients develop resistance towards 
many chemotherapeutics, including tam, and may end up being completely non-
responsive. One way to increase the effectiveness of chemotherapeutics has 
been to use them in combination therapies, such that multiple cellular systems are 
targeted at once. This increases the load on cells, and increases the likelihood 
that cell death will result. Traditionally, such combinations have used established 
chemotherapeutics; however, there is much interest in novel combinations using 
chemicals that produce metabolic stress within cells, but may not be significantly 
toxic themselves. Therefore we decided to combine tam and GW4064 and study 
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the effects of this combination on breast cancer cell lines. Combination therapy 
proposes an advantage of dose reduction and synergistic growth inhibition of 
cancerous cells with reduced toxicity by chemotherapeutic drug. We 
demonstrated for the first time that GW4064 and tam synergistically induce 
cytotoxicity in breast cancer cells. Also, in a study undertaken by Giordano et al., 
activation of FXR by GW4064 and CDCA was shown to induce cell death in both 
naïve and tam resistant MCF-7 cell lines, although the mechanism of cell death 
was unclear (Giordano et al., 2011). In the current study, cell death observed was 
time- (MTT; 24 hours, clonogenic assay; 12 days) and dose-dependent with near 
maximum cell death (approximately 90%) achieved at a combination of 3 µM and 
10 µM tam for MCF-7 and MDA-MB-231 respectively with the lowest dose of 
GW4064 (7 µM and 7.5 µM, MCF-7 and MDA-MB-231, respectively). It is 
noteworthy that tam alone induces less cytotoxicity in MDA-MB-231 cells 
compared to MCF-7, whereas its combination with GW4064 induces high 
cytotoxicity. This is in agreement with studies suggesting less effectiveness of tam 
on MDA-MB-231 due to its estrogen negative status, it shown slower death rate 
(Kallio et al., 2005). We observed strong synergy at concentration levels lower 
than its IC50 value plus at concentration levels 2–4-fold higher than its IC50 in 
both MCF-7 and MDA-MB-231, suggesting that the significantly low 
concentrations would be sufficient to trigger the synergistic effects of the drug 
combination. The current study for the first time establishes the synergistic role of 
FXR agonist GW4064 with tam in ER-negative tumour type, MDA-MB-231 cell line 
which are more aggressive and metastatic tumour type. Considering the ability of 
GW4064 to sensitize this phenotype (ER-) towards tam, this knowledge could aid 
towards the development of new strategies for treating ER-negative tumours.  
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Given the controversies in the literature with regard to the role of FXR activation 
in cell death, it is difficult to arrive at a firm conclusion. However, previous evidence 
and this current work seem to suggest cytotoxic ability of FXR activation in breast 
cancer. Although, the discrepancies within cell line phenotypes and in vitro and in 
vivo conditions, more work is needed in this area to firmly establish FXR role in 
cancer. 
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 CHAPTER 8 
CONCLUSION 
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8.1 CONCLUSION 
 
In an attempt to determine the role of FXR activation in breast cancer, we studied 
the possible involvement of FXR agonists in inducing apoptosis in breast cancer 
cells. Our results are consistent with published data suggesting that FXR activation 
induces cell death in breast cancer (Giordano et al., 2011, Swales et al., 2006) and 
various other cancers (Choi et al., 2003, Maran et al., 2009, Modica et al., 2008). 
Our results indicate that the FXR agonists GW4064 and CDCA induce 
mitochondrial-mediated apoptosis in MCF-7 and MDA-MB-231 breast cancer cells.  
In addition, MCF-7 cells showed a significant level of autophagy, presumably due 
to the lower apoptotic potential caused by a lack of caspase 3 expression. 
Importantly, in addition to characterising the mode of cell death, the results shown 
for the first time that the FXR activator GW4064 synergizes with tam in the inhibition 
of MCF-7 and MDA-MB-231 cell proliferation.  In conclusion, this study supports 
the further examination of FXR activation (by GW4064 or another selective agonist) 
as a combination therapy for the treatment of breast cancer. 
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8.2  Future Work 
 
There are certain directions for future work to continue this study.  
A. First, as my work is based on MCF-7 and MDA-MB-231 breast cancer 
cells, it would be interesting to know effects of FXR activation on normal 
breast cells (MCF-10A) and other phenotypic breast cells such as MDA-
MB-468 (non-metastatic), whether they pro- or anti-proliferative.  
B. Secondly, as all my work was done under in-vitro conditions, I can look 
the FXR activation effects under in-vivo conditions. FXR activation 
effects could be studied using breast tumour xenografts in mouse 
models.  
C. Thirdly, as MCF-7 showed autophagic response in addition to apoptosis, 
I would next examine the key proteins involved in autophagic pathway 
such as beclin-1 and look for any cross-talk. This could demonstrate 
autophagy and apoptosis synergistic or antagonistic relation upon FXR 
activation. 
D. Fourthly, as there is a large amount of evidence of different FXR effects 
owing to phenotypic differences in cell lines, a microarray approach 
could be utilized to examine wider effects of FXR activation in-vitro.  
E. Fifthly, as reported in some studies that GW4064 effects could be 
independent of FXR, I would further investigate FXR dependent and 
independent effects of GW4064 treatment. Cell lines with dominant 
negative FXR expression could be studied, to establish whether the 
effects of GW4064 and CDCA are FXR dependent or not.      
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